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Vaccines have benefited global health by controlling or eradicating multiple 
previously fatal diseases. While many early vaccines were efficacious, sophisticated 
new vaccines and immunotherapies need to address current challenges in the field, 
including diseases that avoid immune detection or lack strong molecular targets for 
the immune system. Overcoming these hurdles requires strategies to specifically 
control the magnitude and type of immune response generated. Biomaterials offer 
attractive features to achieve this goal, including protection of encapsulated signals, 
controlled release of cargos, and tunable features for cell targeting. Intriguingly, 
recent research reveals many common biomaterials activate the immune system, even 
without other signals. This intrinsic activation results, at least in part, from 
biomaterial physicochemical features that mimic pathogens and other foreign 
materials. Surprisingly, although degradable materials are being intensely studied as 
  
vaccines carriers, little research has investigated how the intrinsic immunogenicity of 
these materials changes as polymers degrade. The work in this dissertation reveals 
parameters impacting material intrinsic immunogenicity and exploits this new 
understanding to test the influence of biomaterial-based vaccines on the function of 
lymph nodes (LNs), key tissues that coordinate immunity. In the first aim, the 
immunostimulatory properties of a library of degradable polymers, poly(beta-amino 
esters) (PBAEs), were investigated in cell and animal models. PBAEs in soluble 
forms did not activate innate immune cells (e.g., dendritic cells, DCs). When PBAEs 
were formulated into particles to mimic a common vaccine strategy, DC activation 
increased in a molecular weight-specific manner. Using intra-lymph node (i.LN.) 
injection, a novel technique to control the dose, kinetics, and combination of signals 
in LNs, PBAE intrinsic immunogenicity was confirmed in mice. In the second aim, 
microparticles encapsulating immune signals were introduced into mice via i.LN. 
injection and immune responses were quantified in treated LNs, untreated LNs, and in 
blood. These results elucidated the interplay between local LN rearrangement and 
systemic antigen-specific responses which ultimately led to prolonged survival in 
cancer models. By understanding how the properties and administration of 
biomaterial-based vaccines impact immunity, this dissertation provides information 
that can help create new design rules for future vaccines that actively direct the 
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Chapter 1: Introduction 
 
The ability to reprogram the immune system via vaccination has proven to be a 
powerful tool in combating disease worldwide.[1] The immune system provides the 
first line of defense against pathogens and disease, by creating a barrier and rapid 
recognition system for identifying foreign materials. Through the use of a variety of 
cells and molecules, the immune system can then eliminate these harmful materials. 
Vaccines include three main parts: i) the antigen, a fragment of the specific pathogen 
or molecule that determines the selectively of the immune response, ii) an adjuvant, 
which activates or amplifies the immune response to an antigen, and iii) a vehicle or 
carrier to stabilize the immune cargos. The introduction of economical, global 
vaccination has allowed people around the world to receive vaccines, leading to 
communicable diseases to be reduced or eradicated.[1] However, there are still 
barriers limiting the progress in vaccine development. First, vaccines are not available 
for many important diseases impacting human health (e.g., infections, cancer) which 
require identification of new antigens for efficacy. Also, because of the use of live or 
attenuated pathogens within some vaccines, a safety risk is involved since mutation 
can occur, as well as the possibility of acute toxicity at the injection site. Further, 
even with clinically approved adjuvants such as aluminum salts (alum), the 
mechanism of action is poorly defined, making it difficult to improve upon or mimic 
the response to these materials in a rational way.[2] Because of these limitations and 
the empirical, inefficient nature of vaccine development, clinical approval of vaccines 




enormous losses in scientific and financial resources.[3-8] These issues have 
motivated researchers to design tunable systems that can provide fundamental 
knowledge to enable rational design approaches to build vaccines that are more 
effective and can be created more quickly to save resources. 
 
Biomaterials provide a unique platform to serve as these modular systems for 
vaccines and immunotherapies. Biomaterials are either naturally-derived building 
blocks (e.g., lipids, proteins, peptides, polysaccharides, nucleic acids) or synthetically 
derived (e.g., polymers, metals, ceramics). They can be used as vehicles to deliver 
immune signals and offer tunable properties that can control the loading and release 
of encapsulated antigen and adjuvant. These features create platforms for tunable 
release of signals that can provide increased exposure to antigen to drive robust 
immune response that are specific and provide long-lasting protection (i.e., immune 
memory). While initially biomaterials were thought to be bioinert and thus not 
influence immune response, surprisingly, the past decade has revealed a growing 
number of studies indicating materials can be recognized by and alter immune 
function. In some cases, this influence results in the administered vaccine being 
cleared from the body rapidly and as a consequence, reduces potency. In other 
examples, researchers have found many common biomaterials promote inflammatory 
responses and immune activation.[9] Based on these revelations, there is a pressing 
need to further evaluate how the properties of materials are driving this intrinsic 
immunogenicity so that vaccines can be designed to actively direct the immune 




One particular tissue type of interest for vaccines and immunotherapy are the lymph 
nodes (LNs). These tissues coordinate the immune response by providing a location 
for the cells of the innate immune system, which rapidly respond to pathogens, to 
interact with cells responsible for adaptive immunity, which create specific, long-
lasting responses.[10] Interestingly, recent research has shown that structural 
components of LNs can rearrange following treatment, altering the local 
microenvironment to promote interactions between these cells.[11, 12] Changes to the 
local LN environment ultimately control the resulting systemic response. With this 
new understanding of how local changes can bring about systemic responses, we 
developed a method for directly injecting LNs of mice.[13, 14] Since biomaterials are 
used as vaccine carriers, this platform provides a tool to directly deposit these 
materials into LNs, controlling the dose, kinetics, and combinations of signals that 
reach these tissues, and allowing for investigation into how their properties impact 
local and systemic responses.  
 
The work in this dissertation combines material science and engineering techniques 
with biological and immunological assays in both cell and animal models to study the 
impact that biomaterials have on the immune response. The material science 
techniques used were polymer synthesis and characterization via nuclear magnetic 
resonance and gel permeation chromatography, micro and nanoparticle fabrication, 
and characterization of material physicochemical properties. These were coupled with 




cytometry, and histological analyses to provide a unique setting to investigate two 
main objectives listed below: 
 
1. Evaluate how the intrinsic immunogenicity of biomaterials is altered during 
degradation of polymeric carriers 
a. Study how the form of polymer influences innate cell activation 
b. Determine if intrinsic immune function is attributed to the molecular 
weight of materials  
c. Link changes in innate cell activation driven by specific polymer 
properties to adaptive cell responses 
 
2. Employ i.LN. injection as a tool to investigate changes in local, treated tissues 
and assess the link to systemic immunity 
a. Determine if in vitro intrinsic activation of degradable polymers 
translates to animal models 
b. Investigate impact of vaccine deposition on local LN resident innate 
and adaptive immune cells 
c. Enumerate the antigen-specific systemic response following treatment 
to determine the efficacy in a cancer model 
 
The objectives outlined above advance the understanding of intrinsic immunogenicity 
by elucidating how modulation of the immune system is altered over time as a 




biomaterials carriers, researchers have yet to fully characterize how materials 
properties impact immunogenicity and have not investigated how this may change 
with carrier stability. Additionally, this work provides new knowledge of how the 
localization of biomaterials and immune signals in LNs influences these tissues and 
how these local changes alter the resulting, antigen-specific systemic response. These 
outcomes provide a basis for the design of future vaccines and immunotherapies that 
are fabricated from materials specifically selected to push the immune response 
toward a desired response. This new insight could be applied to a number of disease 
models, either to promote a pro-inflammatory immune response needed for many 
cancer therapies or, conversely, to encourage an anti-inflammatory environment that 
is beneficial for control of autoimmune diseases.  
 
The next chapter begins with a detailed overview of the immune system and reviews 
some of the recent work involving biomaterials and how they are used to modulate 
the immune system toward immunogenic responses that are pro-inflammatory with 
applications for cancer, or tolerogenic responses which restrain the immune system 
and could be beneficial for autoimmune diseases. Chapter 3 investigates how the 
intrinsic properties of a model degradable polymer impact innate and adaptive 
immune cells in vitro. Chapter 4 expands on this work to generalize these findings 
across a small library of polymers and correlates immunogenicity to a characteristic 
molecular weight range. Chapter 5 introduces intra-lymph node (i.LN.) injection and 
reveals that the intrinsic immunogenicity of the polymers from Chapters 3 and 4 




biomaterial-based vaccines into LNs and investigate the local and systemic responses 
to treatment in a cancer model. Chapter 7 introduces a new technology created to 
immobilize cancer cells while maintaining their free-floating dynamics, which allows 
for drug screening of therapeutics and potential identification of new tumor antigens. 
In Chapter 8, the knowledge about biomaterial immunogenicity gained from this 
work and other recent studies involving vaccines and immunotherapies is discussed in 
the context of tissue engineering, a field that relies on biomaterials but has yet to 
capitalize on the potential of the immunogenic features of materials. Chapter 9 
details ongoing and future research directions that must be taken to further understand 
how the properties of materials and localization to immune tissues ultimately impact 
immunity. Chapter 10 lists the contributions to science that have resulted from this 
work. This dissertation ends with an appendix cataloging the publications that I am a 
contributing author on, an appendix of my patent and intellectual property filings, and 






Chapter 2: Harnessing Biomaterials to Engineer the Lymph 
Node Microenvironment for Immunity or Tolerance1 
 
2.1 Introduction 
Vaccination has produced one of the greatest impacts on human health in history [1]. 
No other break-through has virtually eradicated fatal diseases like polio or small pox 
with just a few doses. However, many diseases impacting public health create 
complex challenges for existing vaccine and immunotherapy strategies. For example, 
HIV evades clearance by mutation and concealment in the mucosa, tumors actively 
suppress tumor-destructive immune cells, and many treatments for autoimmune 
disease lack specificity. To address challenges such as these, new vaccines and 
immunotherapies will need to generate potent responses against specific molecules – 
termed antigens – while also tuning the characteristics of these responses to combat a 
target disease. Lymph nodes (LNs) and the spleen are some of the key structures that 
coordinate the type and specificity of these responses.  
 
In the last several years, the impact of nanoparticles (NPs), microparticles (MPs), and 
other biomaterial vaccine and immunotherapy carriers on LNs has been an intriguing 
area of focus. These studies reveal the potential of biomaterials to program the local 
LN microenvironment to control systemic immune response. The broad potential of 
________________________________________________ 
1Adapted from J.I. Andorko, K.L. Hess, and C.M. Jewell “Harnessing biomaterials to engineer the 




biomaterials for vaccination and immunotherapy has recently been reviewed [15-17]. 
This paper focuses more specifically on the interactions of biomaterials with LNs and 
other immune tissues (e.g., spleen) during the generation of stimulatory or regulatory 
immune responses. The discussion begins with background describing how adaptive 
immune responses are generated, with an emphasis on the active role that LN tissues 
and resident cells play in these processes. Key recent examples are then discussed to 
demonstrate how biomaterials enhance the generation of immunity, for example 
against a foreign pathogen, or of tolerance, such as to combat autoimmune disease. 
The review concludes by identifying unanswered questions and highlighting some of 
the ways in which answers to these questions could inform new approaches to exploit 
the interactions between biomaterials and LNs for vaccination, immunotherapy, and 
tissue engineering. 
 
2.2 Adaptive immunity requires structured interactions between immune cells 
2.2.1 Antigens in peripheral tissue must reach LNs to initiate adaptive immune 
response 
The innate immune system is comprised of first-response defense mechanisms 
including i) skin that creates a physical barrier against pathogens, ii) immune cells 
that home to and engulf pathogens or other immunogenic structures, and iii) receptors 
that detect broad classes of molecular patterns absent in mammals but present in 
viruses and bacteria. In contrast, adaptive immunity involves the generation of 
immune responses specific for a particular molecule, termed an antigen. Generation 




immune cells, antigens, and soluble factors in secondary lymphoid organs (SLOs) 
[18, 19]. These tissues include the spleen, LNs, and Peyer’s patches. The spleen 
samples circulating antigens present in blood, while specialized nodules termed 
Peyer’s patches sample antigens in mucosal tissues such as the small intestine.  
 
LNs are found throughout the body, concentrating antigens from a network of 
lymphatic vessels that continually sample tissue for antigens or other immune signals 
[20, 21]. Soluble antigens with molecular weights of ~70kDa or with particle size 
between 20-50nm passively drain along the lymphatics, while larger antigens or 
pathogens are phagocytosed and carried to these LNs by specialized antigen 
presenting cells (APCs) such as dendritic cells (DCs) (Figure 2.1A) [15, 22]. APCs 
continually survey tissue and blood for inflammatory signals and antigens, which 
upon detection, stimulate phagocytosis and a change in the expression of homing 
receptors that allows antigen-experienced APCs to travel to nearby “draining” LNs 
[20]. In LNs, processed antigens are presented by APCs to activate resident T and B 
lymphocytes. Activated lymphocytes and molecules secreted by these cells (e.g., 
antibodies) exit LNs and search the periphery to immobilize or destroy the pathogens 
against which they are armed in LNs. Thus LNs are key structures that vaccines and 
immunotherapies must reach to generate antigen-specific responses that can combat 





Figure 2.1: Schematic overview of cell-mediated and antibody-mediated relating to the LN.  
(A) Graphical depiction of antigen drainage through lymphatics and APC-aided transport to LNs. (B) 
Illustration of the LN microenvironment containing key cells and stromal structures. (C) Activation of 
cytotoxic T cell is induced by DCs which process and present antigens with co-stimulatory molecules 
to naïve CD8+ T cells within the T cell zones of LNs. (D) B cell activation occurs after an activated 
CD4+ helper T cell bind to B cells presenting the same antigen at the periphery of the LN follicle. 
Activated B cells then migrate to GCs where proliferation, somatic mutation, and, with the help of 
follicular DCs and follicular helper T cells, affinity maturation occur. These processes result in plasma 
cells that exit the LN and secrete high affinity antibodies. 
 
2.2.2 LNs contain supportive stromal components, B cell zones, and regions rich in 
APCs and T cells 
LNs are bean-shaped structures surrounded by a collagen-rich fibrous capsule 
(Figure 2.1B). Antigens – in soluble form or phagocytosed within APCs – enter LNs 
via the afferent lymphatic that drains lymph fluid flowing from upstream lymphatic 
vessels [20, 21]. This fluid travels around the periphery via the subcapsular sinus 
(SCS), a region rich in macrophages able to take up and process incoming antigen or 




include fibroblastic reticular cells (FRC) and extracellular matrix (ECM) components 
secreted by FRCs [18]. This network of conduits and cells ensures small, soluble 
antigens can efficiently penetrate deep into LNs.  
 
DCs and T cells comprise an interior region of LNs called the paracortex (“T cell 
zone”), while B cells and specialized follicular dendritic cells (FDCs) make up a 
surrounding cortex called the “B cell zone” (Figure 2.1B) [23, 24]. The degree of 
intermingling between these two regions is controlled by soluble chemotactic factors 
called chemokines. The chemokines CCL19 and CCL21 attract T cells expressing 
CCR7 to the paracortex, while CXCL13 attracts B cells expressing CXCR5 to the 
follicles of the cortex [23, 24]. During generation of adaptive immunity, this balance 
changes: B cells upregulate CCR7 receptors for CCL19/CCL21, while T cells 
upregulate CXCR5 receptors for CXCL13, promoting interactions between APCs, T 
cells, and B cells at the interface of the T and B cell zones. The purpose of these 
interactions is to generate effector cells and secreted antibody molecules specific for a 
particular antigen encountered in organs, blood, or peripheral tissue. Upon activation 
and expansion, T cells and B cells are collected and exit the LN through the medulla 
and efferent lymphatic. Structures called high endothelial venules (HEVs) also 
connect LNs with circulatory vasculature, serving primarily as a conduit for 
lymphocytes to travel between blood and LNs. A summary of the key cells and 






Table 2.1: Key Cells and Structures Comprising Lymph Nodes 
Cell or tissue Acronym Key Function 
Professional antigen presenting 
cell 
APC Cells exhibiting a primary function of processing 
and presenting antigen. Key populations include 
DCs, B cells, and macrophages. 
Dendritic cell DC APCs surveying peripheral tissue for antigen. DCs 
take up antigen, migrate to LNs, then present 
antigen to T and B cells to generate antigen-
specific immunity. 
T lymphocyte T cell Cells involved in direct cell killing of infected host 
cells (CD8+ cytotoxic T cell population) and 
helper functions that support antibody production 
(CD4+ helper T cells). 
B lymphocyte B cell Cells that differentiate to plasma cells that are able 
to secrete antibody molecules that bind antigens. 
Binding leads to neutralization or destruction of 
these targets. 
Fibroblastic reticular cells FRC Stromal cells that support trafficking of soluble 
signals and antigen throughout LNs. These cells 
also organize LN structure by secreting 
extracellular matrix components. 
Follicular dendritic cell FDC Specialized dendritic cell able to capture and 
present antigen to B cells in GCs to promote high-
affinity antibodies. 
 
Capsule    Dense layer of connective tissue that surrounds the 
internal structure of LNs. 
Afferent lymphatics   Entry of antigen and immune cells from 
lymphatics. 
Efferent lymphatics   Exit of immune cells from lymph node to 
lymphatics. 
Subcapsular sinus SCS Drains and distributes lymph throughout LNs. 
Medulla  Drains activated lymphocytes in LNs to efferent 
lymphatics for return to tissue and blood. 
High endothelial venule HEV Portal allowing exchange of lymphocytes with 
blood. 
T lymphocyte zone (paracortex)   Interior domain rich in T cells and DCs. 
B lymphocyte zone (cortex)   Follicular region located at the peripheries of the 
paracortex that is rich in B cells and FDCs.  
Germinal center GC Structures that form to co-mingle specialized DCs, 







2.2.3 Adaptive immunity requires specific interactions between APCs, T cells, and B 
cells in LNs 
The major classes of adaptive responses include cell-mediated immunity, through 
which cytotoxic T lymphocytes directly destroy infected host cells; and antibody-
mediated immunity, which involves binding, neutralization, and clearance of antigens 
by circulating antibodies specific for these pathogens. In the simplest sense, cell-
mediated immunity removes intracellular pathogens such as viruses, while antibodies 
are able to address extracellular toxins and pathogens (e.g., bacteria). Cell-mediated 
and antibody-mediated responses develop following the activation of naïve, antigen-
specific T cells and B cells, respectively [25, 26]. These processes involve 
interactions with APCs in LNs or other SLOs. Naïve CD8+ T cells are activated by 
DCs that have encountered, processed, and are presenting the antigen these T cells are 
specific for (i.e., a “cognate” antigen) (Figure 2.1C). Importantly, this activation 
requires that the cognate antigen be presented by the APCs in a protein complex 
called major histocompatibility complex I (MHC-I). Activation also requires co-
stimulatory surface molecules that are expressed when DCs encounter inflammatory 
signals – often adjuvants in the case of vaccines. These agents enable DCs to co-
present co-stimulatory signals to CD8+ T cells during antigen presentation. This set of 
interactions causes CD8+ T cells to expand and differentiate to cytotoxic T 
lymphocytes (CTLs) that migrate from LNs to destroy host cells expressing the target 
antigen (e.g., due to a viral infection). A similar process occurs in DCs presenting 
antigen in MHC-II to CD4+ helper T cells that play an important role in the activation 





B cell activation is initiated when B cells in the cortex encounter their cognate 
antigen, altering the balance of chemokine receptors on these cells and causing 
migration toward the T cell zone (Figure 2.1D). Simultaneously, helper CD4+ T cells 
with the same antigen-specificity migrate toward the B cell zone following activation 
by DCs. B cells are activated at the edge of the cortex by these helper CD4+ T cells, 
then move back into the cortex and proliferate to form a germinal center (GC). In 
GCs, the affinity of the proliferating B cell for the cognate antigen is increased 
through interaction with resident FDCs that deliver survival signals to B cells that 
strongly bind antigens presented by FDCs. These processes involve somatic mutation 
and affinity maturation and are detailed in recent reviews [27, 28]. The result of these 
events is the differentiation of B cells to plasma cells that migrate to the periphery 
and bone marrow to secrete high affinity, antigen-specific antibodies that enter blood 
and peripheral tissue. 
 
2.2.4 The LN microenvironment actively impacts the development of immunity or 
tolerance  
One of the fascinating developments over the past decade has been the realization that 
stromal components of LNs and other SLOs not only serve a structural function, but 
also actively promote immunity or tolerance. For example, in the absence of antigen 
and activating signals, T and B cell zones are maintained in a segregated arrangement 
(Figure 2.2A) [29]. In contrast, during generation of adaptive immunity, the LN 




cells, and B cells (Figure 2.2B) [29]. The FRC network and other stromal 
components support interactions such as these through production of ECM 
components, transport of antigens and signaling molecules (e.g., chemokines and 
cytokines), and establishment of conduits through which lymphocytes travel. Recent 
studies also illustrate that lymphocytes migrate toward discrete microdomains of LNs 
during inflammation and immunity compared with migration during tolerance. These 
effects also correlate with up regulation and down regulation of specific stromal 
components such as laminins [12]. Thus, the combinations of antigens and immune 
signals present in LNs, along with the specific organization of these tissues, help 
determine the types of immune responses that develop systemically. Below we 
discuss how biomaterials offer new ways to control these parameters to promote 
stimulatory immune responses (i.e., immunity), as well as to regulate or redirect 
response toward immune tolerance.  
 
Figure 2.2: LN reorganization during generation of adaptive immune response.  
(A) A LN in a resting state with distinct B cell and T cell zones. (B) After activation with antigen and a 
strong adjuvant (Complete Freund's Adjuvant), the LN microenvironment rearranges to promote 





2.3 Biomaterials exhibit material properties that activate immune pathways 
The physicochemical properties of biomaterials can act as intrinsic immune signals 
that help shape immunity. Some of the properties which have been studied along 
these lines – reviewed in [15-17] – include molecular weight, surface chemistry, and 
particle shape and size. This body of work has demonstrated that biomaterial 
properties alter lymphatic transport, DC uptake and activation, activation of 
inflammatory pathways (e.g., toll-like receptors, TLRs; inflammasomes), and 
secretion of signaling proteins called cytokines [22, 30-43]. For example, carriers 
such as poly(lactic acid-co-glycolic acid) (PLGA) and polystyrene have been shown 
to activate the immune system through inflammasome signaling even in the absence 
of other immune signals or adjuvants – agents added to vaccines to enhance immune 
response [44-46]. Since synthetic biomaterials such as PLGA or naturally occurring 
biomaterials like chitosan are becoming ubiquitous in the design of vaccine and 
immunotherapy carriers, understanding the link between material properties and 
immune response could allow more rational design of materials that serve not only as 
carriers, but also as agents that actively “tune” immune responses to combat 
infectious diseases, cancer, or autoimmunity. Thus this review focuses on the impact 
of biomaterials on LN organization and function to promote immunity or to regulate 
immune response (tolerance). Emphasis is also placed on highlighting new 
approaches reported in the last several years. Table II summarizes the examples 
presented below that investigate NPs and other biomaterial-based vaccines to help 






Table 2.2: Examples Demonstrating the Impact of Biomaterials on LN Function 
Setting Biomaterial Functional impact on lymph node Ref. 
Immunity Poly (lactic acid-co-
glycolic 
acid)/polystyrene 
Inflammasome activation and increase in 
IL-1β secretion 
[44, 45] 






Targeting of tumor-draining LN; delivery of 
vaccines overcame immunosuppressive 
tumor environment by activating DCs and 
increasing the CD8+ T cells to TREG ratio 
 
[48, 49] 
Immunity Lipid vesicles and 
micelles 
Effective drainage to LN sinuses and 
increased uptake by APCs leading to 




Immunity ICMVs Trafficking to LN-resident macrophages 
and DCs in SCS; Induces GC formation 
resulting in long lasting, high avidity 
antibodies  
[50-52] 
Immunity PLGA with 
Adjuvants/OVA 
Adjuvant-loaded NPs synergistically 
increase antibody-mediated immunity 




Immunity Lipid stabilized PLGA Increased antigen specific CTLs and 
antibody production caused by local depot 





Trafficking to LNs; preferential uptake by 
macrophages and DCs; increases DC 
activation and CD4+ helper T cell 
proliferation; upregulation of PD-L1;  




Tolerance Liposomes Uptake by LN-resident APCs leading to 
expansion of TREGS specific for self-antigens 
included in liposomes 
 
[61] 
Tolerance Iron oxide  Expansion of low avidity TREGS in and 
around LNs that suppress antigen 




Tolerance Polystyrene beads Support antigen presentation to DCs leading 
to inactivation of antigen-specific CD4+ T-
cells; reduction of CD4+ and CD45+ cell 
infiltration into CNS; reduction in antigen-







2.4 The interactions of biomaterials in LNs can be exploited to enhance immunity 
Biomaterials provide a unique platform for vaccination and immunotherapy. 
Interestingly, these materials can mimic some features of clinically-approved 
adjuvants (e.g., alum), for example, by condensing or encapsulating antigen or other 
immune signals into particulate structures with sizes ranging from tens of nanometers 
to several microns. This size range allows efficient uptake by APCs. Biomaterials can 
also be used to passively or actively target immune tissues such as LNs. Lastly, these 
materials allow co-delivery of multiple cargos (e.g., antigen, adjuvant, drug) and 
controlled release of vaccine and immunotherapy components. This last feature of co-
delivery is becoming increasingly important in modulating the types of responses that 
are generated for a specific vaccine or therapy. The sections below will provide 
specific examples of how these properties are being harnessed to enhance 
“traditional” immune responses aimed at arming the body to destroy infectious 
pathogens or cancer. 
  
Table 2.2: Examples Demonstrating the Impact of Biomaterials on LN Function (cont.) 
Setting Biomaterial Functional impact on lymph node Ref. 
Tolerance Poly(ethyleneimine) Trafficking to follicular and marginal zones 
of LNs; promotes interactions between DCs 
and T cells with regulatory characteristics 
 
[64] 
Tolerance Poly(ethylene glycol) 
and poly(lactide)  
DCs and T-cells modified by particles drain 
to LNs, reducing the number and 
proliferative capacity of effector T cells; 







2.4.1 Particle size helps determine the trafficking and retention of biomaterials in 
LNs 
Both traditional (i.e. soluble) and biomaterials-based vaccine components must reach 
LNs to generate adaptive immune responses. Several groups have carefully controlled 
the size of NPs and other vaccine carriers to passively target LNs and the DCs 
residing in these tissues. For example, by altering particle size, the effectiveness of 
drainage through the lymphatics and the retention time within LNs can be changed. In 
studies conducted by Reddy et al., poly(propylene sulfide) NPs with defined sizes 
were injected intradermally into the tail of mice and the particle drainage through the 
lymphatics to LNs was monitored [22, 67]. 20nm and 45nm particles drained 
effectively through lymphatic vessels to the LNs, while 100nm particles largely 
remained at the injection site. Additionally, 20nm particles were preferentially taken 
up by LN-resident macrophages and DCs. These particles were also retained in LNs 
for more than 4 days [67]. A related study demonstrated that the surface chemistry of 
NPs increased DC activation and antigen-specific T cell responses in LNs, 
underscoring that both physical and chemical properties of materials play a role in 
skewing immune function [22]. 
 
The route of injection also helps define if and how NPs of a given size will reach 
LNs. For example, injection of 90nm virus-like particles via multiple different 
injection routes (e.g., subcutaneous, intraperitoneal, intramuscular, intradermal) 
resulted in unique particle drainage patterns to the inguinal, lumbar, popliteal, and 




of the sciatic and popliteal LNs, supporting the hypothesis that these relatively small 
diameter NPs were transported via lymphatic vessels to the LNs. As opposed to larger 
particles trafficked to LNs by APCs, these smaller particles drain freely to the LNs 
through the afferent lymphatics and can then be scavenged by SCS-resident APCs 
(e.g., macrophages). Thus, by controlling the injection route and size of NPs or MPs, 
the domains that these materials reach in LNs can be controlled. This strategy 
provides a route to design vaccines that specifically target APCs within LNs for 
phagocytosis, or that are small enough to penetrate deeper into other domains (e.g., T 
cell zone).  
 
Though there are only a handful of approved – or nearly approved – adjuvants in the 
United States and European Union developed over the last century, in a sense, these 
agents are the original biomaterial-based vaccine components. One of the most 
widely used is aluminum salts (alum), and others include emulsions (MF59 and 
AS03), liposomes (AS01), and synthetic DNA and RNA sequences (PolyIC and 
CpG). Though there is still some debate as to the mechanism by which alum or other 
adjuvants enhance vaccination, these materials often persist at the injection site to 
serve as a depot (i.e., “controlled” antigen release) and increase antigen phagocytosis 
and presentation that enhances DC activation [2]. In a direct comparison of alum with 
poly(lactic acid) (PLA) MPs, intramuscular immunization with either PLA or alum 
promoted antigen-specific antibodies. Interestingly, PLA MPs increased expression of 
MHC-I and MHC-II molecules on DCs, while alum only increased MHC-II 




antigen cross-presentation – a process by which DCs can present phagocytized 
antigens in MHC-I molecules to enhance CD8+ T cell-mediated adaptive response 
instead of MHC-II molecules which is the traditional route for phagocytized antigens. 
In addition to particle size, recent studies have investigated the role that the geometry 
of vaccine carriers plays in immunogenicity. These studies demonstrate that the shape 
and aspect ratio of synthetic carriers play an important role in modulating T cell 
activation [41]. Thus, future vaccines could combine the rational selection of 
properties such as size or shape with targeting or controlled release of multiple 
antigens, adjuvants, or immune signals.  
 
2.4.2 Molecular markers can be used to effectively target LN-resident cells 
In addition to passive targeting by size, LNs and LN-resident cells are being actively 
targeted by conjugating NPs and MPs with specific ligands or receptors. One of the 
molecules that has been targeted is DEC-205 (CD205), a transmembrane protein 
found primarily on DCs. Monoclonal antibodies specific to DEC-205 have been used 
to decorate acid-degradable polymer and liposome vaccines loaded with model 
antigens (e.g., SIINFEKL from ovalbumin) and B16-melanoma antigens [69, 70]. 
Treatment of mice with anti-DEC-205 particles increased the amount of vaccine 
present in DCs residing in the inguinal LN following subcutaneous immunization, 
and in the popliteal LN following a footpad injection. When administered with LPS 
or IFN-γ to activate DCs, this increase in vaccine accumulation in the LNs correlated 
to increases in splenic cytotoxic T lymphocytes. Following an intravenous melanoma 




DEC-205 particles compared to control particles conjugated to an irrelevant targeting 
peptide. This approach demonstrates the promise of actively-targeting biomaterials to 
specific LN-resident populations to enhance systemic adaptive immune responses.  
 
Liu et al. recently used albumin as a shuttle to direct lipid-based vaccines to LNs 
[40]. Albumin is a serum protein that serves to transport fatty acids from the blood 
into lymphatics and to LNs. To exploit this pathway, lipids containing an albumin 
binding domain made from a diacyl tail were conjugated to peptide antigens and CpG 
- a TLR9 agonist that activates TLR pathways triggered by non-mammalian DNA 
(e.g., from bacteria) (Figure 2.3A). These materials are able to self-assemble into 
micelles when placed in aqueous solution due to the hydrophobic diacyl lipid tail. 
Following subcutaneous injections in mice, albumin-targeted micelles efficiently 
drained to axillary and inguinal LNs, while formulations with low albumin binding 
domains were not effectively trafficked to LNs. Interestingly, by altering the length of 
a polyethylene glycol (PEG) spacer or increasing the number of carbons in the lipid 
backbone, vaccine accumulation in the draining LNs could be controlled (Figure 
2.3B) [40]. Mechanistic studies revealed that micelle stability played a crucial role in 
how these materials were trafficked to LNs. Micelles were stabilized with guanine 
repeat units. Stabilization with four or more guanine repeats (Lipo-G4-CpG) did not 
support trafficking of micelles to LNs, whereas reversible (i.e., non-stabilized) 
micelles assembled with zero or two guanine repeats (Lipo-CpG and Lipo-G2-CpG, 
respectively) reached LNs and were co-localized with macrophages and DCs (Figure 




form, albumin is unable to access the binding domain (diacyl lipid tail), preventing 
albumin-mediated trafficking to LNs. Building on these findings of increased 
accumulation and retention time of the albumin-binding micelle vaccines in LNs, 
peptides specific to HPV-derived cervical cancer or melanoma were added to these 
structures and used to immunize mice after tumor inoculation. In both of these disease 
settings, a striking increase in antigen-specific CD8+ T cells and functional 
inflammatory cytokines (IFN-γ and TNF-α) was observed, resulting in tumor 
regression and prolonged survival in immunized mice. These highly promising 
outcomes are fundamentally a result of the higher concentrations (targeting) and 
retention (exposure time) in LNs, important characteristics that motivate the 
discussion below on the role that duration and concentration of antigen and immune 








Figure 2.3: Trafficking of lipid-based vaccines depends on material properties.  
(A) Schematic of amphiphile structure containing an albumin-binding domain, PEG spacer, and 
peptide antigen. (B) Excised LNs of mice imaged by IVIS 24h after treatment with fluorescent 
amphiphiles with increasing PEG spacer length. (C) Immunohistochemical staining of inguinal LNs 
following treatment with micelles with varying amounts of guanine repeats. CpG (green), T cells 
(CD3, blue), B Cells (B220, pink). Adapted with permission [40]. 
 
2.4.3 The kinetics and concentration of antigen delivery in LNs can be exploited to 
enhance immunity 
An intriguing study by Johansen et al. demonstrated that concentration and duration 
by which antigens, adjuvants, and immune signals reach LNs are just as important as 
how efficiently these signals reach LNs. In these studies, mice were immunized 
subcutaneously with soluble antigen and adjuvant using well-defined doses and 
injection regimens: i) one bolus dose, ii) regularly-spaced, equivalent doses, iii) 
regular injections with exponentially-decreasing doses, or iv) regular injections with 
exponentially-increasing doses (Figure 2.4a). Across all of these regimens, only mice 




secretion by CD8+ T cells (Figure 2.4b). Functionally, this effect significantly 
enhanced antiviral response upon a viral challenge with lymphocytic 
choriomeningitis virus [58]. These results suggest that the persistence and 
accumulation of antigen and inflammatory signals is important in inducing effective 
adaptive immune responses. For this reason, the controlled release properties of 
biomaterials are, and have been, of great interest for vaccine and immunotherapy 
applications. As illustrated by several of the examples highlighted in the following 
sections, these approaches hold great potential to direct response, while also reducing 
the burden on patients through decreasing the number or frequency of injections and 
treatments.  
 
Figure 2.4: Immune signal timing and presence in LNs promotes immunity.  
(A) Subcutaneous dosing schedule of mice with antigen (gp33) and adjuvant (CpG). (B) IFN-γ 
production of CD8+ T cells 8 days after vaccination with the schedule seen in (A) and restimulation of 
blood lymphocytes with gp33. Adapted with permission [58]. 
 
2.4.4 Biomaterials carry immune signals to LNs to promote changes in LN structure 
and function 
As alluded to above, NPs, MPs, and other biomaterials offer a unique opportunity to 
alter local LN structure, and subsequently, systemic immunity by delivering 




enhance antibody-mediated immunity by promoting GC creation. These 
microdomains are required for activation and differentiation of B cells into plasma 
cells that secrete high-affinity antibodies targeting a specific pathogen. One 
promising example of this strategy is the synthesis of NPs from interbilayer-
crosslinked multilamellar vesicles (ICMVs) [50-52]. ICMVs are synthesized by 
fusing liposomes using divalent cations to form multilamellar vesicles, then 
crosslinking and PEGylating these structures into 100-300nm particles. ICMVs have 
been loaded with a range of vaccine cargos including models antigens 
(ovalbumin,OVA), helper T cell peptides, and antigens for malaria and simian 
immunodeficiency virus (SIV) gag. Following subcutaneous immunization in mice, 
ICMVs are retained in the draining LN for over 2 weeks and co-localized with 
macrophages and DCs of the SCS, suggesting that both drainage via lymphatics and 
transport after APC phagocytosis contributed to ICMVs trafficking to LNs [50]. 
Importantly, immunization with ICMVs increases the number of GCs in the draining 
LNs compared to soluble vaccine formulations (Figure 2.5A) [50]. These structures 
dramatically enhance cell- and antibody-mediated immunity by increasing antigen-
specific CD8+ T cells and antigen-specific serum antibody levels, respectively. Mice 
immunized and boosted subcutaneously with ICMV formulations loaded with malaria 
antigens (VMP-ICMV) generated high levels of malaria-targeted antibodies 
compared to vaccination with alum as an adjuvant. Strikingly, this effect persisted for 
more than 400 days after inoculation [50]. Since GCs formation is integral for high 
affinity antibody production and strong humoral immune responses, continued 




advantageous for parasitic diseases (e.g., malaria) which involve extracellular 
pathogens that could be bound or neutralized by antibodies. Thus, understanding the 
link between biomaterial features that are trafficked to particular domains (e.g., SCS, 
B cell follicles) or support specific interactions or microdomain formation (e.g., 
GCs) is an important avenue for future research.  
 
Figure 2.5: Biomaterial vaccines can enhance GC formation and antibody avidity.  
(A) Confocal micrograph showing GC formation in draining LN 2 weeks after subcutaneous injection 
of ICMVs. B cells (red, B220), ICMV (blue), GC (green, GL-7). (B) HA-binding affinity of serum-
derived antibodies from mice immunized with biomaterial vaccine formulations 28 days prior. (C) 28 
days after immunization, draining LNs were excised and stained for GC formation. GC (red, GL-7), B 
cells (blue, B220), IgG (green). Panel (A) adapted with permission [50]. Panels (B) and (C) adapted 
with permission [53]. 
 
Several other approaches using conventional or biomaterials-based vaccines have 
sought to induce GCs by delivery of multiple adjuvants or TLR agonists. The 
Pulendran lab has studied the effect of NPs loaded with multiple TLR agonists in 
individual particles compared with co-loading these signals in the same particle [53]. 
In these studies, GC formation was strongly dependent on the particle loading scheme 




and TLR4 agonist (MPL) or loaded with OVA and TLR7 agonist (R837) increased 
GC formation in the LNs of mice following subcutaneous injection.  Strikingly, mice 
treated with particles loaded with OVA, along with both TLR4 and TLR7 agonists 
exhibited a synergistic increase in GCs that also increased the avidity of antibodies 
(Figure 2.5B, C) [53]. TLR4 and TLR7 pathways detect bacterial polysaccharides 
and viral RNA, respectively. Thus, triggering both of these pathways may enhance B 
cell (TLR4) and T cell (TLR7) activation, as well as generally increase DC functions 
such as antigen presentation and co-stimulation. The effects of this more robust 
activation of immune pathways may help inform the design of future materials that 
contain multiple immune cues.  
 
Recently, vaccines composed of chitosan and heparin have been used to mimic 
specialized molecules called granules [47]. Granules are stable particles secreted by 
specialized immune cells (mast cells) in response to a range of stimuli that can 
include pathogen recognition. These particles contain pro-inflammatory cytokines 
such as TNF-α that promote local inflammation. Following footpad immunization 
with antigen-loaded NPs designed to mimic granules, NPs localized to the SCS in 
LNs of mice and increased the number of GCs. The resulting enhancement to 
antibody-mediated immunity increased the survival of mice during a lethal flu 
challenge. Interestingly, empty particles without cytokines also caused a modest 
increase in GCs [47]. This effect emphasizes the theme that biomaterials can enhance 




controlled release), as well as stimulatory pathways activated by the structural 
features of these materials. 
 
2.4.5 NP vaccines can break tumor tolerance through local changes in tumor-
draining LNs 
The examples highlighted thus far share the aim of generating effective immune 
responses against foreign pathogens. However, another prominent goal of 
biomaterials-based vaccines and immunotherapies is centered on treating cancer. 
Cancer cells and the tumor microenvironment exhibit a number of characteristics that 
hinder the ability of the immune system to fight cancer [71]. Notably, effective 
treatments must generate robust responses against antigens overexpressed on tumors, 
allow efficient homing of immune cells to tumors, maintain the function of tumor-
primed immune cells in the immunosuppressive tumor environment, and generate 
tumor-specific memory cells that quickly destroy nascent tumor cells to prevent 
relapse. This a daunting set of challenges, but combination therapies leveraging 
biomaterials and the immune system offer many features that could help address these 
hurdles. Kwong et al. have created liposomes containing both a PEG/CpG lipid that 
was conjugated via lipid insertion and anti-CD40 antibodies that were added via 
maleimide chemistry. When these materials are injected into solid tumors, the 
liposomes drain to nearby LNs and remain in LN sinuses [72]. This persistence 
causes a local adjuvant effect in LNs for at least 48 hours that allowed for a majority 
of LN-resident APCs (DCs and macrophages) to uptake the particles containing CpG, 




controls. Additionally, while soluble treatments caused a bimodal effect of further 
increasing survival in some mice compared to the liposomes and causing earlier death 
in others, liposomal delivery reduced systemic toxicity by decreasing adverse  side 
effects such as weight loss and inflammatory cytokines (IL-6) in blood [72].  
 
Stephan et al. approached cancer immunotherapy with biomaterials by modifying the 
surface of T cells with liposomes or polymeric NPs loaded with cytokines or 
adjuvants. This approach employed biocompatible thiol chemistry to conjugate these 
materials to cells without altering key T cell functions (e.g., proliferation, antigen 
recognition) [73]. Importantly, tumor specific CD8+ T cells modified with NPs then 
injected into mice maintained the ability to home to tumor cells, carrying particles 
and cargo to these sites. This unique approach allowed efficient delivery of cytokine-
loaded NPs to melanoma tumors and resulted in rapid proliferation of tumor-specific 
CD8+ T cells in LNs. Mechanistically, T cells conjugated with NPs polarized CD8+ T 
cells toward a central memory phenotype which is more effective at breaking tumor 
immunosuppression. Thus, mice treated with these tumor-specific T cells modified 
with NPs eradicated tumors, while untreated mice and mice treated with soluble drugs 
and T cells all succumbed. 
 
Jeanbart et al. recently exploited preferential drainage of 30nm poly(propylene 
sulfide) (PPS) NPs in tumor-draining LNs and distal LNs (i.e., non-draining) for 
cancer therapy [48]. This work revealed that tumor-draining LNs were enlarged 




high levels of PD-L1 and PD-1, respectively. Binding of PD-1 on CD8+ T cells to the 
cognate ligand (PD-L1 on APCs), negatively regulates T cell proliferation and pro-
inflammatory cytokine secretion, leading to suppression of T cell function. This 
suppression supports tumor growth during cancer. In these studies, it was shown that 
while the tumor-draining LN was immunosuppressed, these tissues also contained 
more antigen specific T-cells, likely due to the proximity to the tumor [48]. Building 
on this observation, PPS NPs were conjugated with CpG and mixed with antigen-
loaded NPs, then injected intradermally into the footpads of mice. NPs containing 
CpG and tumor antigen (TRP2) or a model antigen (OVA) were injected in the 
footpad on the same side as tumor induction. This approach resulted in targeting of 
NPs to the tumor draining LN. Mice treated in this manner with NPs containing CpG 
and TRP2 or OVA reduced tumor growth in a melanoma model and in an OVA-
expressing lymphoma model. These improvements also correlated with an increase in 
CD8+ T cells specific for the corresponding antigens. Targeting the tumor-draining 
LN also led to a decrease in the number of immunosuppressive cells (e.g., TREGS) 
compared with mice injected on another limb to target the non-tumor draining LN 
[48]. A related study employed similar NPs co-loaded with CpG and Paclitaxel – a 
powerful chemotherapeutic – to create a multi-functional cancer therapy [49]. 
Together, these studies highlight the impact of local delivery on efficacy, with 
particles reaching tumor-draining LNs providing a significantly improved outcome 
compared with particles targeted to non-draining LNs. As discussed earlier, once NPs 




signals or by controlling the release of antigens, adjuvants, and other signals. Below, 
new direct approaches to achieve LN delivery are discussed. 
 
2.4.6 Intra-lymph node injection allows direct targeting and local engineering of the 
LN environment 
Building on the idea that the kinetics and combinations of immune signals delivered 
to LNs play an integral role in the development of cell-mediated and antibody-
mediated immunity, an intriguing area of fundamental and clinical research has 
focused on direct injection of vaccines to LNs. In humans, intra-LN (i.LN.) injection 
generally involves injection of soluble vaccine components to LNs using ultrasound 
guidance, whereas preclinical studies in mice utilize tracer dyes or surgical 
procedures to access the LN for injection [54, 55, 74, 75]. Several important papers 
from the Kündig lab describe clinical trials demonstrating that i.LN injection can 
safely promote tolerance to allergens while dramatically reducing both the cumulative 
treatment dose and the treatment time [75, 76]. These fundamental discoveries 
support the use of i.LN. delivery as a route for generating potent immune response 
with staggeringly small doses. This approach is particularly attractive for therapeutic 
applications, and has nucleated a number of additional recent and ongoing clinical 
trials for chronic conditions, cancer, and allergies [58, 74, 75, 77-85]. For example, 
patients immunized i.LN. with a vaccine against grass pollen became tolerized after 3 
injections over 8 weeks compared to the 54 injections over 3 years when treated with 
subcutaneous immunization [75]. Strikingly, the overall dose needed to evoke this 




conventional vaccination routes. In a similar study, tolerance to a cat dander allergen 
was achieved after 3 i.LN. injections and this tolerance persisted for more than 300 
days [76]. While i.LN. injection may be  less suited for wide-spread prophylactic 
vaccination due to the need for ultrasound guidance and a trained administrator, this 
is an intriguing idea for therapeutic vaccines and immunotherapies that rely on 
delivery of several vaccine components to LNs. However, many of these approaches 
employ multiple injections, or multiple cycles of injections to increase the frequency 
or duration of exposure to antigen. Thus, coupling i.LN. injection with biomaterials 
could further enhance the performance of new therapeutic vaccines and 
immunotherapies while reducing the dose, number, or frequency of injections. 
 
Along these lines, Mohanan et al. tested the delivery of common particle formulations 
(e.g., liposomes, NPs) along intradermal, intramuscular, subcutaneous, and i.LN. 
routes. The response to particles laden with OVA antigen or OVA and adjuvants was 
then assessed by antibody titers and cytokine secretion across injection routes. 
Formulations injected i.LN. resulted in the highest antigen-specific IgG2a antibody 
titers regardless of whether or not a TLR agonist (CpG, TLR9) was present in 
particles. This approach also increased the secretion of INF-γ from splenocytes in the 
presence and absence of adjuvants [86]. 
 
Jewell et al. developed a non-surgical route for enhancing cell-mediated and 
antibody-mediated immunity by i.LN. injection with lipid-stabilized polymer particles 




TLR3 agonist poly(inosinic:cytidylic acid) (PolyIC) were injected with OVA antigen 
into the muscle or into the inguinal LNs of mice (Figure 2.6A). MP formulations 
were retained in the LN as ‘depots’ for at least 4 days, while soluble vaccine 
formulations were quickly cleared. The increased retention of MPs also controlled 
release and drove accumulation of PolyIC within the LN and in LN-resident APCs, 
resulting in more enduring activation of DCs (Figure 2.6B) [54]. These effects 
potently expanded antigen-specific CD8+ T cells circulating in blood one week after 
receiving a single i.LN. injection, an effect that was not observed with soluble vaccine 
formulations (Figure 2.6C). Mice immunized with MPs also developed strong 
antibody responses (Figure 2.6D), demonstrating promotion of both cell-mediated 
and antibody-mediated immune responses. CD8+ T cells from MP-immunized mice 
also exhibited larger, more robust cytokine secretion, and all of these trends persisted 
for at least 6 weeks without boosting. Interestingly, NPs also increased the number of 
antigen-specific CD8+ T cells and the level of cytokines secreted from these cells 
compared with soluble vaccines, but at levels lower than those observed in mice 
vaccinated with MPs [54]. This effect was a function of vaccine retention in LNs, 
with NPs exhibiting a retention time intermediate between the quick-draining soluble 
formulations and the well-retained MP vaccine depots. Thus, delivery of controlled 
release depots in LNs mimics the accumulating dosing schemes discussed earlier 
(Fig. 2.3A) for soluble vaccines and with i.LN. clinical trials, but with fewer or less 
frequent injections [58]. Such approaches could also help ensure that each component 







Figure 2.6: MP depots promote cell-mediated and antibody-mediated immunity after i.LN. 
injection.  
(A) Representative image of inguinal LN following i.LN. injection of fluorescent MPs. B cells (blue, 
B220), T cells (red, CD3), MPs (green). (B) PolyIC signal measured in vivo (top) and histological 
sections of excised LNs (bottom) showing PolyIC signal 24 hours and 96 hours after i.LN. injection. 
(C) OVA-tetramer staining showing percent of blood CD8+ cells specific to OVA 7 days after 
intramuscular or i.LN. injections. (D) OVA-specific IgG serum titers after intramuscular and i.LN. 
immunization with soluble or MP formulations. Adapted with permission [54]. 
 
2.5 Biomaterials can alter LN function to promote immune tolerance 
The examples discussed thus far have used biomaterials to promote stimulatory or 
inflammatory immune responses for vaccination against pathogens or cancer. 
However, in the past few years, enormous progress has been made in harnessing 
biomaterials to regulate dysfunctional or unwanted immune reactions. Many of these 
detrimental reactions occur in autoimmune diseases such as multiple sclerosis, 




and organ transplants. In multiple sclerosis for example, myelin – the protein that 
insulates neurons in the central nervous system (CNS) – is incorrectly recognized as 
foreign by lymphocytes and antibodies [87-89]. This recognition leads to infiltration 
of these cells and molecules into the CNS, resulting in inflammation and destruction 
of myelin, and ultimately, neurologic decline. As with the generation of immunity 
against foreign antigens in healthy individuals, T cells and antibody-producing B cells 
recognizing self-antigens are also expanded in LNs by APCs presenting these self-
molecules. Thus, biomaterials have recently been applied to autoimmunity to stop 
these reactions by destroying (deletion) or inactivating (anergy) pathogenic cells, or 
by expanding specialized regulatory T cells (TREGS) which are able to suppress 
lymphocytes reactive against self-molecules such as myelin. Broadly speaking, these 
regulatory mechanisms all contribute to immune “tolerance”, a state in which the 
immune system does not attack, or no longer attacks, a particular peptide, protein, or 
cell type. One of the greatest challenges facing new therapies for autoimmunity is the 
induction of self-antigen specific tolerance that prevents harmful self-reactions 
without impairing the rest of the immune system. This side effect is a persistent 
problem with many of the drugs currently used to treat patients with autoimmune 
disorders: lifelong treatment regimens with broad immunosuppressants are vital to 
manage disease, but cause patients to be immunocompromised. In this section, we 
will highlight some of the ways in which the interactions between biomaterials and 
LNs or LN-resident cells are being harnessed to promote tolerance. While the 
discussion below is focused on the connection between biomaterials and LNs to 




opportunities to apply biomaterials to autoimmune diseases and tolerance [15, 17, 
90]. 
 
2.5.1 Particles can carry regulatory signals to LNs to alter the interactions of APCs 
and lymphocytes 
One of the most fundamental ways in which biomaterials can be harnessed to 
promote tolerance is as a carrier of drugs or other immune signals to LNs or other 
immunological sites [57, 61, 62, 91-97]. In LNs, these cargos can influence the 
interactions and functions of LN-resident cells, in similar ways to those exploited to 
promote stimulatory responses or immunity. PLGA NPs for example have been 
loaded with mycophenolic acid (MPA), an immunosuppressant used in transplants 
[57]. Systemic injection of these particles resulted in drainage to the spleen and LNs, 
where particles were preferentially taken up my macrophages and DCs. During 
transplant studies, APCs in the LNs of mice treated with particles exhibited elevated 
levels of PD-L1 (inhibitory ligand) that limited the ability of APCs to prime T cells 
reactive against antigens expressed on the tissue grafts. Thus, MPA-loaded particles 
draining to LNs delivered signals that impaired the ability of APCs to expand 
graft/self-reactive T cells, resulting in tolerance that improved graft survival [57]. 
 
The ability of biomaterials to co-deliver multiple cargos has also been exploited to 
regulate the function of APCs in LNs. In these studies, liposomes were loaded with a 
self-antigen that is recognized as foreign in mouse models of arthritis, along with a 




that is over-expressed in many chronic inflammatory diseases (i.e., arthritis) [61]. 
Uptake of liposomes by LN-resident APCs reduced NF-κβ levels and the 
proliferation of self-reactive T cells, leading to reduced severity of arthritis. These 
effects were achieved in part through the expansion of TREGS in mice treated with the 
liposomes [61]. Importantly, the TREGS generated in this study were specific for the 
self-antigens included in the liposomes, emphasizing the goal stated earlier: inducing 
tolerance against specific self-antigens, without broad suppression of normal immune 
functions.  
 
One intriguing approach being developed to promote antigen-specific tolerance is 
based on design of NPs decorated with complexes of self-antigen loaded in MHC 
molecules [62]. As discussed earlier, MHCs are the complexes APCs load antigens 
into for presentation to lymphocytes, along with costimulatory signals. Presentation 
of antigen in MHCs without co-stimulation can cause T cells to become inactive or 
promote regulatory functions. In this study, iron oxide NPs were functionalized with 
complexes of MHC and self-antigens associated with disease in type 1 diabetes 
(T1D), without co-stimulatory signals [62]. Treatment of prediabetic or diabetic mice 
with NPs resulted in expansion of a pool of low avidity (i.e., weakly binding) 
regulatory T cells in and around LNs near the pancreas – the organ destroyed by self-
reactive immune cells in diabetes. These cells suppressed antigen presentation by 
APCs in these LNs, as well as exhibited direct APC killing in the pancreatic LNs 
(PLN) compared with LNs remote from the pancreas (MLN) (Figure 2.7A) [62]. The 




cells that otherwise could have migrated to and attacked the pancreas. The effects of 
this treatment were striking, maintaining and restoring control of blood glucose in 
mouse models of T1D when mice were treated with MHC/NP complexes loaded with 
T1D antigens, but not when mice were treated with MHC/NP complexes loaded with 
irrelevant antigens or following injection of soluble T1D antigens (Figure 2.7B) [62]. 
Thus, the examples in this section underscore the potential of NPs to deliver drugs 
and immune signals to alter the interactions of APCs and lymphocytes in LNs during 
inflammation and autoimmunity.  
 
Figure 2.7: NPs decorated with self-antigen loaded MHC induce DC death and regulate diabetes.  
(A) NPs decorated with MHC molecules specific to T1D are able to reduce the ratio of CD11c+ DCs in 
the pancreatic LN (PLN) to distal LNs such as the mesenteric LN (MLN) compared to peptide MHC 
NPs loaded with an irrelevant antigen control. (B) Mice with T1D treated with NPs conjugated with 
MHC/diabetes antigen complexes maintain normal blood glucose levels compared to treatments with 
soluble peptide or peptide MHC complexes loaded with irrelevant antigens. Adapted with permission 
[62]. 
 
2.5.2 Association of cargo with biomaterials can alter antigen trafficking to promote 
tolerance 
Another set of approaches recently harnessed to generate tolerance with biomaterials 
exploits the differences in the mechanisms by which soluble and particulate antigens 
are trafficked in LNs and spleens. Whereas relatively low molecular weight soluble 




macrophages and other APCs in the SCS engulf and process larger particles to 
support presentation of antigenic fragments from these materials. These differences 
have been exploited to promote antigen-specific tolerance by conjugating 500nm 
polystyrene beads (PSB) or PLGA particles with a myelin peptide (MYE) – the self-
antigen attacked by the immune system in MS [63, 98]. Following i.v. injection, 
antigen-conjugated particles drained to the spleen and were localized to macrophages 
expressing the scavenger receptor MARCO, whereas free antigen was not (Figure 
2.8A, B) [63]. The MARCO receptor plays an important role in clearing apoptotic 
cell debris – processes that normally occur without inflammation. Thus PSB-MYE 
may support presentation of MYE peptide to APCs in a manner that promotes 
tolerance (e.g., without co-stimulation). This idea was supported by studies 
demonstrating that antigen-specific cells in LNs of treated mice exhibited reduced 
proliferation when challenged with antigen. Treatment with PSB-MYE formulations 
also effectively treated progressive and recurring models of MS in mice, while 
treatment with PSBs decorated with irrelevant antigen (PSB-OVA) did not (Figure 
2.8C). These findings illustrate the antigen-specific nature of tolerance in this system. 
Mechanistically, this efficacy resulted from increased TREG function, along with 
reductions in activity of inflammatory T cells (e.g., through anergy/inactivation) [63]. 
These suppressive effects resulted in reduced lymphocyte infiltration to the CNS and 





Figure 2.8: Particles targeting the MARCO receptor induce tolerance against a mouse model of 
multiple sclerosis.  
(A) Immunohistochemical staining of spleens following intravenous injection of polystyrene particles 
conjugated with a myelin peptide (PSB-MYE, green)  showing co-localization of particles with 
MARCO (red) (B) Immunohistochemical staining as in (A) of spleen after treatment without 
polystyrene particles (No PSB). (C) Disease severity following immunization with PSB-MYE or 
polystyrene particles conjugated with an irrelevant peptide (PSB-OVA) showing that antigen-
specificity is necessary for treatment. Adapted with permission [63]. 
 
Approaches related to the PSB strategies have also been applied to other targets 
including transplantation and inflammatory diseases including colitis, peritonitis, and 
myocardial infarction [99, 100]. Of note are studies with inflammatory models using 
particles exhibiting controlled surface charges but lacking specific antigens. These 
studies have revealed that inflammatory monocytes engulf negatively-charged 
particles and migrate to the spleen instead of inflammation sites, resulting in 
apoptosis of these cells and reduced inflammation. Interestingly, neutral particles did 
not support these therapeutic effects [99]. Thus, this strategy could provide a general, 
non-antigen specific route for reducing inflammation, and further underscores the role 
of physicochemical properties in determining the types of immune responses 
biomaterials elicit. Along these same lines, Broere and colleagues have shown that 
the response to antigen encapsulated in polymers with different carrier structures 
alters how LN-resident APCs present and interact with helper T cells in LNs [56, 59]. 
In particular, PLGA NPs and TMC-TPP (N-trimethyl chitosan-tri-polyphosphate) 




PLGA promoted regulatory function and reduced hypersensitivity reactions while 
TMC-TPP stimulated antibody responses. Although the mechanisms of these 
differences are under investigation, potential contributing factors may include size 
(which could alter how antigen is trafficked in LNs) or the duration over which these 
particles release antigen [56]. 
 
In addition to solid polymer particles encapsulating or displaying antigen, 
electrostatically-driven condensation of immune signals such as bacterial DNA 
affects how these components are trafficked within LNs. An approach based on this 
idea recently revealed that particles formed from bacterial DNA and 
poly(ethyleneimine) (PEI), a cationic polymer, were rapidly trafficked to the 
follicular and marginal zones of LNs and the spleen. These complexes stimulated 
enzyme pathways that promoted DCs and T cells with regulatory characteristics, 
effects not observed when either PEI or bacterial DNA was administered alone [64]. 
Together the examples highlighted in this subsection illustrate the potential of 
designing specific structures or chemistries into biomaterials that can help actively 
direct how NPs and cargos are trafficked in LNs, as well as to alter the interactions 
between LN-resident APCs and lymphocytes. 
   
2.5.3 Biomaterials can be used to directly modify cells to exploit regulatory immune 
pathways  
In addition to using particles to transport drugs to LNs, or change how antigens are 




red blood cells with NPs to promote tolerance or regulate immune response. One 
group used nanoprecipitation to prepare particles from PEG and poly(lactide) (PLA) 
conjugated with an immunosuppressant (cyclosporine A, CsA) [65, 66]. CsA-loaded 
particles were phagocytized by DCs incubated with these carriers in vitro, and 
subsequent injection of these DCs into mice resulted in drainage of the particle-
loaded DCs to LNs. These cells locally reduced the number and proliferative capacity 
of effector T cells in LNs. Other approaches have focused on modification of T cells 
with, for example, NPs decorated with antibodies specific for the CD4+ molecules 
expressed on helper T cells [60]. These particles were loaded with leukemia 
inhibitory factor (LIF) – a cytokine that can promote the development of TREGS – then 
incubated with donor-reactive cells from the spleens of mice. CD4-targeted LIF-NPs 
bound CD4+ T cells in vitro and transfusion of these cells significantly increased the 
percentage of TREGS in LNs over 5 days. Thus, modifying T cells with regulatory 
immune signals can serve as a route to deliver cues to LNs that alter how T cells 
develop during antigen presentation. This goal of controlling T cell differentiation 
shares similarities with the work of Stephan, et al., though their approach aimed to 
generate immunostimulatory responses for cancer therapy by modifying T cells, as 
discussed earlier [73]. 
 
Significant fractions of erythrocytes (i.e., red blood cells) are rapidly produced and 
destroyed on a daily basis in healthy individuals. In these cases, cell destruction 
occurs through a non-pathogenic mechanism of cell death, apoptosis [101]. This 




owing to natural regulatory mechanisms that clear self-antigens without co-
stimulation, or due to activation of suppressive pathways triggered by apoptotic cell 
debris. This natural tolerance pathway has recently been exploited to generate 
antigen-specific tolerance against model antigens in disease models of T1D [102]. To 
conduct these studies, a target antigen (OVA) was conjugated to a peptide (ERY1) 
that binds glycophorin-A molecules (GYPA) expressed on the surface of erythrocytes 
(Figure 2.9A). Ex vivo incubation of ERY1-OVA with mouse erythrocytes resulted 
in efficient labeling of these cells with the target antigen (Figure 2.9B, bottom), 
whereas incubation of un-modified OVA with red blood cells did not result in cell 
labeling (Figure 2.9B, top). Intravenous injection of cargo-modified ERY1 (e.g., 
OVA, fluorescent dye) quickly labeled circulating erythrocytes and led to increased 
trafficking to the spleen and uptake by resident APCs. Mice treated with ERY1-OVA 
after injection of OVA-responsive transgenic T cells exhibited reduced proliferation 
of these cells in LNs and in the secretion of inflammatory cytokines (e.g., IFNγ) 
(Figure 2.9C). This idea was also exploited to protect mice from T1D by stimulating 
proliferation and rapid deletion of self-reactive CD4+ T cells in LNs when mice were 
treated with ERY1 conjugated to T1D antigens, but not when soluble T1D antigens 
were administered. Together, these approaches demonstrate that a diverse set of cell 
modification approaches can alter how APCs and T cells function, as well as harness 
natural apoptotic clearance and tolerance mechanisms to regulate or redirect 





Figure 2.9: Erythrocyte decorating with NPs leads to immune tolerance.  
(A) Graphic depicting the conjugation of OVA-NPs to the surface of erythrocytes via ERY1 binding of 
glycophorin-A. (B) Confocal images showing an erythrocyte treated with soluble OVA (top) and with 
OVA-NP (bottom). OVA (red) is colocalized with glycophorin-A (GYPA, green). (C) Percentage of 
antigen-specific CD8+ T cells within the draining LN 4 days after immunization with erythrocytes 
labeled with OVA-NPs (ERY1-OVA) or soluble OVA. Adapted with permission [102]. 
 
2.6 Conclusions and looking forward  
Biomaterials have already demonstrated great potential in the field of immunology. In 
coming years, continuing to improve our understanding of how material properties 
impact molecular signaling will remain an important issue, as this knowledge will 
lead to more rational design of vaccines. Employing biomaterials as tools to study 
new fundamental questions will also provide new opportunities to inform vaccine and 
immunotherapy design. An exciting avenue of research centers on engineering 
biomaterials with specific properties that allow for precise interactions with LNs and 
LN-resident cell populations that effectively modify the structure of these tissues. 
Some of these questions may also focus on understanding how the kinetics and 
combinations of immune signals in LNs impact stromal function (e.g., FRC network, 
laminins), and if these changes can be induced or exploited to direct immunity. 




that could locally recapitulate the functions of these tissues, perhaps eliminating the 
targeting challenges facing many vaccines and treatments. Biomaterials offer unique 
opportunities to address each of these areas, and the answers to these questions will 
continue to push the forefront of what may become possible in modulating immune 
function.   
 
In Chapter 3, a common, biodegradable polymer system is used to investigate 
intrinsic immunogenicity. The form of the polymer (soluble or particulate) as well as 
other physicochemical properties are explored to determine which features of 
biomaterials most influence their intrinsic ability to activate the immune system. In 
particular, these studies focus on how immunogenicity evolves over time, as materials 









Chapter 3: Intrinsic immunogenicity of rapidly-degradable 
polymers evolves during degradation2 
 
3.1 Introduction 
Biomaterials have become important components in many emerging vaccine and 
immunotherapy strategies. These materials provide cargo protection, controlled 
release of antigens or immune signals, and targeting of immune cells and secondary 
lymphoid organs such as lymph nodes (LNs) – key tissues that help coordinate 
immune function [103-105]. Intriguingly, as mentioned in Chapter 2, several recent 
studies demonstrate that poly(lactic-co-glycolic acid) (PLGA), polystyrene, chitosan, 
and other polymers ubiquitous in the biomedical field exhibit intrinsic 
immunostimulatory properties, even in the absence of antigens, adjuvants, or other 
immune signals [9, 45, 103, 106-109]. Pattern recognition receptors (PRRs) of the 
innate immune system have the ability to recognize pathogen-associated and danger-
associated patterns through Toll-like receptor (TLR) and inflammasome pathways 
(e.g., nucleotide-binding oligomerization domain-like receptors, Rig-like helicases) 
[110]. These pathways drive pro-inflammatory caspases and cytokines that many 
polymers such as PLGA or polystyrene are able to activate. For example, when 
dendritic cells (DCs) are treated with PLGA or non-degradable polystyrene particles 
and a TLR agonist (TLRa), these particles cause an increase in expression of surface 
________________________________________________ 
2Adapted from J.I. Andorko, K.L. Hess, K.G. Pineault, and C.M. Jewell. “Intrinsic immunogenicity 




activation markers (e.g., CD40, CD80, CD86) [9, 45, 109]. Many of these important 
polymers also increase inflammatory cytokines such as IL-1β, a key mediator of the 
inflammasome that supports early immune responses [9, 45, 110]. Several studies 
have investigated the link between these types of inflammatory/immunostimulatory 
processes and physicochemical polymer properties such as molecular weight 
(MW),[107, 111-114] particle size,[108, 115-117] charge,[118, 119] 
hydrophobicity,[120] shape,[41, 121, 122] and chemical functionality [123-128]. 
These studies confirm polymer properties can modulate immune function. 
Developing a better understanding of these phenomena and how immunogenicity 
evolves during degradation could support rational design of polymers that serve not 
only as carriers but also as agents that help direct or tune immune response.  
 
The mechanistic studies above have focused on non-degradable or slowly-degrading 
polymers such as polystyrene and PLGA, respectively. However, vaccines which 
allow for tunable, rapid delivery of antigens, adjuvants, or other small molecules offer 
new potential for modulating the development of specific immune characteristics, for 
example, by rapidly releasing immune-polarizing drugs during DC activation or T 
cell expansion. Poly(beta-amino esters) (PBAEs) are cationic, pH-sensitive polymers 
that degrade over hours to days depending on polymer structure [129, 130]. PBAEs 
have been used in drug delivery, for DNA and RNA delivery, and as vaccine carriers 
[131-141]. In the latter case, PBAEs are have been used for DNA vaccination through 
condensation of nucleic acids encoding plasmid antigens to promote T cell mediated 




preferentially target glioblastoma, [142-148]. Although PBAEs are becoming 
increasingly useful in vaccination and immunotherapy, little is known about if and 
how these materials elicit intrinsic immunostimulatory or inflammatory effects, and 
how the rapid degradation of PBAEs or other materials changes the intrinsic 
immunogenic properties in cells or tissues.  
  
We hypothesized that PBAEs would exhibit intrinsic immunostimulatory effects that 
change as a function of polymer form (i.e., free, particles) and the extent of polymer 
degradation (MW). To test this idea, a prototypical PBAE, Poly 1, was synthesized 
from a four-carbon diacrylate monomer. The ability of this material to activate DCs 
and T cells in co-culture was then assessed (Figure 3.1). Free Poly1 did not activate 
DCs or drive synergistic responses during co-treatment with a TLRa. Since the 
immune system has evolved to detect particulate materials and pathogens, we tested if 
the properties of PBAE particles change during degradation and if these effects 
impact intrinsic immunostimulatory function. In contrast to free polymer, particles 
formed from intact Poly1 using electrostatic condensation to mimic a common 
vaccine formulation method exhibited significant intrinsic immunostimulatory 
function that decreased with the extent of polymer degradation. These changes 
corresponded to changing physicochemical properties including increasingly negative 
particle charges, increased particle diameter, and decreased particle concentration. 
Mechanistic studies using particles assembled from Poly1 fragments with distinct 
MWs confirmed this trend, revealing that Poly1 differentially activates immune cells 




(i.e., degree of degradation). These studies confirm the intrinsic immunogenicity of 
PBAEs and provide insight into how the evolving properties of degradable polymers 
drive immunogenicity in ways that could support design of new vaccine carriers able 
to adjuvant or modulate immune function. 
 
Figure 3.1: Schematic depicting the approach to investigate the intrinsic immunogenicity of 
Poly1, a degradable, cationic PBAE.  
DCs and T cells are treated with free Poly1 or one of two Poly1 particle formulations: i) particles 
formed from intact Poly1 then degraded to mimic a common vaccine formulation strategy, or ii) Pools 
of Poly1 degradation fragments with distinct MWs formed into particles to mechanistically study the 
link between PBAE properties (e.g., MW, physical form) and DC activation, antigen presentation, and 





3.2 Materials and Methods 
3.2.1 Materials 
Monomers for polymer synthesis (1,4-butanediol diacrylate and 4,4′-
trimethylenedipiperidine) were purchased from Alfa Aesar and Sigma-Aldrich, 
respectively. Tetrahydrofuran (THF), diethyl ether, sodium acetate (SA) buffer, 
poly(sodium 4-styrenesulfonate) (SPS), and lipopolysaccharide from Escherichia coli 
0111:B4 (LPS) were also purchased from Sigma-Aldrich. THF used in GPC studies 
was purchased from Macron Fine Chemicals. Agilent LS EASICAL PS-1 polystyrene 
GPC standards were from Fisher Scientific. Deuterated-chloroform (CDCl3) was 
bought from Cambridge Isotope Laboratories. RPMI-1640 media was purchased from 
Lonza. Fetal bovine serum (FBS) was supplied by Corning. Low MW polyinosinic-
polycytidylic acid (PolyIC) was purchased from Invivogen. CD11c microbeads were 
purchased from Miltenyi Biotec. Spleen Dissociation Medium and CD4 negative 
selection kits were from STEMCELL Technologies. Carboxylate-functionalized and 
amine-functionalized polystyrene particles were purchased from Polysciences and 
Spherotech, Inc.. Brefeldin A and fluorescent antibody conjugates were purchased 
from BD or eBioscience. 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester 
(CFSE) was purchased from Sigma-Aldrich. 40 µm cell strainers were from VWR. 
3.2.2 Cells and Animals 
Female C57BL6 mice (4-8 weeks, stock #000664) and male C57BL/6-
Tg(Tcra2D2,Tcrb2D2)1Kuch/J (2D2) mice (10-12 weeks, stock #006912) were from 




myelin oligodendrocyte glycoprotein, residues 35-55 (MOG35-55). All animals were 
cared for in compliance with Federal, State, and local guidelines, and using protocols 
reviewed and approved by the University of Maryland's Institutional Animal Care and 
Use Committee (IACUC). 
 
3.2.3 Poly1 synthesis, degradation, and characterization 
Poly1 was synthesized via a Michael-type addition reaction as described previously 
[129, 130, 132]. Briefly, 9 mmol of 4,4′-trimethylenedipiperidine was dissolved in 
anhydrous THF to form a 500 mg mL-1 solution. This solution was added to 9 mmol 
of 1,4-butanediol diacrylate and the reaction was heated to 50°C and stirred for 16 
hours. The reaction was cooled to room temperature and the resulting polymer was 
precipitated in vigorously stirred ice cold diethyl ether. After collecting the polymer 
and washing with additional diethyl ether, the polymer was lyophilized. A 16 mg mL-
1 solution of Poly1 was prepared in CDCl3 and 1H NMR was used to confirm the 
structure. Poly1 was dissolved in THF at 2.5 mg mL-1 and a THF-based gel 
permeation chromatography (GPC) system (Waters) was used to determine polymer 
MW compared to polystyrene standards. For degradation studies, Poly1 was placed in 
either pH 7 buffer (1x PBS) or pH 5 buffer (100 mM SA) and incubated at 37°C for 
increasing intervals to form polymer fragments. Following incubation, the degraded 





3.2.4 Poly1 particle formation and characterization 
Poly1 particles were assembled from either intact polymer then degraded, or 
assembled from polymer fragments with distinct MWs formed by degradation prior to 
particle assembly. For the former studies, intact Poly1 was used to prepare particles 
via electrostatic condensation by mixing 5 mM Poly1 and 20 mM SPS at a SPS:Poly1 
w/w ratio of 1:1.6. These particles were then incubated at 37°C for specific intervals 
to determine how degradation of particles influences the intrinsic immune activity. 
For mechanistic studies involving pre-degraded polymer, Poly1 was degraded in pH 5 
buffer for specific intervals to form fractions with distinct MW fragments of Poly1, 
then mixed with SPS as above to prepare particles. For each particle preparation, 400 
µg of 5 mM Poly1 was used to form particles with SPS in pH 5 water while 
maintaining a fixed overall volume. Thus the amount of polymer (Poly1, SPS) was 
constant in either case, irrespective of whether particles were formed from intact 
Poly1 then degraded, or assembled from Poly1 fragments. GPC, as above, was used 
to quantify the extent of degradation for Poly1 particles formed then degraded. Laser 
diffraction (Horiba LA950) was used to determine the diameter of the particles. Zeta 
potential was determined using a Malvern Zetasizer Nano ZS90.  
3.2.5 DC activation, antigen presentation, and flow cytometry 
Primary CD11c+ DCs were isolated from spleens of C57BL6 mice via positive 
selection using the recommended protocols for Spleen Dissociation Medium 
(STEMCELL) and CD11c Microbeads (Miltenyi). Isolated DCs were plated at 
100,000 cells per well in a 96 well plate and cultured at 37°C, 5% CO2. DCs were 




non-essential amino acids, 10 mM HEPES buffer, 1x penicillin and streptomycin, and 
55 μM β-mercaptoethanol. For DC activation studies, DCs were treated with either 
buffer (“vehicle”), 10 µg mL-1 of TLR3a (PolyIC), 1 µg mL-1 of TLR4a (LPS), 400 
ng of Poly1 in free form or in one of two particle formulations: i) particles assembled 
from intact Poly1 incubated to form degraded fractions from each time point, or ii) 
particles assembled from each molecule weight fraction of degraded polymer. A 
subset of these formulations was also studied in combination with the TLRa 
treatments, as indicated. For all DC studies, 48 hours after treatment, cells were 
stained for viability (DAPI) and for surface activation markers (i.e., CD40, CD80, 
CD86, and Major Histocompatibility Complex II (MHCII)) using fluorescent 
antibodies conjugates. Cells were examined by flow cytometry (BD CantoII) and data 
were analyzed using FlowJo v. 10 (TreeStar). For antigen presentation assays, DCs 
were co-incubated with 1 µg of a model antigen (SIINFEKL) in soluble form and 
each of the polymer formulations indicated and hypothesized to exhibit an adjuvant 
effect. After 48 hours, cells were stained with an antibody specific to SIINFEKL 
presented via MHCI (H-2Kb) then analyzed by flow cytometry to determine the 
percentage of DCs processing and presenting SIINFEKL in MHCI.  
 
3.2.6 DC/T cell co-culture and T cell proliferation 
For studies involving DC and T cell co-cultures, primary DCs (CD11c+) were isolated 
from C57BL6 mice as above, and then treated with Poly1 in free or particle form. A 
sub-optimal dose (0.05 µg in 10 µL) of a model antigen (MOG35-55) in soluble form 




After 48 hours in culture, CD4+ T cells were isolated from the spleens of 2D2 mice 
using the manufacturer’s recommended protocol (STEMCELL). Following isolation, 
T cells were labeled with CFSE by adding 50 µM of CFSE (in media) per mL of 
cells, incubated for 5 minutes at room temperature, and then washed twice with 10 
volumes of media. 300,000 CFSE-labeled CD4+ 2D2 T cells were added to each well 
containing DCs, then incubated for 72 hours with 50% media replacement every 24 
hours. After incubation, cells were collected, and stained with DAPI and antibodies 
specific to the T cell surface markers (i.e., CD3e, CD4).  Flow cytometry was used to 
determine the extent of T cell proliferation via CFSE dilution, with cells gated beyond 
the second generation selected as a criterion for proliferated cells. 
 
3.2.7 Statistical Analysis 
One way ANOVA with a Tukey post-test was performed using Graphpad Prism 




3.3.1 Poly1 degrades to form low MW fragments 
Poly1 was synthesized and the reaction product was confirmed via NMR after 16 hrs 
of synthesis (Figure 3.2A). Poly1, with a MW of 3.8kDa (Figure 3.2B), was then 
dissolved in pH 5 buffer. The MW of Poly1 decreased to 39.9% (~1.5kDA) of the 




(Figure 3.2B,C). This degradation rate corresponded to a half-life of ~17.7 hours and 
as previously reported [129], degrades to form byproducts of 1,4 butanediol and 
bis(β-amino acid). The intrinsic immunogenicity as polymers degrade to fragments 
was then studied in culture and in mice using Poly1 in different forms (i.e., free, 
particles) and at different extents of degradation (i.e., MWs). 
 
Figure 3.2: Poly1 synthesis, characterization, and degradation to low MW polymer chains over 
one week in buffer.  
(A) 1H NMR shifts of Poly1 integrated with respect to deuterated chloroform including chemical shift 
definitions. (B) GPC chromatograph depicting the change in MW of Poly1 after degradation in pH 5 
buffer (100mM SA). Increased elution time correlates to lower MW fragments. (C) Poly1 MW 
changes after incubation in pH 5 and pH 7 (1x PBS) buffers. Data are relative to polystyrene standards 
and pooled from three independent experiments for each incubation time. Error bars represent SEM. 
 
3.3.2 Poly1 in free form does not activate DCs 
DCs were incubated with Poly1 degradation fragments that were 100%, 88%, 40%, 
20%, or 8% of the starting MW. These fragments were used to treat primary DCs in 
the absence of antigen or adjuvants. Following treatment, common DC activation 




antigen to T cells, CD80 (B7-1) and CD86 (B7-2) which are costimulatory markers 
that need to be co-expressed with MHC complexes in order for proper T cell 
activation, and CD40, a membrane protein also expressed on DCs when activated that 
has links to both humoral and cell-mediated lymphocyte activation [149-152].  
Compared with control cells treated with buffer (Figure 3.3, “vehicle”), free Poly1 
(Figure 3.3, blue) did not increase characteristic DC activation markers including 
CD40 (Figure 3.3A), CD80 (Figure 3.3B), CD86 (Figure 3.3C), and MHCII 
(Figure 3.3D). To test if free Poly1 mediated a synergistic effect on DC activation in 
the presence of other adjuvants, DCs were co-cultured with Poly1 fragments and a 
TLR3a (PolyIC, Figure 3.3, red) or a TLR4a (LPS, Figure 3.3, green). DCs treated 
with PolyIC or LPS were strongly activated, but DCs treated with both Poly1 and 
either TLRa did not exhibit any further increases in activation. These data indicate 
that Poly1 in free form does not exhibit strong intrinsic immunogenicity or cause 





Figure 3.3: Free Poly1 does not activate DCs.  
Expression levels of (A) CD40, (B) CD80, (C) CD86, or (D) MHCII on primary CD11c+ DCs treated 
with free Poly1 degradation fragments of varying MW. Cells were incubated for 48 hours with the 
indicated Poly1 fragments in the absence (blue) or presence of a TLR3a (PolyIC, red) or TLR4a (LPS, 
green), respectively. Expression levels are indicated among DAPI- cells and are representative of three 
similar experiments with samples conducted in triplicate with error bars depicting SEM.  
 
3.3.3 Particles assembled from intact Poly1 exhibit the greatest levels of intrinsic 
immunogenicity at early stages of degradation 
We hypothesized that the form of polymer in solution may impact the intrinsic 
immune characteristics of Poly1 by altering the ability of APCs to detect, internalize, 
and process Poly1. To test this idea in a well-controlled manner, particles were 
formed by electrostatic condensation of Poly1 with a stable polyanion (SPS). This 




whereby antigen-encoding plasmid is condensed by PBAEs or other cationic 
polymers or lipids. These particles were then incubated in buffer at 37°C. GPC results 
confirmed that over time, Poly1 in the particles continued to degrade, leading to a 
reduction in MW and a lower particle concentration that resulted in increased optical 
transmittance (Figure 3.4). During this process, particle size increased, while zeta 
potential – which was initially positive (~15 mV) – decreased (Figure 3.5A,B).  
Further, the number of particles decreased to undetectable levels as degradation 
progressed (Figure 3.4C, 3.5A). Particle size measurements (volume basis, Figure 
3.6A) and image analysis (Figure 3.6C) at each stage of degradation revealed that the 
decreased particle concentration was due not only to degradation, but also from 
aggregation of individual particles into larger, but fewer, agglomerates. After 
confirming SPS had no effect on cell viability (Figure 3.7), we screened the 
immunogenicity of the Poly1 particles by treating DCs with particles at each stage of 
degradation. While SPS at the concentration used was non-immunogenic, Poly1 
particles at early stages of degradation strongly activated DCs (Figure 3.5C-F). This 
activation then waned as a function of increasing particle degradation time and 
decreasing MW (Figure 3.5C-F). These effects were most evident in CD86 and 
CD80 expression – markers associated with co-stimulation. Thus, particles formed 
from Poly1 exhibit intrinsic immunogenicity, and these effects vary as a function of 
polymer degradation which alters the physicochemical properties of these particles. 
Building on this discovery, we designed a series of experiments to examine how the 
extent of polymer degradation influences particle properties and immune function in 





Figure 3.4: Poly 1 particles degraded for specific intervals following formation exhibit a rapid 
drop in MW that decreased particle concentration.  
(A) GPC chromatograph depicting the change in MW of Poly1 particles after degradation in pH 5 
buffer (100mM SA). Increased elution time correlates to lower MW fragments. (B) The peak 
corresponding to the MW distribution of Poly1 changes as particles degrade in pH 5 buffer. (C) 
Particle concentration and transmittance of Poly1 particles formed by condensing intact Poly1 prior to 
degradation alters over the extent of degradation.  
 
 
Figure 3.5: Pre-formed particles exhibit intrinsic characteristics that activate DCs during early 
stages of particle degradation.  
(A) Particle size and (B) zeta potential shift as a function of degradation time. “Too dilute” designates 
formulations for which size measurements could not be reliably obtained due to insufficient particle 
concentration at long degradation times. Expression of (C) CD86, (D) CD80, (E) CD40, or (F) MHCII 
after treatment of CD11c+ DCs with 400 ng of Poly1 particles at varying extents of degradation.  Data 
correspond to samples prepared in triplicate with error bars representing SEM. For panel B, error bars 






Figure 3.6: Degrading Poly1 particles result in large particle size due to aggregation.  
Average particle diameter by volume of Poly1 particles formed then degraded (A) or formed using pre-
degraded Poly1 (B) increases with extent of degradation. ‘Too dilute’ designates particle formulations 
that when measuring size did not result in a reliable reading due to insufficient particle concentration. 
Microscope images of Poly1 particles formed then degraded (C) or formed using pre-degraded Poly1 






Figure 3.7: Poly1 does not influence DC viability.  
SPS or Poly1 in free and particle form did not influence DC viability 48 hours after treatment. Data are 
representative of three similar experiments with samples prepared in triplicate. Error bars represent 
SEM. 
 
3.3.4 Immunogenicity of particles assembled from Poly1 fragments depends on the 
extent of degradation 
To more directly isolate the role of MW in defining the intrinsic immunogenicity of 
PBAEs, we used Poly1 fragments with distinct MWs as in Figure 3.2 to form 
particles through condensation with SPS. As observed with particles degraded after 
formation (Figure 3.4C), the concentration of Poly1 particles formed from distinct 
MW fragments generally decreased with degradation time while transmittance 
increased. Interestingly, a slight increase in particle concentration was observed at 4 
hrs (Figure 3.8A), and also observed by microscopy (Figure 3.6D). Depending on 
the degree of degradation, particles formed using each pool of Poly1 fragments 
exhibited sizes of 1.62 μm for intact polymer, increasing to 9.96 μm when particles 
were formed from fragments collected after a one week degradation period (Figure 
3.8B). The zeta potential of particles, which was positive (~15 mV) at early stages, 




extends of degradation; particles formed with Poly1 fragments degraded for one week 
exhibit values of -9 mV (Figure 3.8C). In general, as the degree of degradation 
increased, particles exhibited more negative surface charges, and by the end of the 
study, a greatly increased diameter. Compared to the aggregation observed in 
particles formed prior to degradation (Figure 3.6A,C), particles formed from pre-
degraded Poly1 remained largely free of aggregation until mostly degraded by 168 
hours. These results were indicated by particle size analysis (Figure 3.6B) and 
inspection of microscopy images (Figure 3.6D). We next tested the ability of these 
particles to activate DCs. Poly1 particles exhibited significant levels of DCs 
activation when prepared from intact poly1 or Poly1 fragments from short 
degradation times (i.e., high MW) (Figure 3.8D-G). These effects then decreased as a 
function of polymer degradation time, with near-baseline activation levels by the end 
of the study. Interestingly, CD80 and CD86 levels were elevated with Poly1 
fragments degraded to 40% of the original MW, an observation that correlated with a 





Figure 3.8: Poly1 particles formed with pre-degraded Poly1 fragments induce MW-dependent 
activation of DCs.  
(A) Particle concentration and transmittance of particles formed by condensing Poly1 fragments 
generated by degradation in buffer prior to condensation. (B) Particle size and (C) zeta potential of 
Poly1 particles alters the extent of degradation. Expression levels of (D) MHCII, (E) CD40, (F) CD80, 
or (G) CD86 following treatment of primary CD11c+ DCs with 400 ng of Poly1 particles at different 
extents of degradation. Vehicle and TLR4a indicate cells treated with buffer or LPS, respectively. 
Analysis was conducted 48 hours after treatment. Expression levels are indicated among DAPI- cells 
(i.e., live cells). Data are representative of three similar experiments with samples prepared in 
triplicate. Error bars represent SEM. For panel C, error bars are smaller than the data markers. 
 
3.3.5 Poly1 particles increase antigen presentation through MHCI and MHCII, and 
drive T cell expansion 
To test if Poly1-induced DC activation impacts antigen presentation, DCs were 
treated with a model antigen (SIINFEKL) and either free Poly1 or particles formed 
from each MW pool of poly1 fragments. SIINFEKL presented by these cells in 
MHCI (H-2Kb) was then quantified by flow cytometry. While free Poly1 (Figure 




controls (Figure 3.9A, gray), DCs treated with Poly1 particles (Figure 3.9A, red) 
caused a dramatic increase in SIINFEKL presentation. In agreement with DC 
activation data (Figure 3.8D-G), presentation levels depended on the extent of 
degradation, with the highest levels associated with Poly1 degraded for short times 
(i.e., higher MWs) (Figure 3.9A). These results indicate that Poly1 particles stimulate 
DCs in a manner that enhances the ability of DCs to effectively present antigen via 
the MHCI pathway – an arm of adaptive immunity important in response to viral 
infection.  
 
Figure 3.9: Poly1 particles increase MHCI-mediated antigen presentation and antigen-specific T 
cell proliferation.  
(A) MFI of signal pertaining to SIINFEKL presented in MHCI following treatment of DCs with no 
SIINFEKL (“Untreated”, gray), buffer with SIINFEKL (“SIIN Only”, gray), free Poly1 with 
SIINFEKL (blue), or Poly1 particles with SIINFEKL (red) and gated under DAPI- cells. 48 hours after 
treatment of primary DCs as in (A) but with 0.25ug mL-1 of a different model antigen, MOG35-55,CD4+ 
cells isolated from 2D2 mice with T cell receptors specific to MOG35-55 were added to the wells and 
incubated for 72 hours. (B) Representative flow cytometry traces showing CFSE dilutions after 
treatment with MOG35-55 and either buffer (“MOG Only”, gray), TLR4a LPS (“TLR4”, black), free 
Poly1 (“Free”, blue), and Poly1 particles formed (“Particles”, red). (C) MFI of CFSE signal among 
DAPI-/CD3+/CD4+ cells following treatments as in (B). (D) Percentage of DAPI-/CD3+/CD4+ cells 
proliferated beyond the 2nd generation following treatment as in (B) as determined by CFSE dilution. 
The Poly1 MW used for treatment is displayed under each bar as a percent of original MW. Samples 




To determine if DC activation and antigen presentation induced by Poly1 particles 
drives T cell expansion, CD11c+ DCs from C57BL6 mice were co-cultured with 
CD4+ transgenic T cells from 2D2 mice. T cells from 2D2 mice display T cell 
receptors specific for a well-defined cognate antigen (MOG35-55). In these studies, 
DCs were cultured for 48 hours with MOG35-55 and either free Poly1, Poly1 particles 
formed with pre-degraded Poly1, LPS, or buffer. Freshly isolated CD4+ 2D2 T cells 
labeled with CFSE were then added to the culture for 72 hours. Figure 3.9B depicts 
representative flow cytometry traces of CFSE dilutions (among DAPI-/CD3+/CD4+ 
cells) for each treatment group. Samples treated with vehicle and MOG35-55 or 
positive controls (i.e., LPS with MOG35-55), caused 8.26% (Figure 3.9B, light gray) 
and 36.3% (Figure 3.9B, dark gray) of T cells to proliferate beyond the second 
generation (Figure 3.9B, left gates), respectively. Consistent with DC activation and 
antigen presentation studies (Figure 3.8 and Figure 3.9A), cultures treated with free 
Poly1 (Figure 3.9B, blue) did not exhibit differences in T cell proliferation compared 
to the vehicle control (Figure 3.9B, gray). Intriguingly, cells treated with Poly1 
particles (Figure 3.9B, red) induced strong T cell proliferation, resulting in three 
distinct generations beyond the second generation. This expansion was comparable to 
that observed in co-cultures treated with a strong TLR3a or TLR4a (i.e., PolyIC, LPS, 
respectively) and much greater than the negligible expansion observed in vehicle-
treated cultures (Figure 3.9B,C,D). Compared with free Poly1, Poly1 particles 
caused significantly more proliferation as reflected in both MFI analysis (Figure 
3.9C) and as a percentage of proliferated cells for each formulation (Figure 3.9D). 




extent of degradation (i.e., MW), with proliferation generally decreasing at lower 
MWs (Figure 3.9C,D). However, the statistical power of these trends were weak. 
Thus, Poly1 particles induce DC activation and antigen presentation that drives 
antigen-specific T cell expansion in a manner that is at least partially dependent on 
the extent of polymer degradation.  
 
3.4 Discussion  
In vaccination and immunotherapy, biomaterials offer the ability to control the 
delivery kinetics of immune signals; however, how the intrinsic immunogenicity of 
synthetic carriers change as these materials degrade is an area that is not well studied. 
Several recent studies demonstrate the intrinsic effects of polymer chemistry and 
physicochemical properties. For example, the Rotello group investigated the effect of 
specific chemical groups on inflammatory cytokine production using well- controlled 
chemistry to display these moieties on stable, gold nanoparticles.[120] Here, we have 
carried out mechanistic studies to test if the changing properties of polymer particles 
during degradation alters dendritic cell activation, processing and presentation of 
antigen through MHC-I and MHC-II pathways, and expansion of antigen-specific T 
cells. To explore these possibilities, we used PBAEs as a rapidly-degradable carrier 
platform. Since PBAEs are commonly used to condense nucleic acids for gene 
therapy or DNA vaccination, we formed particles by electrostatic condensation to 
mimic this polymer-enable vaccination strategy [142-148]. This approach also 
eliminated stabilizers, surfactants, or other complex compositions required for 




emulsion/phase inversion. These additional components could hinder isolation of the 
immunogenic effects of PBAEs and the change in these characteristics during 
degradation. 
 
Our primary findings in this study are i) that PBAEs exhibit intrinsic 
immunogenicity, and ii) that the extent of this activity depends both on the form and 
extent of degradation of Poly1. Past studies with low MW fragments of polymers 
such as hyaluronic acid indicate that these materials - which were 4-14 
oligosaccharides in size (1500-5300 Da) - induce DC activation, cytokine secretion, 
and T cell proliferation, while high MW hyaluronic acid (80,000-1,000,000 Da) does 
not [111, 112]. In contrast, our studies with free PBAEs reveal that free Poly1 does 
not activate DCs (Figure 3.3). This observation may result from the inability of DCs 
to efficiently internalize the soluble/relatively low MWs that both intact and 
degrading Poly1 exhibit. Although DCs use pinocytosis to internalize smaller 
antigens, DCs are able to sample larger, particulate antigens more efficiently through 
phagocytosis [153].  
 
Unlike free Poly1, particles formed from intact Poly1 were immunogenic, exhibiting 
the greatest activity at early stages of degradation, with diminishing intrinsic function 
at longer times. Poly1 MW became significantly lower at these longer intervals, while 
the charge became negative, particle size became much larger, and particle 
concentration decreased (Figure 3.4, 3.5A-B). Thus, a likely explanation for the 




time is i) the reduced number of particles to interact with immune cells, ii) the 
negative surface charge that could hinder association with negatively charged cell 
membranes [154], and iii) large particle sizes that limits the efficiency of endocytosis.  
 
Our findings that Poly1 particles formed from intact Poly1 exhibit changing 
immunogenicity as Poly1 degrades motivated mechanistic studies to investigate more 
directly how Poly1 fragments alter the properties – and resulting immunogenicity – of 
particles. Thus we prepared particles from pools of Poly1 fragments with distinct 
MW ranges. As with our studies involving particles degraded after formation from 
intact Poly1 (Figure 3.5), we discovered that particle size increased inversely with 
the MW of the Poly1 fragments used for assembly, and zeta potential became 
increasingly more negative with increased degradation time (Figure 3.8). In general, 
the trends in DC activation were also similar (Figure 3.8D-G), with greater activation 
at lower extents of degradation where particle size was low (~2µm) and zeta potential 
was less negative. When Poly1 particles were formed from smaller MW fragments to 
mimic longer degradation times, particles became larger (Figure 3.8B) and surface 
charge shifted from positive to neutral or slightly negative (Figure 3.8C). However, 
we also observed a transient elevation in activation with particles formed from 
fragments 40% of the starting MW, though the statistical power of this trend was 
weak. Our observation of this effect underscores an important role for particle 
concentration, as the properties of particles formed with these fragments resulted in 
an increased concentration of particles (Figure 3.7D, Figure 3.8A) for the same 




conclusions. First, activation is high when particles are at an easily-internalized size 
(e.g., one to several microns), but before exhibiting a strong negative surface charge 
that could hinder electrostatic association with negatively charged cell membranes. 
As degradation continues to greater extents (e.g., 8% of starting MW), particle 
diameters reach sizes that may be too large to internalize and exhibit negative 
surfaces. Second, since the Poly1 dose was fixed, particle concentration changes both 
because polymer is degrading and due to aggregation that results in larger, but fewer, 
particles. These effects result in particle concentration generally decreasing with time. 
The transient increase in concentration – and corresponding increase in DC activation 
– observed with the 40% fragments could result from dispersion of small aggregates 
(e.g., dimers or trimers) that may form during initial condensation, but that are 
separated as the particles begin to degrade. However, additional studies are needed to 
confirm this possibility. In support of the types of interactions discussed in this 
section, Bishop et al. similarly observed that directly synthesizing PBAEs with 
different MWs impacts the size and zeta potential of electrostatically-condensed 
PBAE particles, though this study did not investigate the immunogenicity of the 
particles [155]. Together, the two approaches we used to characterize the impact of 
MW on the changing immunogenicity of Poly1 reveal that these changes are a 
function, at least in part, of changes in particle charge, size, and concentration that 
result during degradation. 
 
Another interesting result was observed in studying the impact of Poly1 particle 




pathway is important in promoting cell-mediated (i.e., CD8+ T cells) responses to 
destroy cells infected with intracellular pathogens (i.e., viruses) and in new 
therapeutics such as cancer vaccination and immunotherapy. Our studies reveal an 
increase in SIINFEKL antigen presentation at low extents of degradation (Figure 
3.9A). Using T cells from transgenic mice, we also discovered that, in general, Poly1 
particles cause an adjuvant effect to promote antigen-specific proliferation through 
the MHCII pathway at levels that are comparable to those observed in mice treated 
with LPS and the cognate antigen (Figure 3.9B-D). Further, proliferation was not 
observed when only the antigen was present. Proliferation was only a weak function 
of MW, though this may be expected due to the exponential nature of T cell 
expansion and the complexity of the signals playing a role in engaging the T cell 
receptor (e.g., DC signals, cytokines/soluble factors, cell-cell contacts). These co-
cultures studies demonstrate that Poly1 particles serve as adjuvants by activating DCs 
to present antigen through both the MHCI and MHCII pathways, as well as enhancing 
the co-stimulatory molecules needed to expand antigen-specific T cells. These data 
also highlight the ability of Poly1 – even in the absence of any other immune cues – 
to drive functional responses in a manner that is dependent on the form and 
degradation state of the polymer.  
 
The “danger model” describes the evolution of immune pathways that function by 
detecting pathogens through broad structural features that are uncommon in animals 
and humans [156]. Some of these characteristics include materials in a particulate 




polymers or other repetitive structures such as the polysaccharides that commonly 
comprise bacterial membranes. In our studies, when Poly1 particles were at an 
optimal size for internalization and positive or neutral, activation was greatest. These 
effects correlated to other functions such as antigen presentation and proliferation. 
However at low molecular weights, activation diminished. Thus, in line with the 
danger model, our results suggest that broad physicochemical features (e.g., size, 
charge), as well as direct effects from changing MW and number of repeat units – 
account for the evolving immunostimulatory properties of Poly1. 
 
3.5 Conclusion 
Previous studies have confirmed the intrinsic immunogenicity of several biomaterials 
important in the delivery of drugs, vaccines, and immunotherapies. However, these 
studies have not focused on how this activity may evolve as materials degrade, and 
have not been carried out using rapidly-degradable polymer classes such as PBAEs. 
Here, we have demonstrated that PBAEs, an important polymer class in recent drug 
delivery and vaccine studies, exhibit strong intrinsic immune effects in a particle 
form, but not in a free form. Our results also indicate that these effects depend on the 
extent of polymer degradation, and at least in part, occur because the degrading 
polymer impacts particle properties such as size, charge, and concentration. Future 
studies involving treatment of mice with Poly1 at differing extents or rates of 
degradation will reveal how these materials impact LN structure and function with 
respect to polymer properties. Additionally, more mechanistic studies could 




entry and processing of antigen in these cells. This approach could also provide new 
knowledge of how the intrinsic immunogenicity observed here or with other polymers 
translates to polarization of functional immune outcomes when antigens or other 
adjuvants are present. Ultimately, this knowledge could contribute to the design of 
polymers that allow better control over the types, durations, and magnitudes of 
responses generated with new vaccines or immunotherapies. 
 
Building on the studies performed in this chapter, in Chapter 4, a small library of 
PBAEs was synthesized to form polymers with similar structures but different 
starting MWs. Using these polymers, we generalize the findings that PBAEs are 
intrinsically immunogenic by identifying particular physicochemical properties that 





Chapter 4: Impact of Molecular Weight on the Intrinsic 
Immunogenic Activity of Poly(Beta Amino Esters)3 
 
4.1 Introduction 
New vaccine and immunotherapies that employ biomaterial carriers have the ability 
to protect encapsulated immune cargos, control the release kinetics of these 
components, and target specific immune cells or organs such as lymph nodes (LNs) - 
tissues that coordinate adaptive immunity.[103-105] Despite these advantages, many 
recent studies outline above also show that many biomaterials, including poly(lactic-
co-glycolic acid) (PLGA), polystyrene, and chitosan exhibit intrinsic 
immunostimulatory properties that can activate immune cells, even in the absence of 
adjuvants or inflammatory cues.[9, 45, 103, 106-109, 157] This immune stimulation 
can occur through activation of pattern recognition receptors (PRRs), the 
inflammasome, and toll-like receptor (TLR) signaling. These receptors are found on 
and within many immune cells, including dendritic cells (DCs) – antigen presenting 
cells (APCs) that link innate and adaptive immunity.[110] When immature DCs are 
plated on a thin-film of PLGA, for example, the DCs become activated, increasing 
co-stimulatory markers (CD80, CD86, and CD83) and antigen presentation 
complexes.[109, 157] These effects drive increased pro-inflammatory cytokine 
secretion and T-cell proliferation in vitro,[109, 157] features in line with seminal in 
________________________________________________ 
3Adapted from J.I. Andorko, K.G. Pineault, and C.M. Jewell. “Impact of molecular weight on the 





vivo studies illustrating the intrinsic immune effects of PLGA and polystyrene.[9, 45] 
One recent strategy seeks to simplify vaccines and immunotherapies by eliminating 
carriers completely using self-assembly of immune signals in a manner that mimics 
attractive features of biomaterials.[158-162] Alternatively, understanding the 
interactions between biomaterials with defined properties and the immune system 
could enable design of new carriers that deliver vaccine and immunotherapy cargos 
with direct control over the particular immune functions or phenotypes that arise from 
these treatments. 
 
Building on this discovery of intrinsic immunogenicity and as mentioned in Chapter 
3, many studies have set out to understand the link between immunogenicity and 
physicochemical properties such as molecular weight (MW),[107, 111-114] particle 
size,[108, 115-117] charge,[118, 119] hydrophobicity,[120] shape,[41, 121, 122] and 
chemical functionality.[123-128] For instance, silica micro-rods functionalized with 
poly(ethylene glycol) (PEG), PEG-RGD, or PEG-RDG to facilitate cellular uptake 
and incubated with bone marrow derived DCs cause increased activation and 
cytokine secretion, a phenomena that also occurs when these materials are implanted 
subcutaneously in mice.[128] Research by the Anderson lab recently explored how 
size and shape impact innate immunity in response to implanted biomaterials. These 
studies revealed that larger particles reduced the foreign body response in mice and 
non-human primates.[116] As one illustration, comparing macrophage responses to 
low and high MW hyaluronic acid, low MW hyaluronic acid promoted a classically 




MW hyaluronic acid induced alternative macrophage activation, highlighting MW as 
a key polymer property in these activation studies.[114]  
 
While many biomaterials carriers use polymer degradation to achieve controlled 
release of immune cargos, the link between the extent of degradation and the 
evolution of intrinsic immunogenicity is not well understood. This information is 
important because during degradation, as material properties change, immune cells 
and tissues interact with the initial and the altered forms of biomaterials, making it 
difficult to discern the impact of the signal and the carrier at a particular time 
(corresponding to a particular degradation state). Toward addressing this gap, in 
Chapter 3, a rapidly-degradable poly(beta-amino ester) (PBAE) was used to show 
that these polymers exhibit intrinsic immunogenic activity, and importantly, that the 
extent of the effects are dependent on the degree of polymer degradation.[163] 
PBAEs are cationic, pH-sensitive polymers used in drug and DNA delivery owing to 
their ability to efficiently condense nucleic acids and promote endosomal escape via 
the proton sponge effect.[129, 130, 132, 134, 135, 137, 138, 141, 164, 165] PBAEs 
have been employed in DNA vaccination by condensing plasmid DNA encoding 
antigens relevant for both cellular- and antibody-mediate immunity.[142-148] In the 
previous research outlined in Chapter 3, a prototypical PBAE, denoted as Poly1, did 
not activate primary DCs in a free (soluble) form but was able to activate DCs when 
formulated into particles via electrostatic condensation, a technique mimicking a 




differential activation of DCs and T cells depending on the extent of polymer 
degradation. 
 
Expanding on the results from Chapter 3, in this work, the intrinsic immunogenicity 
of a small library of PBAEs with similar structures but different starting MWs was 
investigated. PBAEs were synthesized from diacrylate monomers with an increasing 
number of carbons in the backbone, then degraded in a controlled fashion to form 
fragments. Using electrostatic condensation mimicking commonly used DNA vaccine 
formulation strategies, we formed particles using these sets of materials. MW was 
determined before and during degradation, and the immunogenicity was then 
investigated during culture with primary DCs (Figure 4.1). We show that the 
properties (e.g., size, charge, concentration) of fragments and particles are a function 
of the extent of degradation, and these changes alter the intrinsic immunogenicity. 
Further, irrespective of starting MW, the intrinsic immunogenicity reaches a 
maximum as polymers degrade to a range of ~1500-3000 Da. This knowledge could 
provide insight into the design of future vaccine carriers with properties that actively 
modulate the immune response towards a particular phenotype, allowing for more 
rational design of carriers used in vaccines and immunotherapies for infectious 







Figure 4.1: Schematic representation of PBAE preparation and treatment. 
PBAEs were fabricated to have similar structures but increasing carbons in the polymer backbone are 
degraded into fragments, formed into particles, and cultured with DCs to determine how the properties 
of PBAEs impact DC activation and antigen presentation. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Diacrylate monomers used in polymer synthesis (1,4-butanediol diacrylate, 1,6-
hexanediol diacrylate, and 1,10-decanediol diacrylate) were purchased from Alfa 
Aesar and 4,4′-trimethylenedipiperidine was purchased from and Sigma–Aldrich. 
Tetrahydrofuran (THF), diethyl ether, sodium acetate (SA) buffer, poly(sodium 4-
styrenesulfonate) (SPS), and lipopolysaccharide from Escherichia coli 0111:B4 (LPS) 
were also purchased from Sigma–Aldrich. THF used in GPC studies was purchased 
from Macron Fine Chemicals. Agilent LS EASICAL PS-1 polystyrene GPC 
standards were from Fisher Scientific. Deuterated-chloroform (CDCl3) was bought 
from Cambridge Isotope Laboratories. RPMI-1640 media was purchased from Lonza 
(Allendale, NJ). Fetal bovine serum (FBS) was supplied by Corning (Tewksbury, 
MA). Low MW polyinosinic-polycytidylic acid (PolyIC), a TLR3 agonist (TLRa), 
was purchased from Invivogen. CD11c microbeads were purchased from Miltenyi 
Biotec. Spleen Dissociation Medium was from STEMCELL Technologies. 4',6-




Scientific and fluorescent antibody conjugates were purchased from BD or 
eBioscience.  
 
4.2.2 Cells and animals 
C57BL/6J Mice Stock #000664 (Individual, Female, 4-8 weeks old) were from 
Jackson Laboratories and used as a source of primary DCs. All animals were cared 
for in compliance with Federal, State, and local guidelines and using protocols 
approved by the University of Maryland’s Institutional Animal Care and Use 
Committee (IACUC). 
 
4.2.3 PBAE synthesis, characterization, and degradation 
PBAEs were synthesized with a Michael-type addition reaction similar to the reaction 
previously described in Chapter 3.[163] Briefly, 4,4′-trimethylenedipiperidine was 
dissolved in anhydrous THF to form a 500 mg mL-1 solution. This solution was added 
to one of three diacrylates, 1,4-butanediol diacrylate, 1,6-hexanediol diacrylate, or 
1,10-decanediol diacrylate, in equal molar ratios (9 mmol) to form either PBAE-4, 
PBAE-6, or PBAE-10, respectively. The reaction was heated to 50°C and stirred for 
16 h, then cooled to room temperature. The resulting polymers were precipitated in 
ice cold hexanes or diethyl ether. After collection and additional washing in the 
solvent used for precipitation, each polymer was lyophilized. After drying, each 
PBAE was prepared at 16 mg mL-1 solution in CDCl3, and 1H nuclear magnetic 
resonance (NMR) spectroscopy was performed to confirm polymer structure. A THF-




starting MW of each PBAE and the MW at distinct degradation times relative to 
polystyrene standards. For degradation studies, each PBAE was dissolved in pH 5 SA 
buffer at 1mM and incubated at 37°C for increasing time intervals (e.g., 0-168 h) to 
form free polymer fragments. Following incubation, degraded samples were 
lyophilized and the resulting MW (weight average) was determined by GPC as 
described above. Degradation constants (λ) were calculated for each PBAE using the 
exponential decay equation: 
y=MWie-λx (1) 
where MWi was the intact (starting) MW of each PBAE. 
 
4.2.4 PBAE particle formation and characterization 
Each formulation of PBAEs was assembled into particles through electrostatic 
condensation by mixing 1mM of intact (full MW) or degraded PBAE fragments with 
distinct MWs with 20mM of anionic polymer (SPS) at a 1:2 SPS:PBAE w/w ratio. 
400 µg of PBAEs were used for each particle formulation, while maintaining a fixed 
overall volume. Zeta potential of PBAE particles was determined using a Malvern 
Zetasizer Nano ZS90 and particle diameter was determined using laser diffraction 
(Horiba LA950). Particle concentration was calculated by mixing a known volume of 
PBAE particles with Trypan Blue at a 1:1 v/v ratio and counting using a 
hemocytometer. Transmittance was determined at 600nm using an Evolution 60 UV-






4.2.5 Flow cytometry, DC activation, and antigen presentation 
PBAE intrinsic immunostimulatory ability was tested using primary CD11c+ DCs 
isolated from spleens of C57BL6 mice using recommended protocols for Spleen 
Dissociation Medium and CD11c Microbeads. Isolated DCs were plated at 100,000 
cells per well in 96 well plates and cultured at 37°C, 5% CO2 in RPMI 1640 
supplemented with 10% FBS, 2 mM L-glutamine, 1x non-essential amino acids, 10 
mM HEPES buffer, 1x penicillin and streptomycin, and 55 μM β-mercaptoethanol. 
For activation studies, DCs were treated with either 10 µg/mL of TLR3 agonist 
(PolyIC), 1 µg/mL of TLR4 agonist (LPS), a vehicle control of buffer, or 400 ng of 
each PBAE in free or particle formulations, fabricated from low MW PBAE 
fragments. For antigen presentation experiments, primary DCs were isolated and 
treated as above with the addition of 1 µg of soluble model antigen SIINFEKL (SIIN) 
to samples. After 48 hours in culture, cells were stained using fluorescently-tagged 
antibodies (BD) for viability (DAPI) and either of the classic DC activation markers 
(e.g., CD80, CD86, CD40, and I-A/I-E (mouse MHCII)) or an antibody specific to 
SIIN presenting within MHCI H-2Kb (eBioscience). Flow cytometry was used to 
quantify relative viability (% cells DAPI- relative to a positive control) and the extent 
of surface marker presentation (activation) and SIIN presentation via median 
fluorescent intensity (MFI) and the percentage of cells highly expressing each marker. 
Correlations between particle properties (MW, concentration, diameter, and zeta 
potential) and DC activation (expression of CD40, CD80, CD86, and I-A/I-E) were 





4.2.6 Statistical Analysis 
For in vitro studies, two way ANOVA with a Tukey post-test was performed using 




4.3.1 PBAE synthesis and characterization 
A small library of PBAEs with similar chemical structures but with different numbers 
of carbons in the diacrylate monomer backbone was synthesized via a Michael-type 
addition reaction. The chemical structures of PBAE-4 (which has the same structure 
as Poly1 used in experiments throughout Chapter 3) (Figure 4.2A, top), PBAE-6 
(Figure 4.2A, middle), and PBAE-10 (Figure 4.2A, bottom), were confirmed using 
1H NMR. As expected, increasing the numbers of carbons in the diacrylate backbone 
during synthesis resulted in increased area under the curve in the alkane region (1.0-
1.5ppm), with PBAE-10 exhibiting the greatest level of alkane bonds (Figure 4.2A, 
dotted boxes). Using THF-based GPC, chromatographs were obtained for each 
PBAE prior to degradation to determine the starting MW (Figure 4.2B). PBAE-4 had 
the lowest MW of 2319 ± 81 Da, while PBAE-6 had a larger MW of 3178 ± 192 Da, 
and PBAE-10 had the highest starting MW of 5045 ± 99 Da (Figure 4.2C). After 
degrading each PBAE for up to 168h (1 week) in SA buffer at 37°C, the change in 
MW for each PBAE was determined and degradation constants (λ) were calculated. 




and PBAE-6 resulting in a value of λ = -0.9, and PBAE-10 degraded at a slightly 
faster rate (λ = -1.1) (Figure 4.2D).  
 
Figure 4.2: PBAEs are synthesized with similar structures but varied starting MW.  
(A) NMR spectrographs of PBAE-4, PBAE-6, and PBAE-10 showing chemical structures only differ 
in the alkane region (1.0-1.5ppm, boxed region). (B) GPC chromatographs of intact PBAE-4 (blue), 
PBAE-6 (red), and PBAE-10 (green) depicting differential starting MW (C). (D) Degradation profiles 
and constants (λ) for PBAE-4 (blue), PBAE-6 (red), and PBAE-10 (green) after being incubated in pH 
5 buffer for 7 days at 37°C. Samples were prepared in triplicated and errors bars represent SEM. 
 
4.3.2 Fabrication and characterization of PBAE particles 
After confirming the structure of each PBAE after synthesis, we investigated how the 
MW of PBAE fragments generated across similar degradation rates influenced the 
formation and properties of particles. Intact and degraded forms of PBAE-4, PBAE-6, 
and PBAE-10 were fabricated into particles through electrostatic condensation with 
SPS, a technique we previously used to mechanistically investigate intrinsic 
activation and which eliminates confounding factors such stabilizers commonly used 




diameter, particles formed from intact PBAE-4 (i.e., prior to degradation) were 
micron sized, with an average diameter of 1.61 ± 0.52 µm (Figure 4.3A; blue). These 
particles also exhibited a positive zeta potential of 6.34 ±1.08 mV (Figure 4.3B; 
blue). Upon degradation, PBAE-4 particles exhibited similar sizes around 1.60 µm – 
regardless of the extent of degradation – until particles were prepared from PBAE-4 
degraded for 168h (22.5% of starting MW). At this point, particle size increased and 
particle concentration decreased, as indicated by an increase in transmittance (Figure 
4.3A, C, D; blue). The zeta potential of PBAE-4 particles, while initially positive, 
became increasingly negative when fabricated with PBAE-4 that was degraded for 
increased time (i.e., lower MW). In a similar fashion, particles synthesized from 
PBAE-6 showed initial diameters of 1.59 ±0.52 µm but with a zeta potential of 9.09 ± 
0.79 mV (Figure 4.3A, B; red), slightly higher than the zeta potential of particles 
formed with intact PBAE-4. These PBAE-6 particles also showed increasingly 
negative zeta potential when formed with degraded PBAE-6 fragments and 
maintained their diameter, concentration, and transmittance until formed with PBAE-
6 that was degraded for 168h (22.6% of starting MW) (Figure 4.3; red). 
Surprisingly, PBAE-10 had an initial particle size on the nanometer scale, with 
particles formed from intact PBAE-10 exhibiting a diameter of 191.09 ± 75.06 nm 
(Figure 4.3A; green) and a strongly positive zeta potential of 19.57 ± 2.19 mV 
(Figure 4.3B; red). While PBAE-10 particle zeta potential decreased slightly when 
formed with degraded PBAE-10 fragments, it remained positive throughout, with a 
zeta potential of 4.22 ± 1.64 mV when formed with PBAE-10 degraded for 168h 




particles formed with PBAE-10 degraded for 48h exhibiting particle sizes greater 
than 5 µm (Figure 4.3A; green). Over this same interval, particle concentration 
quickly dropped (Figure 4.3C, D; green). Light microscopy revealed the 
morphology and relative concentration of particles in each of the formulations over 
time. PBAE-4 and PBAE-6 formed uniform, monodispersed spherical particles at 
each degradation time point until 168h, where particle concentration (i.e., the number 
of individual particles) dramatically decreased as the presence of large agglomerates 
and aggregated particles increased (Figure 4.4; left and center). Particles formed 
with PBAE-10, while much smaller, also aggregated more at earlier times, with large 
agglomerations at the longer degradation times (Figure 4.4; right). 
 
Figure 4.3: Physicochemical properties of particles formed from degraded PBAEs alters as a 
function of degradation time and MW.  
(A) Particle size, (B) zeta potential, (C) conentration, and (D) percent transmittance for particles 
formed from intact and degraded forms of PBAE-4 (blue), PBAE-6 (red), and PBAE-10 (green). 






Figure 4.4: Increased degradation time leads to particle aggregation.  
Bright field micrographs of particles formed from PBAE-4, PBAE-6, and PBAE-10 that were 
degraded for 0, 4, 24, 48, or 168 hours. Increased degradation time led to aggregation of particles, most 
apparent in PBAE-10 particles starting at early times and in PBAE-4 and PBAE-6 by 168 hours. Scale 








4.3.3 PBAE particles are non-toxic, activate DCs, and promote antigen presentation 
Using sets of particles analogous to those above, primary DCs were cultured with 
each PBAE formulation to assess the intrinsic immunogenic properties of the 
polymers as a function of the extent of degradation for each structure. Cytotoxicity 
was first investigated to ensure that the dose of PBAEs used in these experiments did 
not detrimentally affect DCs. As expected with unstimulated primary immune cells, 
viability was low in untreated and vehicle controls, and high in cells treated with 
strong activating signals: positive controls of either LPS or PolyIC, TLR4a and 
TLR3a, respectively. None of the PBAE formulations caused toxicity relative to 
untreated, media controls (Figure 4.5A). In some cases, treatment with PBAE-4 and 
PBAE-6 particles led to significant increases in viability – analogous to results 
observed in control wells stimulated with the positive control adjuvant treatments 
(Figure 4.5A). In a free form, PBAEs did not induce any increase in viability relative 





Figure 4.5: PBAE particles exhibit intrinsic immunogenicity as a function of degradation and 
MW.  
(A) Relative viability of DCs after 48 hours in culture treated with LPS (“TLR4a”, gray), PolyIC 
(“TLR3a”, gray), buffer only (“Vehicle”, gray), soluble PBAE-4 (light blue), PBAE-6 (light red), and 
PBAE-10 (light green) or PBAE-4 (dark blue), PBAE-6 (dark red), and PBAE-10 (dark green) 
particles or left untreated (“Untreated”, gray). Expression levels of classic DC activation markers (B) 
CD40, (C) CD80, (D) CD86, and (E) I-A/I-E following treatment as above, gated under DAPI- cells. 
(F) MFI of signal pertaining to SIINFEKL presented in mouse MHCI following treatment of DCs with 
no SIINFEKL (“Untreated”, gray), buffer with SIINFEKL (“Vehicle”, gray), or SIINFEKL treatment 
with soluble PBAE-4 (light blue), PBAE-6 (light red), and PBAE-10 (light green) or PBAE-4 (dark 
blue), PBAE-6 (dark red), and PBAE-10 (dark green) particles, gated under DAPI- cells. Samples were 







We next assessed DC activation by measuring expression of the surface markers 
CD40, CD80, CD86, or I-A/I-E (mouse MHCII). None of the free forms of the 
PBAEs activated DCs (Figure 4.5B, C, D, E, lighter shades). PBAE-4 particles 
caused potent activation at time points corresponding to early stages of degradation 
and then returned to basal levels at longer degradation times (Figure 4.5B, C, D, E, 
dark blue). PBAE-6, which exhibited a higher starting MW but a similar degradation 
profile to PBAE-4, also activated DCs. However, PBAE-6 particles, which caused 
little activation at early degradation times, activated DCs to the greatest extent at 
intermediate levels of degradation (i.e., 24h, 48h) (Figure 4.5B, C, D, E, dark red). 
For PBAE-4 and PBAE-6, the most significant effects were measured for markers of 
co-stimulation (CD80 and CD86) and antigen-presenting (I-A/I-E). In some cases, 
these increases were comparable to or exceeded the levels of activation observed 
when DCs were treated with LPS or PolyIC. PBAE-10, which had the highest starting 
MW, had minimal effects on activation compared to PBAE-4 and PBAE-6; activation 
only occurred with the longest extents of degradation and was primarily limited to 
increases in I-A/I-E expression (Figure 4.5B, C, D, E, dark green). Similar trends to 
those above were evident in analyzing DC activation as a percentage of total cells 





Figure 4.6: PBAE particles induce higher frequencies of DC activation markers.  
Frequency of cells expressing high levels of (A) CD40, (B) CD80, (C) CD86, and (D) I-A/I-E after 48 
hours in culture treated with LPS (“TLR4a”, gray), PolyIC (“TLR3a”, gray), buffer only (“Vehicle”, 
gray), soluble PBAE-4 (light blue), PBAE-6 (light red), and PBAE-10 (light green) or PBAE-4 (dark 
blue), PBAE-6 (dark red), and PBAE-10 (dark green) particles or left untreated (“Untreated”, gray), 
gated under DAPI- cells. Samples were prepared in triplicated and errors bars represent SEM. (* 
p<0.05; ** p<0.01; *** p<0.001, ****p<0.0001). 
 
Building on the clear levels of DCs activation observed for each PBAE, we explored 
if these changes drove antigen presentation, the next step in generating functional T 
cell and B cell responses. To study this, primary DCs were treated with each PBAE in 
a free form or the various particle forms, along with a model antigen, SIINFEKL 
peptide. This peptide was selected to support direct measurement of peptide 
presentation by using an antibody that binds SIINFEKL when presented in the mouse 
MHCI complex. In agreement with low levels of activation observed with free forms 
of PBAEs (Figure  4.5), free forms of PBAEs along with SIINFEKL did not increase 




PBAEs (Figure 4.5F). Treatment with PBAE-4 particles resulted in statistically 
significant increases in antigen presentation at early extents of degradation; these 
increases then diminished at longer degradation time (Figure 4.5F, dark blue). 
Interestingly, while not statistically significant, the antigen presentation profiles for 
PBAE-6 and PBAE-10 mimicked the DC activation profiles; PBAE-6 had exhibited a 
transient increase at intermediate MWs (Figure 4.5F, dark red) and PBAE-10 
caused small increases at the late stages of degradation (Figure 4.5F, dark green).   
 
To determine if generalizable trends occurred between PBAE properties and DC 
responses, we analyzed the responses as a function of the physical properties of the 
particles formed from each set of PBAEs. Figure 4.7 plots the MW of each PBAE 
against the level of each DC activation marker, indicated by MFI. In each of these 
analyses, the dotted line represents the value for the DCs treated with buffer alone 
(vehicle controls). While no global relation was apparent, when analyzing the CD40 
marker, a trend developed in which fragments with MW in the range of ~1500-3000 
Da were immunogenic (Figure 4.7A). For the costimulatory markers CD80 and 
CD86, activation was seen at all low MWs until reaching a maximum around a MW 
of ~2000- 2500 Da. Trends for I-A/I-E were even less apparent, but generally, 
activation was higher at lower MWs. Similar analyses were performed to compare 
particle size, zeta potential, and concentration to DC activation (Figure 4.8). While 
particle concentration did not seem to have a large impact on activation (Figure 
4.8A), in general, particle sizes between 1-4µm (Figure 4.8B) and neutral to slightly 





Figure 4.7: Correlation between PBAE MW and DC activation.  
Expression levels of DC activation markers (A) CD40, (B) CD80, (C) CD86, and (D) I-A/I-E 
correlated to the MW of PBAE-4 (blue), PBAE-6 (red), and PBAE-10 (green) used to form the 
particles. Dotted lines represent the mean value for DCs treat with buffer alone (vehicle control). 






Figure 4.8: Correlation between DC activation and PBAE particle concentration, diameter, and 
zeta potential.  
Expression levels of DC activation markers CD40, CD80, CD86, and correlated to the (A) PBAE 
particle concentration, (B) diameter, and (C) zeta potential of PBAE-4 (blue), PBAE-6 (red), and 
PBAE-10 (green) used to form the particles. Dotted lines represent the mean value for DCs treat with 
buffer alone (vehicle control). Samples were prepared in triplicated and errors bars represent SEM. 
 
4.4 Discussion 
Countless studies aim to exploit the ability of biomaterials to encapsulate, transport, 




tuning materials. Physicochemical properties of materials that evolve during 
degradation can impact interactions with immune cells, particularly DCs; these cells 
play an integral role in linking innate and adaptive immunity. However, this evolution 
of intrinsic immunogenicity is poorly understood and there is a need to understand 
what properties cause these responses, as well as how significant the effects are. In 
our previous research, we used a PBAE as a prototypical, rapidly-degrading polymer 
to test if this class of polymer also exhibits intrinsic immunogenic properties.[163] 
Here we expanded on our previous findings to a small library of PBAEs, synthesized 
to have similar polymer structures but with different starting MWs.  
 
One of our most interesting results was that irrespective of starting MW, the 
immunogenicity of each degrading polymer peaked when the MW decreased to a 
range of ~1500-3000 Da; these effects were irrespective of the degradation time to 
reach this range. The immune system has evolved to detect foreign pathogens that 
have structures not commonly found in humans and animals. Interestingly, many of 
the characteristics that activate inflammasomes, TLRs, and other danger-sensing 
pathways include particulate form, hydrophobic fragments, and short repetitive 
motives—for example, that might resemble bacterial polysaccharides.[156] The 
degraded particles we studied share some of these features. Further, although the 
immunogenicity of PLGA as a function of degradation state has not been studied, 
more general reports on PLGA and other common materials indicate that intrinsic 
immunogenicity is driven at least in part by inflammasome and TLR signaling.[9, 45] 




in a manner that is optimal during the low MWs mentioned above. This is an 
intriguing idea as polymers might be designed to degrade or evolve in ways that 
activate target pro-immune pathways. in vitro studies investigating the link between 
PBAE degradation and the mechanism of uptake by antigen presenting cells could 
provide insight into which immune-stimulatory pathways are activated, for example, 
by first systematically inhibiting specific internalization mechanisms. During these 
studies, the activity level of surface, cytosolic, or endosomal pattern recognition 
receptors (e.g., TLRs, inflammasome) could then be used to link uptake, processing, 
and pro-immune signaling. Similarly, in vivo studies in TLR and inflammasome 
knock-out mice could provide insight in a more translational setting. This exciting 
avenue of research could shed new insight into how the properties and stability of 
carriers impact processing and immune cell activation. 
 
When evaluating each property’s influence on activation, MW seemed to play the 
clearest role (Figure 4.7), as just discussed, while size, zeta potential, and 
concentration were less distinct (Figure 4.8). The optimal particle diameter for DC 
uptake is in the range of ~1-6µm, though in our studies, not all particles of this size 
caused DC activation (Figure 4.8B). Additionally, while the most potent activation 
occurred with slightly negatively or positively charged particles, there was little 
correlation between zeta potential or concentration with activation. Based on these 
observations, it is likely that a combination of particle properties are impacting DC 
activation and the intrinsic immunogenicity of PBAEs cannot be attributed to a single 




contexts studying similar ideas, analogous trends are arising. For example, one recent 
study demonstrates that platelet-like particles require an optimal set of properties (i.e., 
size, shape, functionality) to reduce bleeding time in contrast to optimizing a single 
property.[166]  
 
The evolution of particle concentration also exhibited some interesting dynamics 
which could impact immunogenicity or inform design rules. PBAEs at early extents 
of degradation initially remained stable, with PBAE-4 and PBAE-6 forming micron-
sized particles and PBAE-10 forming nanoparticles (Figure 4.3A). However, when 
formed with PBAEs that were degraded for longer times (e.g., lower MW), the 
resulting PBAE particles aggregated, leading to a larger average size. Due to 
aggregation of many smaller particles into one larger particle, with increased average 
size, there was a corresponding decrease in particle concentration. This effect could 
decrease particle uptake by DCs because of the larger particle sizes, and also because 
of the decreasing number of particles (i.e., there are fewer, but larger particles).[167] 
Future studies might also yield new insight by focusing on the most immunogenic 
fragments and investigating how changing a particular particle property alters 
immune function. For example, using the most immunogenic forms of the degraded 
PBAEs to form particles with a range of sizes, then testing how these changes impact 
DC activation. Such experiments might allow isolation of the relative importance of 
polymer properties (e.g., MW, structure) compared with more general features such 





In general, the zeta potential for each PBAE became more negative when formed with 
PBAEs that were degraded for a longer time (Figure 4.3B). Interestingly, while 
PBAE-4 and 6 both became negatively charged, PBAE-10 particles maintained a 
positive charge, regardless of the MW of the PBAE used to form the particles (Figure 
4.3B). With increasingly negative zeta potential, particles could be less likely to 
associate with the negatively charged cell membrane of DCs, again leading to 
diminished activation. In gene and drug delivery, cationic materials are often desired 
for condensing nucleic acids, and also for aiding in association with negatively 
charged cell membranes. However, recent studies also indicate that surface charge 
modulates immunogenicity. For example, one recent study demonstrated that 
negatively charged polymer particles can be used to promote immunological 
tolerance.[99] Thus the role of charge in intrinsic immunogenicity remains 
amorphous, and is likely one of several important parameters impacting immune 
signaling and interactions with antigen presenting cells. 
 
In addition to assessing the role of MW, we successively increased the number of 
carbons in the backbone of each PBAEs. We hypothesized this change might increase 
polymer hydrophobicity, decreasing the degradation rate while maintaining the same 
chemical functionality on each polymer. However, between the different polymers, 
the degradation constants were similar (λ=-0.9 to λ=-1.1), preventing study of the role 
of degradation rate. This line of investigation might be facilitated in future studies by 





Lastly, we also observed that PBAEs caused some characteristic effects on viability 
relative to what one might find with strong inflammatory or danger signals. Each 
PBAE, regardless of formulation or MW, was nontoxic to the primary splenic DCs 
over a 48 hour culture. In some cases, PBAE particles had a statistically higher 
viability compared to the untreated control, suggesting the particle-induced 
stimulation activates some of the same cell survival and maintenance signals 
triggered by strong adjuvants such as LPS.[168] Additionally, only PBAE particles 
were immunogenic, not free forms, further emphasizing the role of form in which the 
materials are encountered. The activation profile for each of the PBAEs, while similar 
for each individual polymer across the markers, varied across the different polymers. 
These results are in agreement with previous studies by Babensee group which 
reveals DCs plated on a variety of natural and synthetic biomaterial films 
differentially activate DCs.[109, 157]  
 
4.5 Conclusion 
Our results demonstrate PBAEs exhibit intrinsic immunogenicity that changes with 
degradation state, but irrespective of starting properties, immunogenicity reaches a 
peak as polymer MW decreases to low values. Other properties (e.g., size, charge, 
concentration) also changed as a function of degradation state; these changes 
occurred with changes in DC function, but not in a way that could be correlated. 
Thus, elucidating the role of each property requires greater understanding of how 
properties changing in combination impact the interactions and signaling in DCs. 




several different polymers evolves during degradation, and that these materials are 
most immunogenic as particles reach MWs in a characteristic range. Ultimately, 
through continued investigation of the mechanism of action of degradable polymers, 
new knowledge could allow for better design of polymer carriers that accounts for 
how these materials might interact differently with the immune system over the 
course of degradation.  
 
In the coming chapters, biomaterials including PBAEs are introduced into LNs of 
mice to probe if these intrinsic immunogenic properties are conserved in animals. 
Chapter 5 introduces the methods for intra-lymph node (i.LN.) injection, a non-
surgical technique to directly deposit materials into LNs of mice. Using this tool, the 
dose, kinetics, and combinations of signals that reach these important immune tissues 
can be controlled, allowing investigation into the impact that each of these immune 















The lymph nodes (LNs) are the tissues of the immune system that coordinate the 
adaptive immune response. At this immunological site, antigen presenting cells 
(APCs) prime naïve lymphocytes against specific foreign antigens to activate cell-
mediated and antibody-mediated immune responses. LNs have thus become an 
attractive target for delivery of vaccines and immunotherapies. Unfortunately, most 
vaccine strategies result in inefficient, transient delivery of antigen and adjuvants to 
the lymphoid tissue.[17] Approaches that improve the targeting and retention of 
vaccine components in LNs could therefore have a significant impact on the potency 
and efficiency of new vaccines. 
 
One strategy for circumventing the challenge of LN targeting that has demonstrated 
great interest in new clinical trials is direct, intra-LN (i.LN.) injection.[83, 84, 169] 
These trials employed ultrasound guidance to deliver vaccines to LNs as a simple 
outpatient procedure. Compared to traditional peripheral injection routes, this 
approach resulted in significant dose-sparing and improved efficacy in therapeutic 
________________________________________________ 
4Adapted from a) J.I. Andorko*, L.H. Tostanoski*, E. Solano, M. Mukhamedova, and C.M. Jewell. 
“Intra-lymph node injection of biodegradable polymer particles.” J Vis Exp. 2014, 83 and b) J.I. 
Andorko, K.L. Hess, K.G. Pineault, and C.M. Jewell. “Intrinsic immunogenicity of rapidly-




contexts including allergies and cancer.[83, 84, 169] These studies employed i.LN. 
injection of soluble vaccines (i.e., biomaterial-free) which were rapidly cleared by 
lymphatic drainage. Therefore, multiple injections – or cycles of multiple injections – 
were administered to achieve these impressive therapeutic effects. Improved retention 
in the LN could enhance the interaction between antigen and/or adjuvant and immune 
cells, further improving the potency of immune cell priming. This potential is 
supported by recent studies that show kinetics of antigen and adjuvant delivery play a 
critical role in determining the specific immune response generated.[54, 170, 171] 
Further, localizing and minimizing drug and vaccine doses could reduce or eliminate 
systemic effects, such as chronic inflammation.  
 
Biomaterials have been studied extensively to enhance the potency and efficiency of 
vaccines.[17, 172, 173] Encapsulation in or adsorption on biomaterial carriers can 
physically shield cargo from degradation and overcome solubility limitations. 
Another notable feature of biomaterial carriers, such as polymeric micro- or nano-
particles, is the ability to co-load several classes of cargo and, subsequently, release 
these cargos over controlled intervals. However, a significant limitation that continues 
to hinder biomaterial vaccines and immunotherapies in vivo is inefficient targeting of 
immune cells and limited trafficking to lymph nodes. For example, peripheral 
injection of biomaterial vaccines through conventional routes (e.g., intradermal, 
intramuscular) typically exhibit poor LN targeting, with up to 99% of the injected 
material remaining at the site of injection.[169, 174] More recently, the size of 




drainage of these vaccines to LNs through interstitial flow.[172, 174] These advances 
have led to enhanced cellular and humoral immune responses, underscoring the 
importance of targeting and engineering the LN environment for new vaccines. 
 
Building on recent studies employing surgical techniques for i.LN. injection in 
mice,[170, 171, 175, 176] we developed a quick, non-surgical strategy for injecting 
biomaterial vaccines, comprised of  combines lipid-stabilized polymer particles, to 
LNs of mice to generate controlled release vaccine depots.[54, 177] The early studies 
combining i.LN. delivery with biomaterial vaccine carriers potently enhanced CD8 T 
cell response within 7 days after a single injection of controlled release vaccine 
depots.[54] A strong humoral response (i.e., antibody titers) was also generated; and 
both enhancements were linked to increased retention of vaccine components in LNs 
that was mediated by controlled release from the biomaterial carriers. Interestingly, 
the size of vaccine particles altered the fate of these materials once in the LNs: 
nanoscale particles showed heightened direct uptake by cells, while larger 
microparticles remained in the extracellular LN environment and released cargo (e.g., 
adjuvant) that was taken up by LN-resident antigen presenting cells.[54]  
 
The work below describes the i.LN. technique used to control the dose, kinetics, and 
combination of immune signals that reach LNs. First, as a proof of concept, 
biodegradable lipid-stabilized polymer particles were synthesized using a modified 
double emulsion strategy and the particle properties were characterized by laser 




the inguinal LNs identified non-surgically using a common, non-toxic tracer 
dye.[178] Post-injection analysis of LNs by histology or flow cytometry verified the 
distribution of particles within the LN environment and monitored cellular uptake and 
retention of particles over time. When i.LN. injection was used to explore the intrinsic 
immunogenicity of PBAEs that were previously found to be immunostimulatory in 
cell studies (see Chapters 3 and 4), PBAE particles caused increased to the number 
and activation states of LN-resident cells.  
 
5.2 Materials and Methods 
5.2.1 Synthesis of Lipid-stabilized PLGA Micro- and Nanoparticles 
In a 7 mL glass vial, lipids (DOPC, DSPE-PEG, and DOTAP, Avanti Polar Lipids) 
were mixed at a 60:20:20 molar ratio and dried nitrogen gas for 10 minutes.  In a 
separate, 20 mL glass vial, 80 mg of PLGA (Sigma-Aldrich) was dissolved in 5 mL 
of dichloromethane to generate a polymer stock solution. 5 mL of the PLGA polymer 
solution was added to the vial containing the dried lipids, capped, and vortexed for 30 
seconds. 
 
For microparticles synthesis, the organic phase containing the polymer and lipid were 
sonicated on ice at 12 W. A water-in-oil (w/o) emulsion was created by adding 500 
µL of distilled H2O and the solution was sonicated for 30 seconds at 12 W on ice. 
During sonication, the vial was gently rocked up and down and side to side around 




emulsion was formed by pouring the first w/o emulsion into 40 mL of H2O in a 150 
mL beaker which was then homogenized for 3 minutes at 16,000 rpm. For 
nanoparticle synthesis the first sonication was at 14 W for 30 seconds. The second 
emulsion was formed by pouring the w/o emulsion into 40 mL of H2O in a 150 mL 
beaker and sonicating for 3-5 minutes at 14 W on ice. To remove the excess solvent, 
microparticle or nanoparticle w/o/w emulsions were stirred overnight. For particles 
containing a fluorescent dye, 10 µL of DiD (Invitrogen) was added to the organic 
phase with the polymer and lipids prior to sonication. For particles containing 
peptide, 1mg of fluorescein-labeled myelin oligodendrocyte glycoprotein, residues 
35-55, was suspended in the 500 µL of distilled H2O used to form the first emulsion. 
 
The following morning, after allowing ~16 hours for the organic phase to evaporate, 
particles were washed and collected. To do this, the emulsion was poured through a 
40 µm nylon mesh cell strainer into a 50 mL conical tube. Microparticles were then 
centrifuged for 5 minutes at 5,000x g. Nanoparticles were collected by centrifuging 
for 5 minutes at 24,000x g. The supernatant was then decanted, particles were washed 
by re-suspending in 1 mL of H2O, and then transferred to 1.5 mL microcentrifuge 
tubes. Particles were then collected by centrifuging for 5 minutes at 5,000x g (for 
microparticles) or 24,000x g (for nanoparticles). Particles were washed twice more by 
removing supernatant, re-suspending in 1 mL H2O, and centrifuging as above. After 






5.2.2 PLGA Particle Characterization 
Particle size was determined using a Horiba LA-950 via the manufacturer’s protocol. 
Briefly, 10mL of distilled H2O was added to the clean glass fraction cell with a 
magnetic micro stir bar. After aligning the lasers, a baseline reading was recorded 
with the fraction cell containing only distilled H2O. Then, 10 µL of particle 
suspension (typically approximately 0.5 mg) was added into the fraction cell, 
ensuring enough particles were added to generate signal strength in the appropriate 
range as indicated on the instrument software interface. Particle size was measured 
using a refractive index of 1.60 by both a number and volume basis.  
 
To visualize particles, particle suspensions were diluted to 1 mg/mL in deionized 
water. Then, a microscope slide was prepared by adding 3 μL of the diluted particle 
suspension and mounted using a coverslip at a 45° angle to avoid bubble formation. 
Particle images were captured using bright field and the appropriate filter sets for any 
fluorescent cargo. 
 
5.2.3 PBAE synthesis, degradation, and characterization and particle fabrication 
PBAEs were synthesized via a Michael-type addition reaction as described previously 
in Chapters 3 and 4 [129, 130, 132, 163, 179]. Briefly, 9 mmol of 4,4′-
trimethylenedipiperidine was dissolved in anhydrous THF to form a 500 mg mL-1 
solution. This solution was added to 9 mmol of 1,4-butanediol diacrylate and the 
reaction was heated to 50°C and stirred for 16 hours. The reaction was cooled to 




cold diethyl ether. After collecting the polymer (Poly1) and washing with additional 
diethyl ether, the polymer was lyophilized. A 16 mg mL-1 solution of Poly1 was 
prepared in CDCl3 and 1H NMR was used to confirm the structure. Poly1 was 
dissolved in THF at 2.5 mg mL-1 and a THF-based gel permeation chromatography 
(GPC) system (Waters) was used to determine polymer MW compared to polystyrene 
standards. To form particles, Poly1 was first degraded by incubating in pH 5 buffer 
(100 mM SA) at 37°C for 24 hours to form polymer fragments. Poly1 particles were 
then assembled via electrostatic condensation by mixing 5 mM degraded Poly1 and 
20 mM SPS at a SPS:Poly1 w/w ratio of 1:1.6.  
 
5.2.4 Preparation of Mice for i.LN. Injection 
A 0.1% (w/v) solution of tracer dye (Evan’s Blue, VWR) was formed by dissolving 
10 mg of dye powder with 10 mL of distilled H2O and sterilized using a 0.2 µm 
syringe filter. One day prior to injection, 4-6 week old C57BL6 mice (Jackson 
Laboratories) were anesthetized using isoflurane. All studies conducted were done in 
accordance with approval from the University of Maryland IACUC. To evaluate 
depth of anesthesia, a toe pinch reflex test was performed and breathing rate was 
monitored throughout to ensure a respiratory rate of approximately 100-140 BPM. 
Next, the hair at base of tail and hindquarter of the mouse was shaved using clippers. 
Hair was removed from the ventral side of the animal and laterally around to the 
dorsal side just above the joint of the hind leg (hip). 
 
To administer tracer dye, 10 µL of dye solution was transferred into a 




Dye solution was injected subcutaneously on each side of the tail base where the hair 
was clipped. To remove the remaining hair on the mouse, a mild depilatory cream 
was applied via cotton swabs and allowed to incubate on the skin for ~3 minutes. 
After incubation, using a wet gloved hand, depilatory cream was gently rubbed into 
skin and then removed by wetting a gloved hand with warm H2O and rubbing tail 
base and hindquarter repeatedly. Any residual depilatory was removed from the 
mouse by wetting a paper towel with warm H2O and in a single motion, wiping the 
lower portion of mouse. Mice were then allowed to recover under a heat lamp and 
once fully recovered, returned to holding. 
 
5.2.5 i.LN. injection of PLGA or PBAE particles into inguinal LNs of mice 
A day after prepping the mice for injection, mice that were shaved and injected with 
tracer dye were anesthetized using isoflurane. Drainage of the tracer dye was then 
visually confirmed in each inguinal LN (the LN appears as a dark spot near the hind 
thigh and abdomen). Particles were then prepared in distilled H2O at desired injection 
concentrations, 10 µL of the particle solution was transferred into a microcentrifuge 
tube, and aspirated into a 31 gauge insulin needle attached to a 1 mL syringe. For 
studies with Poly1, 6.5 µg of free Poly1, Poly1 particles, or a sham consisting of 
buffer were prepared for injection into each inguinal LN. After visualizing the LNs, 
the skin around the LN was tightened using the thumb, index finger, and middle 
finger to pull skin taunt and allow for controlled placement of the injection volume. 
Then, LNs were injected by approaching the LN with the needle at a 90° angle to the 




injecting. After injection, mice recovered under a heat lamp and returned to holding 
or conduct additional testing.  
 
5.2.6 In vivo DC activation, LN cell phenotyping, and lymphadenopathy 
24 hours after injection of PBAEs in particle or soluble form, mice were euthanized 
and the inguinal LNs were removed and placed in PBS. A single cell suspension was 
prepared by passing each LN through a 40 µm strainer with PBS and the total cell 
number was enumerated using an automated cell counter (NanoEnTek). A portion of 
the cells were then stained for surface markers using fluorescent antibodies (BD 
Biosciences, eBioscience, Abcam) and analyzed by flow cytometry for viability 
(DAPI-), phenotype (DC, CD11c+; B cell, B220+; T cell, CD3+), and DC activation 
markers (i.e., CD40, CD80, CD86, MHCII). 
 
5.3 Results 
5.3.1 Lipid-stabilized particles fabricated with varied sizes can encapsulate immune 
signals  
Figure 5.1 depicts the synthesis and characterization of biodegradable polymer 
particles, stabilized by amphiphilic lipids. The PLGA particles resulting from the 
double emulsion, solvent evaporation synthesis protocol (Figure 5.1A) were first 
qualitatively assessed by visual inspection of the final emulsions generated. Particle 
batches were homogenous, stable emulsions with an opaque appearance. Quantitative 




distribution (Figure 5.1B). As expected, the resulting PLGA particles had a tight, 
monomodal distribution for both microparticles and nanoparticles, indicating a 
uniform population. The synthesis parameters described in this chapter generated 
number-averaged distributions centered at approximately 100 nm or 3 µm for 
nanoparticles and microparticles, respectively. Further qualitative assessment of 
particle synthesis was achieved through the incorporation of multiple classes of 
fluorescent cargo. In Figure 5.1C, microscopy images of microparticles loaded with a 
fluorescent peptide (‘Peptide’, green), a lipophilic dye (‘Partile’, red), and an overlay 
image (yellow) confirmed creation of particles within the desired size range and 
encapsulation of peptide within the volume of the particle. 
 
Figure 5.1: Synthesis and characterization of lipid stabilized particles.  
(A) Schematic diagram describing the synthesis of lipid-stabilized particles prepared by 
emulsion/solvent evaporation. (B) Size distributions of microparticles (solid line, diameter = 2.8 µm) 
and nanoparticles (dashed line, diameter = 113 nm). (C) Fluorescent microscopy images of particles 
loaded with fluorescently-labeled peptide and a fluorescent particle dye. Labels: peptide (green), 





5.3.2 PLGA particles can be successfully deposited into LNs 
Following the successful fabrication of particles, i.LN. injection was used to introduce 
these materials into LNs. The first two panels of Figure 5.2 illustrate the preparation 
of animals for the i.LN. injection strategy described above. Inguinal LNs were first  
marked by peripheral injection of a non-toxic tracer to identify the location for 
subsequent i.LN. injection of particles (Figure 5.2A).[54] Drainage of the tracer dye 
following subcutaneous injection at the tail base enabled the visualization of the 
inguinal LNs (Figure 5.2B).[54]  
 
Figure 5.2: i.LN. Injection and distribution of biodegradable particles within LNs.  
(A) Methodology for i.LN. injection. (B) Visualization of LNs in a mouse through skin (upper image) 
and following necropsy (lower image).[54] (C) Histological staining of a LN confirming deposition 
and distribution of fluorescently-labeled polymer microparticles (particles, green; T-cells, red; B-cells, 
blue). (D) Fluorescently-labeled nanoparticles (50 nm, left image) and microparticles (6 µM, right 
image) in LNs 24 hours after injection. 
 
Confirmation of local delivery to the inguinal LN can be evaluated through 
observation or histology. In these studies, LN volume was monitored visually during 




successful injection, allowing for efficient cargo distribution throughout the LN 
structure, without significant leakage to adjacent tissues or cells. Also, after injection, 
the injected fluid displaced and diluted the tracer dye within the LN, causing the 
concentration and coloring of the dye to become less intense following treatment. 
Histological processing of excised LNs was used to definitively confirm delivery of 
cargo to the lymphoid tissue, as shown in Figure 5.2C and Figure 5.2D.  
 
5.3.3 Poly1 particles activate DCs and expand immune cells in mice 
After using PLGA particles as a model system to confirm that biomaterials could be 
directly deposited into LNs using i.LN. injection, the effect of Poly1 on secondary 
lymphoid organs and local immune function was determined using this technique.[13, 
14]. Poly1 was successfully synthesized, degraded into low molecular weight 
fragments, and formulated into particles after degradation (See Figures 3.2, 3.6, 3.8). 
To study the effect of Poly1 in vivo, vehicle (i.e., buffer), free Poly1, or Poly1 
particles were introduced to the inguinal LNs of mice. After 24 hours, mice were 
euthanized and LNs were collected. Following treatment, the percentage of CD11c+ 
DCs found in the LNs treated with vehicle, free Poly1, or Poly1 particles (Figure 
5.3A) did not significantly change, regardless of treatment. Next, we assessed the 
impact of Poly1 treatment on the activation of LN-resident cells by measuring 
expression of CD40 (Figure 5.3B), CD80 (Figure 5.3C), CD86 (Figure 5.3D), and 
MHCII (Figure 5.3E). Treatment with free Poly1 (Figure 5.3, blue) did not alter 
activation compared with the vehicle injection control (Figure 5.3, gray). In contrast, 




cells expressing each marker compared to vehicle or to free Poly1 treatments. In line 
with the results of the DC activation studies, treatment with Poly1 particles (Figure 
5.3F, red) also increased the total number of cells compared to treatments with 
vehicle (Figure 5.3F, gray) or free Poly1 (Figure 5.3F, blue). No significant 
differences were observed in the relative levels of B and T lymphocytes (Figure 
5.3G, H) between each group, although treatment with Poly1 particles appeared to 
cause a modest increase in T cells and a corresponding decrease in B cells. These 
results indicate that Poly1 exhibits intrinsic immunogenicity both in primary immune 
cells and in animals.  
 
 
Figure 5.3: Poly1 particles induce DC activation and lymphadenopathy while maintaining cell 
phenotype balance following i.LN injection into inguinal LNs of mice.  
(A) Percentage of CD11c+ DCs in LN and expression levels of DC activation markers (B) CD40, (C) 
CD80, (D) CD86, and (E) MHCII following treatment of C57BL6 mice treated with buffer alone 
(“Vehicle”, gray) or 24 hour degraded (40% original of MW) free Poly1 (“Free”, blue) or Poly1 
particles (“Particle”, red). (F) Lymphadenopathy as determined by total cell number and percentage of 
B cells (G) and T cells (H) in the LN following treatment as in (A-E). Data are representative of 






The i.LN. injection technique described in this Chapter allows for controlled delivery 
of vaccines to LNs and to LN-resident antigen presenting cells. Biomaterials 
encapsulating various immune cargos can be localized within the LN, enabling 
manipulation of the doses of one or more types of cargo delivered to the LN 
microenvironment. The localization and controlled release from polymer particles has 
been shown to generate a potent cellular and humoral immune response at 
significantly lower doses than conventional approaches. Further, through the 
manipulation of biomaterial carrier size, the primary mode of cellular processing can 
be modulated between direct uptake of nanoparticles or extracellular cargo release 
from larger microparticles.[54] These results establish the feasibility of i.LN. 
biomaterial delivery as a platform for therapeutic vaccine delivery.  
 
PLGA particles were chosen as a model biomaterial system to test i.LN. injection 
because the synthesis of PLGA particles by emulsion/solvent evaporation has been 
widely employed in drug delivery applications.[180, 181] Thus potential challenges 
associated with this technique relate mostly to successful identification and deposition 
of vaccines in the LN target site. To facilitate visualization of target inguinal LNs, 
tracer dye that specifically drains to LNs was used and hair was removed by shaving 
and the application of a depilatory. To further identify a successful injection, injected 
mice can be necropsied and the size of LNs from treated animals can be compared 
with an uninjected control LN. One limitation of this technique is the physical limit of 




injection volume of 10 µL is used for introduction into mice, though other studies 
have reported larger injection volumes at least as high as 20 µL.[176] However, direct 
delivery of vaccines via i.LN. injection permits dramatic dose-sparing so the function 
of these vaccines should generally not be limited by volume constraints. 
 
As noted, changing the physical properties of particles (i.e., size) is an effective 
mechanism to alter the pathway or outcomes induced by biomaterials and 
encapsulated cargos in LN tissue. The double emulsion, solvent evaporation synthesis 
allowed for simple, procedural modifications to alter size and can be used in the 
future to incorporate a variety of cargos or polymers that can alter other physical or 
chemical properties such as surface charge or functionality, and the rate of 
biodegradation/cargo release.[181, 182] For example, the release kinetics can be 
tuned through alternative polymer compositions, and surface function can be altered 
using modified lipid compositions or poly(vinyl alcohol). The cargo loaded in 
particles can be easily manipulated to contain different antigens or adjuvants for 
target pathogens. The advantage of this approach is achieved through the combination 
of i.LN. delivery with local, controlled release of cargo from biomaterials. This 
synergy establishes a platform that can be exploited to efficiently generate adaptive 
immune responses using minute doses and with reduced non-specific/systemic side 
effects. 
 
To begin to investigate how polymer carriers may be causing some of these non-




of PBAEs revealed in Chapters 3 and 4 translated to mice. When Poly1 was 
introduced into mice, we discovered that Poly1 alters the composition and function of 
LNs. Local injection in these studies allowed careful control over the composition 
and dose of the materials in LNs, revealing that, in agreement results from cell studies 
(see Chapters 3.3 and 4.3), Poly1 (i.e., PBAE-4) is immunogenic in vivo and that the 
level of this activity depends on the material properties (Figure 5.3). Treatment with 
Poly1 particles led to an increase in the number of cells in LNs and activated DCs, 
while the effects of free Poly1 on LN-resident cells were more modest. Together, 
these observations suggest that the intrinsic immunogenicity of Poly1 promotes a 
general (innate) stimulatory effect, with only a weak polarization of the T or B cell 
compartment. However, these analyses were carried out after 24 hours; at later time 
points and in future studies when antigen and adjuvant are present, antigen-specific 
effects may be observed. Supporting this possibility, a small biasing toward the T cell 
compartment was observed in LNs after treatment with Poly1 particles, slightly 
increasing the frequency of T cells (Figure 5.3H) and slightly decreasing the 
frequency of B cells (Figure 5.3G).  
 
5.5 Conclusion 
The continued exposure of LNs to vaccine cargos has shown to result in a robust 
systemic immune response. The new, i.LN. injection technique outlined in this 
chapter provides a platform to directly control the amount of immune signals that 




tool, precise control over the timing and combination of signals to these important 
immune tissues allows for the study of the local response to these tissues.  
 
In this chapter, the intrinsic immunogenicity of a degradable PBAE was investigated 
and confirmed in an animal model. In Chapter 6, i.LN. injection is used to introduce 
biomaterial carriers encapsulating vaccine components into LNs of mice. These 
studies provide new knowledge of how these cues impact the local LN 






Chapter 6: Targeted programming of the lymph node 
environment causes evolution of local and systemic immunity5 
 
6.1 Introduction 
Historically vaccine design has focused on generating potent, specific immune 
responses. However, equally important for vaccines aimed at persistent and emerging 
diseases, is the need to better control the nature of the immune responses that are 
generated. For example, in the context of cancer vaccination, tumor-specific CD8+ T 
cells that exhibit memory-like characteristics and proliferate at very high rates might 
help overcome the immunosuppressive tumor microenvironment[183, 184]. Even 
vaccines aimed at well controlled pathogens – such as flu – could benefit from 
formulations that offer better immunomodulatory capabilities, in this example, by 
conferring increased production of mucosal antibodies[185]. Another area of intense 
research along these lines is in the exploitation of new adjuvants – such as toll like 
receptor agonists (TLRas) that stimulate pathogen-detecting inflammatory pathways. 
These molecules can be delivered alone, or in combination to create polarizing or 
synergistic effects[186-190]. Better understanding of the effects of specific vaccine 
components, adjuvants, and carriers, along with knowledge of how these agents work 
together, would help support the design of more effective vaccines.  
 
________________________________________________ 
5Adapted from J.I. Andorko*, J.M. Gammon*, L.H. Tostanoski, Q. Zeng, and C.M. Jewell. 
“Engineering local lymph node function with degradable polymer depots to generate systemic 




Lymph nodes (LNs) are tissues that initiate, maintain, and regulate adaptive immune 
response, and are thus critical targets for vaccines and immunotherapies. At these 
sites, antigen presenting cells (APCs) display antigens to T and B cells with the same 
specificity to mount antigen-specific effector function[20]. Thus the local signals 
integrated in LNs help define the specificity, magnitude, and nature of the resulting 
systemic responses. A key hurdle facing new vaccines and immunotherapies is 
efficiently targeting these sites[191]. For example, to effectively prime lymphocytes 
against a specific antigen, both the antigen and an adjuvant or other stimulatory 
immune signal need to be localized to the same tissue, while the combinations and 
relative concentrations of vaccine components dramatically impact the characteristics 
of this response. Unsurprisingly, significant interested has developed in strategies that 
allow more efficient delivery to LNs and more precise control over the local 
environment in these tissues.  
 
To address the challenges above, many reports in the past several decades have 
investigated biomaterial carriers (e.g., polymer particles[49, 192], liposomes[193-
196]) that encapsulate or adsorb combinations of antigens and adjuvants.[103] The 
tunable sizes, particulate nature, and ability to co-deliver cargos make these vehicles 
attractive as vaccine formulations that can be injected and drain to LNs or can be 
carried there by APCs[15]. Particle size plays a major role in the efficiency and route 
by which these vaccines reach LNs[197], an area that has been heavily 
investigated[15, 103]. While many exciting approaches have been reported, even 




over the routes or doses by which particles reach LNs after injection. Instead, 
vaccines generally rely on passive draining through lymphatic vessels, uptake by 
APCs and subsequent trafficking to LNs, or more recently, active targeting using 
receptor/ligand interactions[15, 103]. Thus, a relatively small faction of the total 
injected dose actually reaches LNs[105, 197], increasing the required dose in some 
cases, or preventing efficacious response in others. These effects are also important 
since some vaccine or immunotherapy components have toxic or inflammatory 
effects that limit the dose or frequency of administration.  
 
A consideration specific to biomaterial carriers is the growing list of polymers, such 
as poly(lactic-co-glycolic acid) (PLGA), polystyrene, and others[103, 198-200], that 
exhibit intrinsic inflammatory effects even in the absence of other immune 
signals[103]. PLGA, for example, is used in countless vaccine and immunotherapy 
studies, but can activate the inflammasome and increases stimulatory response to 
TLRas[200]. While these are characteristics that can be harnessed, they can also 
complicate vaccine research because of the increased complexity resulting from 
“carrier-effects” that alters how the immune system responds to antigens or other 
vaccine components. A better understanding of how immune signals – and their 
biomaterial carriers – interact with the local LN microenvironment, and how these 
interactions direct systemic immunity would help improve vaccine performance, 





We recently developed a strategy to deposit biomaterial vaccine depots directly in 
LNs of mice using intra-lymph node (i.LN.) injection (see Chapter 5) [13, 14, 198]. 
This platform allows direct control over delivery of vaccine components to LNs, and 
sustained release of encapsulated cargo within these tissues. In previous work using 
i.LN. delivery, microparticles (MPs) encapsulating adjuvant generate more potent 
responses than nanoparticles or soluble adjuvant because these large particles are 
better retained in LNs[13]. Therefore, in this work, i.LN. injection of adjuvant-loaded 
MPs was used as a tool to study the evolution of these local and systemic responses 
over time in mice. The data demonstrates that i.LN. deposition of vaccine depots 
consisting of PLGA MPs loaded with a TLR3a and suspended in soluble ovalbumin 
(OVA) antigen increases the number of APCs and lymphocytes in LNs over the 
course of 7 days. Treatment does not alter the relative composition of these 
compartments, but does increase the activation of resident APCs. A single treatment 
with these vaccine depots expands antigen-specific CD8+ T cells locally in treated 
LNs and systemically in peripheral blood, evolving from a potent effector response at 
day 7 to a memory response by day 28. It is next revealed that this approach is 
generalizable: i.LN. injection of vaccine depots loaded with either PolyIC or CpG – 
potent TLRas being explored in human trials – and then mixed with conserved human 
melanoma antigens potently expand tumor-specific CD8+ T cells. These effects 
correlate with slowed tumor progression during an aggressive challenge with 
metastatic melanoma. Together this work demonstrates that local programming of 
distinct LNs with adjuvant depots can be used to drive local alterations that promote 




6.2 Materials and Methods 
6.2.1 Particle Synthesis 
Degradable MPs synthesized via a double-emulsion, solvent evaporation 
technique[13, 14].  For lipid stabilized particles, 1,2-dioleoyl-sn-glycero-3-
phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000], and 1,2-dioleoyl-3-trimethylammoniumpropane 
(Avanti Polar Lipids) were prepared at a 60∶20∶20 mol ratio and dried under nitrogen. 
80mg of PLGA (Sigma) was dissolved with the 5.15μmol of lipids in 5mL of 
dichloromethane. An inner aqueous phase containing 500μL of water or 5mg of 
polyinosinic-polycytidylic acid (PolyIC) (Invivogen) in 500μL of water was added to 
this organic phase containing polymer and lipid and sonicated for 30 seconds at 12W 
to form the first emulsion. This emulsion was then added to 40mL of water, 
homogenized for 3min at 16,000rpm, and then allowed to evaporate overnight while 
stirring to remove any excess organic solvent. Particles stabilized with poly(vinyl 
alcohol) (PVA, Sigma) were formed as above by removing lipids and replacing the 
second water phase with a 2% w/v solution of PVA. For particles containing CpG 
(sequence: 5’ T-C-C-A-T-G-A-C-G-T-T-C-C-T-G-A-C-G-T-T 3’, IDT), 3mg of CpG 
in 500μL of water was used for the first aqueous phase. After overnight stirring, all 
particle formulations were passed through a 40μm cell strainer to remove any large 
aggregates and collected via centrifugation (5000g, 5min, 4°C). Supernatants were 
removed and particles were washed three times with 1mL of water then suspended in 




preparation of fluorescently-labeled particles, 5μL of DiI (Invitrogen) was added to 
the organic phase.  
6.2.2 Particle Characterization 
Particle diameter was determined using an LA-950 laser diffraction analyzer 
(Horiba). Zeta potential was measured using a Malvern Zetasizer Nano ZS90. PolyIC 
and CpG loading levels were determined via UV/Vis spectrophotometry after 
hydrolyzing a known mass of lyophilized particles overnight in 0.2N NaOH. 
Absorbance values were compared to standard curves of known masses of PolyIC or 
CpG to determine a mass of cargo per mass of polymer.  
 
6.2.3 i.LN. Injection 
For each animal study, were prepared as outlined in Chapter 5. Briefly, a small 
region of fur was removed from the lateral hind quarter of 4-6 week old C57BL6 
mice (The Jackson Laboratory) by shaving the area and applying a mild depilatory. 
Tracer dye (Evan’s Blue) was then injected subcutaneously (s.c.) on each side of the 
tail base as previously reported[13, 14, 198]. After allowing 16hrs for the tracer dye 
to drain to the inguinal LNs for visualization, a 31G insulin needle was used to inject 
10μL containing the indicated treatment into each inguinal LN. For visualization of 
particles in LNs, 1mg of DiI labeled MPs were injected. For model antigen studies, 
vaccinations consisted of 1mg of particles encapsulating ~8.5μg PolyIC/mg MPs 
suspended in PBS with 25μg soluble ovalbumin (OVA, Worthington) (‘PolyIC 
MP/OVA’), an injection of 1mg of PLGA MPs with no cargo (‘Empty’), or an 




CpG depots, equivalent doses of adjuvant encapsulated in MPs were administered 
i.LN, after being suspended in PBS with 25 μg of soluble OVA or soluble Trp2 
(SVYDFFVWL, Genscript)  antigens. After priming, mice were boosted with soluble 
vaccine treatments s.c. at each side of tail base at day 21, with each injection 
consisting of 25 μg antigen + 25 μg adjuvant. For studies comparing melanoma 
antigens (Trp2, hgp100), treatments included 1mg of particles containing ~3.5μg 
CpG/mg MPs suspended in PBS with 25μg of soluble Trp2 (‘CpG MP/Trp2’) or 
soluble hgp100 (KVPRNQDWL, Genscript; ‘CpG MP/hgp100’) antigens, or strong 
pre-clinical vaccine consisting of 50μg of CpG and 50μg peptide formulated with 
montanide ISA 51 (Seppic; ‘Montanide/CpG/Trp2’ or ‘Montanide/CpG/hgp100’). 
After vaccinating i.LN. at day 0, subsequent boosts for MP groups were given at days 
15 and 36 post prime and were identical to the prime but administered s.c. at the tail 
base. For the montanide groups, all injections were s.c., but the second boost 
consisted of soluble Trp2 or soluble hgp100 mixed with CpG (see caption). All 
animal studies were approved by the University of Maryland IACUC and conducted 
in accordance with local, state, and federal guidelines. 
 
6.2.4 Tissue Collection, Processing, and Flow Cytometry 
At the indicated times after treatment, LNs were collected from mice, placed in PBS, 
and processed into single cell suspensions by mechanical dissociation through a 
40μm strainer. Cells were split into three portions. One portion of cells was 
centrifuged (800g, 5min, 4°C) and suspended in FACS buffer (1x PBS with 1% w/v 




Counting Beads (BD) to quantify cell viability and enumerate total cell numbers 
using a FACS Canto II (BD), respectively. The other two portions of cells were 
washed once with 1mL of FACS buffer then blocked with Fc Block (anti-
CD16/CD32, BD) for 10 minutes at room temperature to inhibit any non-specific 
binding. After blocking, one portion of cells was stained for innate cell type and 
activation with indicated antibodies against cell surface markers including CD11c, 
F480, CD40, CD80, CD86, and I-A/I-E (mouse MHCII). Cells were then washed 
twice, suspended in FACS buffer, and quantified via flow cytometry. The final 
portion of cells was stained for lymphocyte populations and antigen-specific tetramer 
levels. First, 25μL of anti-SIINFEKL tetramer was added and incubated for 30min at 
room temperature. Then, 25μL of antibodies against surface markers including B220, 
CD3, CD4, and CD8 were added and incubated for 20min at room temperature. Cells 
were then washed and evaluated, as above. The frequency of each cell population 
(percent of parent population) and number of counted cells per identical acquisition 
volume (80μL) was evaluated. The B220 antibody was purchased from eBiosciences 
and all other antibodies were purchased from BD. 
 
6.2.5 MHC Tetramer Staining of Peripheral Blood 
Every 7 days, 100μL of blood was collected from mice treated as above via 
submandibular bleeding. Red blood cells were removed by adding 1mL of ACK lysis 
buffer to the blood, incubating for 3min, collecting cells via centrifugation (800g, 
5min, 4°C), and repeating with 1mL of fresh ACK lysis buffer. After the second 




Block, and stained with a tetramer specific for either SIINFEKL (CD8-epitope of 
OVA), Trp2, or hgp100 for 30min at room temperature. All tetramers were purchased 
from MBL International. Following incubation, cells were stained against surface 
markers CD3, CD8, CD44, and CD62L for 20min at room temperature. After 
washing twice with FACS buffer, cells were suspended in FACS buffer containing 
DAPI and the percentage of antigen-specific cytotoxic T cells (DAPI-, CD8+, 
tetramer+) was quantified via flow cytometry. To determine generation of central 
memory T cell phenotypes, tetramer+ CD8+ cells were gated for CD44high/CD62Lhigh 
populations and compared to the percentage of effector memory T cells 
(CD44high/CD62Llow).  
 
6.2.6 Tumor Challenge Studies 
In some studies, after treating mice with the indicated vaccines, mice were 
administered 300,000 B16-F10 cells (ATCC) in 100μL of 1x PBS s.c. at the hind 
flank. Each day following inoculation, body weight was monitored and tumor burden 
were calculated as a product of two orthogonal diameters. Mice were euthanized 
according to IACUC-approved humane endpoints when the aggregate tumor burden 
reached 150mm2.  
 
6.2.7 Immunohistochemical Analysis 
At indicated time points, inguinal LNs were removed and frozen in OCT compound 
(Tissue-Tek). Using a Microm HM 550 cryostat (Thermo Fisher Scientific Inc.), 6μm 




tissue was then fixed for 5min in ice-cold acetone then washed in 1x PBS. Samples 
were then blocked for non-specific binding of secondary antibody using 5% goat and 
5% donkey serum in 1x PBS for 30min. After washing in PBS, tissues were stained 
for cell surface markers including B220 (eBioscience), CD3 (Abcam), and CD11c 
(BD) for 1hr at room temperature. After washing twice with PBS, fluorescent 
secondary antibodies (Jackson Immunoresearch) were added for 45min then washed 
three more times. After staining, sections were fixed with 4% paraformaldehyde, 
washed with PBS, quenched with 1% glycerol in PBS, and washed again before 
mounting in Prolong Diamond Antifade Mountant (LifeSciences) and imaging using 
an Olympus IX83 fluorescent microscope. Processing of images was conducted 
versus an antibody iso-type control and levels were adjusted equally for all similar 
channels. 
 
6.2.8 Statistical Analysis 
Student’s t tests were used in comparison of two groups. One-way ANOVA with a 
Tukey post-test was used to compare three or more groups, or two-way ANOVA for 
comparisons over time. In all cases, analyses were carried out with Graphpad Prism 
(version 6.02). Error bars in all panels represent the mean ± SEM and p-values < 0.05 
were considered significant. Levels of significance were defined as *p<0.05; 





6.3.1 PLGA MPs are dispersed in LNs following i.LN. injection 
PLGA MPs were synthesized via a double-emulsion/solvent evaporation technique 
allowing for the inclusion of negatively charged nucleic acid TLRa adjuvants PolyIC 
or CpG with loading levels of 8.5μg/mg MP or 3.5μg/mg MP, respectively (Table 
6.1). Addition of PolyIC led to an increase in particle diameter from 2.2μm to 4.3μm 
and a shift in zeta potential from 24.9mV to -23.7mV; replacement of PolyIC with 
CpG led to similar shifts (Table 6.1). To first confirm retention of injected MPs into 
LNs, we injected DiI-labeled MPs into inguinal LNs of mice using the approach we 
previously described (Figure 6.1A)[13, 14, 198]. 28 days after injection, LNs were 
removed and then stained for B cell (Figure 6.1B, cyan) and T cell zones (Figure 
6.1B, white). Fluorescent microscopy confirmed retention of MPs in the LNs at this 
time point (Figure 6.1B, green). 
 
Table 6.1: Characteristics of adjuvant loaded PLGA-MPs used in i.LN. injection studies. 
 
 Diameter (μm) 
Loading 
(μg cargo/mg MP) 
Zeta Potential 
(mV) 
Empty 2.19 ± 0.14 n/a 24.93 ± 0.91 
PolyIC 4.26 ± 0.09 8.53 ± 0.46 -23.70 ± 0.71 







Figure 6.1: Vaccine depots can be locally deposited in LNs via i.LN. injection.  
(A) Schematic depicting i.LN. injection of vaccine depots. A tracer dye is injected s.c. at the tail base, 
which then drains to the inguinal LNs allowing visualization of the LN through the skin. Vaccine 
depots can then be injected into the LN. (B) Histological section of LN 28 days after i.LN. injection of 
fluorescent depots. B cells (B220+, cyan), T cells (CD3+, white), PLGA MPs (DiI, green). Scale bar= 
200μm. 
 
6.3.2 i.LN. injections of PolyIC MP/OVA increases the number of APCs and 
lymphocytes in LNs 
After confirming MPs are retained in LNs of mice over 4 weeks, we used i.LN. 
injection to administer a vaccine of PolyIC MPs mixed with soluble OVA (PolyIC 
MP/OVA), or to administer a buffer injection (sham). Cell viability and the frequency 
and number of DCs, macrophages, T cells, and B cells in the treated nodes were then 




PolyIC MP/OVA, while slightly diminishing initial cell viability relative to sham, did 
not impact viability after 1 week (Figure 6.2A). Particles did cause an increase in the 
overall number of cells (Figure 6.2B), as well as the volume of each LN (discussed 
below), with nodes treated with PolyIC MP/OVA exhibiting significantly more cells 
per LN than the sham at day 1 (p<0.01); a similar trend was observed over one week. 
In investigating how PolyIC MP/OVA treatment influenced innate immune cell 
populations, we discovered the frequency of DCs (CD11c+) did not significantly 
change over 1 week, while a slight elevation in macrophage (F4/80+) frequency was 
observed (Figure 6.2C). However, the number of each of these cell types (normalized 
to equivalent tissue cell suspensions) increased over time, with significantly more 
DCs (p<0.001) and macrophages (p<0.01) accumulating in the LNs over 7 days 
following PolyIC MP/OVA injection (Figure 6.2D). Similarly, we observed modest 
changes in the frequency of lymphocytes in the B cell (B220+) and T cell (CD3+; 
CD3+/CD4+; CD3+/CD8+) compartments relative to sham injections (Figure 6.3A). 
However, enumeration of the number of lymphocytes again revealed PolyIC 
MP/OVA increased the number of cells in each population, with the maximum 
difference between groups occurring 7 days after the immunization. 
Immunohistochemical staining of the LNs at 1 day (Figure 6.4A) and 7 days (Figure 
6.4B) after injection confirmed the increased total number of cells, indicated by the 
increased area evident in each section; all sections are presented at the same scale. 
These studies also qualitatively confirmed the increased DC levels we measured in 
response to PolyIC MP/OVA treatment relative to sham, and the increase in DC 




at day 7 (i.e., sham vs. PolyIC MP/OVA) and the insets of Figure 6.4A and Figure 
6.4B for PolyIC MP/OVA (i.e., day 1 v. day 7), respectively.  
 
 
Figure 6.2: i.LN. injection of PolyIC MP/OVA depots increases innate cell numbers in the LNs 
without affecting cell viability.  
(A) Viability and (B) total number of LN cells after i.LN. injection of PolyIC MP/OVA depots or a 
sham injection of PBS at days 1, 3, and 7. (C) Percentage of total LN cells which are DCs (CD11c+) 
and macrophages (F480+) and (D) number of DCs and macrophages in LNs counted in an identical 







Figure 6.3: i.LN. injection of PolyIC MP/OVA depots increases total number of T and B 
lymphocytes within LNs.  
(A) Percentages and (B) total numbers of B cells (B220+), T cells (CD3+) as well as CD4+ T cells 
(CD3+/ CD4+) and CD8+ T cells (CD3+/ CD8+) in LNs after i.LN. injection of PolyIC MP/OVA depots 
or a sham injection of PBS at days 1, 3, and 7. Numbers are counted in an identical acquisition volume 







Figure 6.4: Increased LN size and DC numbers in LNs occurs by day 7 after i.LN. injection of 
PolyIC MP/OVA depots.  
Histological staining of LNs for B cells (B220+, cyan), T cells (CD3+, white), and DCs (CD11c+, 
green) in LNs 1 day (A) and 7 days (B) after i.LN. injection of PolyIC MP/OVA depots or a sham 





6.3.3 PolyIC MP/OVA treatment activates LN-resident APCs 
After determining that i.LN. treatment with PolyIC MP/OVA increases the number of 
APCs, we tested if these populations exhibited an increased activation state by 
staining for surface activation markers associated with co-stimulation and antigen 
presentation (i.e., CD40, CD80, CD86, I-A/I-E). In all cases, PolyIC MP/OVA 
caused a significant increase in the number of cells positive for each marker 
compared to the sham injected control (Figure 6.5A). Interestingly, the number of 
activated DCs increased over time with the highest levels of each marker occurring 7 
days after treatment (Figure 6.5A, red). The macrophage population exhibited 
similar activation effects (Figure 6.5B). However, compared to DCs, which showed 
increases in the number of cells expressing each marker over time, only CD40 and I-
A/I-E increased as a function of time. Macrophage expression levels of CD80 and 
CD86 – while higher than levels in sham-injected nodes – remained at a near-





Figure 6.5: PolyIC MP/OVA depots injected i.LN. drive prolonged increase in surface activation 
marker expression in DCs and macrophages.  
Number of DCs (A) and macrophages (B) in LNs expressing activation markers CD40, CD80 CD86 
and I-A/I-E at 1, 3, and 7 days after i.LN. injection of depots. Numbers are counted in an identical 
acquisition volume (80µL). n=9-10 LNs per group with bars depicting mean ± SEM. (*p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001) 
 
6.3.4 Local changes in APC function drive local and systemic antigen-specific CD8+ 
T cell response 
We next used MHC-I tetramer staining to investigate if the local activation we 
observed drove generation of antigen-specific T cells, both in treated nodes and 
systemically. Analysis of LNs after treatment revealed that vaccinating with PolyIC 
MP/OVA increased both the frequency and number of antigen-specific CD8+ T cells 
within the LN (Figure 6.6A, B). While the sham injection (Figure 6.6A, B, blue) 
remained at a constant, low level, the PolyIC MP/OVA treated mice exhibited a 
significant (p<0.01) increase in SIINFEKL-specific T cells 7 days after priming. To 




changes in antigen-specific responses, mice were treated with either PolyIC 
MP/OVA, empty MPs, a sham injection, or left untreated. After vaccination on Day 
0, blood was collected weekly and SIINFEKL tetramer staining was used to 
determine the percentage of antigen-specific CD8+ T cells circulating in peripheral 
blood. Figure 6.6C-F depicts representative flow cytometry plots showing the gating 
scheme applied to samples from naïve (Figure 6.6C, gray), sham (Figure 6.6D, 
blue), empty MP (Figure 6.6E, green), or PolyIC MP/OVA (Figure 6.6F, red) 
treated mice 7 days after immunization. The average SIINFEKL tetramer levels 
revealed that treatment with PolyIC MP/OVA significantly increased (p<0.0001) 
systemic levels of SIINFEKL-specific CD8+ T cells 7 days after treatment, followed 
by a prototypical contraction period through day 28 (Figure 6.6G). The elevated level 
of SIINFEKL-specific CD8+ T cells at day 28 suggested development of immune 
memory, which we assessed using common markers for effector T cells and memory 
T cells among CD8+/Tetramer+ cells. These studies revealed a nearly 2-fold increase 
in the percentage of central memory T cells (CD62Lhigh/CD44high among SIINFEKL-
specific CD8+) and a subsequent decrease in effector memory phenotypes 









Figure 6.6: i.LN. injection of depots drives antigen-specific T cell responses locally in LNs and 
systemically in the periphery.  
(A) Percentage and (B) numbers of SIINFEKL-tetramer+ CD8+ T cells in LNs at 1, 3 and 7 days after 
i.LN injection of PolyIC MP/OVA depots or a PBS sham injection. Numbers are counted in an 
identical acquisition volume (80µL). n=9-10 LNs per group with bars depicting mean ± SEM. 
(**p<0.01; ***p<0.001) Mice were immunized i.LN. with PolyIC MP/OVA depots, Empty MPs, a 
sham injection of PBS or left untreated (naïve), and leukocytes from peripheral blood were stained for 
SIINFEKL-tetramer+ CD8+ T cells weekly starting 7 days after immunization. Representative flow 
cytometry plots illustrating the gating scheme for SIINFEKL tetramer staining of untreated mice (C), 
mice immunized i.LN. with a sham injection of PBS (D), Empty MPs (E), or PolyIC MP/OVA depots 
(F) 7 days after treatment. (G) Mean percentage of SIINFEKL-tetramer positive T cells and (H) 
percentage of SIINFEKL positive T cells with effector (CD62Llow/CD44high) or memory phenotypes 
(CD62Lhigh/CD44high) in mice from treatment groups detailed in C-F. n=8 mice for Day 0, n=10 mice 
per group at Day 7, and n=4-5 mice per group for Days 14-28. (**p<0.01; ***p<0.001; ****p<0.0001 





To test the robustness and modularity of this platform, we next tested if i.LN. 
injection expands antigen-specific T cells with vaccines containing different TLRas 
or other antigens, in particular, Trp2 peptide – a clinically-relevant tumor associated 
antigen conserved in murine and human melanoma[201]. Depots were formulated 
with either PolyIC or CpG – a potent adjuvant being studied to induce anti-tumor 
immunity[49, 202] – and mixed with soluble OVA or Trp2. Mice were immunized 
i.LN at day 0 with vaccine depots encapsulating identical doses of adjuvant, and then 
boosted at day 21 with soluble vaccine components s.c. at the tail base. At days 7 and 
28 (7 days after the prime and boost injections), peripheral blood was drawn and 
MHC-I tetramer staining was used to quantify the percentage of antigen specific 
CD8+ T cells (Trp2 tetramer for Trp2 immunized mice, SIINFEKL tetramer for OVA 
immunized mice). For mice immunized with OVA vaccine depots both treatments 
induced very potent antigen-specific responses, but no significant differences were 
measured between responses induced by CpG MPs and PolyIC MPs at either day 
(Figure 6.7, left). However, in mice treated with Trp2 vaccine depots, a significantly 
higher level of Trp2 specific CD8+ T cells was observed in mice immunized with 





Figure 6.7: CpG MPs induce superior tumor-specific CTL responses compared to PolyIC MPs.  
Mice were primed at day 0 i.LN. will either PolyIC MPs or CpG MPs, and either a model antigen 
(OVA) or a melanoma associated antigen (Trp2) in a soluble form. Mice were boosted at day 21, and 
antigen-specific MHC-I tetramer was used to measure antigen specific CD8+ T cell responses 
compared to a sham injection. (A) 7 days after priming, PolyIC and CpG MPs both induced potent 
levels of SIINFEKL-specific CD8+, but no differences were observed as a function of TLRa. In the 
Trp2 model, both PolyIC and CpG MPs increased the levels of Trp2-specific CD8+ T-cells, with CpG 
exhibiting a statistically significant increase compared to both the sham and PolyIC MP injections. (B) 
At day 28, 7 days after the boost, a similar response was seen with a robust response in the OVA 
model for both PolyIC and CpG MPs, but without dependence on the specific TLRa included in the 
particles. In the Trp2 studies, only CpG MPs induced a significant, potent recall response. (* p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001). 
 
6.3.5 Local administration of CpG particles promotes anti-tumor immunity 
We next used an aggressive melanoma model – B16-F10 – to test the functionality of 
anti-tumor immunity induced by vaccine depots administered by the i.LN. route. 
Since vaccine depots formulated with CpG promoted superior expansion of Trp2-




immunized mice with CpG depots containing 3.5µg of CpG and suspended in either 
Trp2, or another conserved melanoma antigen, hgp100[203, 204].  In these studies, 
mice were primed on day 0 with either CpG MP/tumor antigen, or as a potent 
benchmark, 50µg CpG and tumor antigen emulsified in montanide, one of the 
strongest adjuvants currently under study[205, 206]. Animals were then boosted on 
day 15 with identical doses and formulations, but all injections were administered s.c. 
as a heterologous prime-boost regimen. MHC-I tetramer staining for either Trp2- or 
hgp100-specific CD8+ T cells revealed formulations containing CpG MPs exhibited 
significant increases in these populations relative to other groups after both priming 
and booster injections (Figure 6.8A, B). After a second boost on day 36, mice were 
challenged with B16-F10 metastatic melanoma by implantation of 3 x 105 cells s.c. at 
the hind flank. Compared to the untreated group (Figure 6.8C, H), the mice primed 
s.c. with montanide/CpG/hgp100 (Fig. 8D, H) or i.LN. with CpG MPs/hgp100 
(Figure 6.8F, H) did not exhibit any therapeutic gains. In contrast, i.LN 
immunization with CpG MP/Trp2 slowed tumor growth, resulting in 40% survival at 
day 20 (Figure 6.8G, H), while all untreated mice succumbed by this day (Figure 
6.8C, H). Interestingly, while Montanide/CpG/Trp2 prolonged survival of mice to 29 
days after tumor challenge (Figure 6.8E, H) the effect appeared less potent than 
those generated by CpG MP/Trp2 vaccine regimens, which survived for up to 35 
days. The mean survival was 23.0±4.5 days for the CpG MP/Trp2 treated group, 
compared to 20.0±2.4 days for the Montanide/CpG/Trp2 treated group, and 16.3±1.7 
days for the untreated group, further demonstrating the ability of local LN treatment 





Figure 6.8: i.LN. injection of CpG MP/Trp2 depots promote functional anti-tumor immunity.  
(A) Mice were left untreated, immunized s.c. with Montanide/CpG/Trp2, or immunized i.LN. with 
CpG MP/Trp2, followed by s.c. boosts consisting of identical treatments at Day 15. Trp2-tetramer 
specific T cells were quantified in peripheral blood at 6, 14 and 21 days after immunization. (B) A 
study conducted using identical treatment regimens as in (A), but including an additional tumor 
antigen, hgp100. hgp100-specific CD8+ T cell responses in peripheral blood were quantified using 
hgp100 MHC-I tetramer in peripheral blood at 6, 14 and 21 days after immunization. Values indicate 
mean ± SEM. (**p<0.01; ***p<0.001; ****p<0.0001 between CpG MP groups and naïve; ##p<0.01; 
###p<0.001; ####p<0.0001 between CpG MP groups and montanide). (C-H) Mice were left untreated, 
immunized with Montanide/CpG/hgp100, Montanide/CpG/Trp2, CpG MP/hgp100 (i.LN.), or CpG 
MP/Trp2 (i.LN.) followed by s.c. boosts at Day 15 and Day 36 as described in the methods. 43 days 
after the priming injection, mice were challenged with B16-F10 melanoma. Individual tumor traces of 
untreated mice (C), mice immunized with Montanide/CpG/hgp100 (D), Montanide/CpG/Trp2 (E), 
CpG MP/hgp100 (F) and CpG MP/Trp2 (G). (H) Percent survival of mice in the groups shown in C-G.  
 
6.4 Discussion 
Biomaterials offer a robust platform to co-deliver immune signals, target vaccines to 




formulations with multiple components, and understanding how each component 
influences the immune response alone or together has been challenging thus far. 
Previous research has shown that altering material properties can influence and 
improve the targeting of vaccines to LNs through lymphatic drainage or trafficking 
within specific APCs after internalization[48, 49, 67, 191, 207]. i.LN. delivery, 
however, offers a unique opportunity to directly study how the form and combination 
of signals that ultimately reach LNs impact immune response without the 
complexities that occur after vaccines are administered by traditional routes. For 
example, even efficacious vaccines only result in a small fraction of the injected dose 
reaching the LN and spleen – as little as 0.1%, whereas pre-clinical and clinical trials 
studying i.LN. delivery of soluble vaccines have demonstrated dose-sparing factors as 
high as 106 relative to common peripheral injection routes[77, 78, 80]. With respect to 
nanoparticles, past studies have revealed that particles administered along common 
peripheral routes drain to LNs most efficiently when the diameters are in the range of 
20-30nm, whereas even 100nm particles drain an order of magnitude less 
efficiently[197]. Microparticle drainage relies heavily on APC trafficking[103]. Past 
findings from our lab demonstrate that improved retention of adjuvant in LNs 
achieved by encapsulation in MPs too large to freely drain from LNs after i.LN. 
injection drives very strong T cell responses compared to equivalent doses of soluble 
adjuvant administered i.LN., or adjuvant MPs administered peripherally (e.g., in 
muscle)[13]. In contrast, nanoparticles or soluble adjuvant are retained in LNs at 
intermediate and low levels, respectively, driving correspondingly lower responses 




of how these local treatments alter LN function over time, and how this local 
evolution impacts systemic immunity.  
 
With respect to local changes in LNs, several of the findings together suggest an 
adjuvant mechanism underpinned by increased activation of LN-resident APCs. First, 
generally a large difference was observed in the number of immune cells in treated 
nodes relative to sham injections, with more modest differences in the relative cell 
compositions. These frequencies – for both innate and adaptive immune cells – were 
similar to those previously reported in LNs of C57BL6 mice[208]. Second, 
persistence of fluorescent MPs was observed for at least 4 weeks 9 (Figure 6.1B), 
and increased activation of LN-resident APCs (e.g., macrophages, DCs) as soon as 1 
day after injection. Thus, one important role for the depots appears to be enhanced 
local APC function that could help increase lymphocyte proliferation and infiltration. 
The resulting antigen-specific responses showed enhancements consistent with strong 
T cell response. For example, OVA-specific T cells developed locally in LN over 7 
days, by which time a dramatic increase was measured in peripheral blood. This 
evolution is consistent with primed lymphocytes migrating out of the LNs as they 
expand against SIINFEKL presented in these sites[209]. Similarly, a shift towards a 
central memory phenotype and away from effector response was also observed over 
time, a goal for effective vaccines[210]. Interestingly, it was observed that both 
depots and sham injections caused modest – sometimes, transient – increases in the 
frequency of B cells and CD4+ T cells. Thus, an additional enhancing mechanism 




adhesion molecules (e.g., P-, E-selectin) to better retain circulating T and B cells. The 
absence of toxicity, and the intact follicular structure of LNs after either sham or 
adjuvant MP treatment, further supports the compatibility of this strategy for 
fundamental or applied uses.  
 
The link between the kinetics of vaccine dosing and induction of immune response is 
well established, with elegant studies demonstrating that increasing dosing regimens 
drive synergistic immune responses more effectively than equivalent doses 
administered in a bolus or at evenly spaced equal doses.[211] This discovery supports 
the basic premise for delivery of controlled release depots to LNs, as the local dose of 
vaccine components locally increases in LNs as cargo is released from degrading 
polymer particles[13]. Further, while there is significant potential made possible by 
determining whether vaccine particles loaded with antigen, adjuvant, or both might be 
most potent for a particular vaccine[187], design of adjuvant-loaded particles offer 
the appeal of “plug-n-play” vaccination whereby the particle is simply mixed with a 
soluble adjuvant of interest.  
 
It was found that i.LN. injection of adjuvant MPs drove antigen-specific T cell 
responses against both model antigen (i.e., OVA) and tumor-associated antigens (i.e., 
Trp2, gp100) mixed with the depots. Interestingly, for OVA, both PolyIC-loaded and 
CpG-loaded depots performed equivalently, while CpG was more effective in 
generating responses against tumor-associated antigens. CpG has stimulated great 




response[49, 196, 202, 212, 213]. Thus, i.LN. delivery of CpG MPs mixed with 
common conserved melanoma antigens was benchmarked against these same 
antigens emulsified with CpG and montanide, one of the strongest vaccine 
formulations under study[205, 206]. With respect to both tumor-specific T cell 
expansion and anti-tumor immunity, i.LN. depots were superior to montanide, but 
interestingly, the dose of CpG in MP formulations (3.5 µg/LN) was 14-fold lower 
than the 50 µg dose of CpG emulsified in the montanide vaccines. Thus, although the 
efficacy achieved with i.LN. depots in this study was modest (~40% of mice exhibited 
significantly increased survival), the enhanced performance compared with 
montanide and this dose-sparing supports the potential of future MP-based vaccines 
administered to LNs. 
 
There are some considerations that might account for the limited efficacy observed in 
tumor challenge studies. First, the chosen melanoma model is highly aggressive. 
Second, general features of the tumor microenvironment likely limit immunogenicity, 
including suppression and antigen editing that prevents tumor-specific CTLs from 
maintaining function or recognizing antigens in tumors[184, 214]. Third, in these 
experiments, much higher frequencies of SIINFEKL-specific T cell responses were 
observed after a single i.LN immunization with OVA depots relative to either 
melanoma antigen, even after the latter were administered in several booster 
injections. OVA is a foreign antigen, whereas Trp2 and hgp100 are self-antigens and 
typically much less immunogenic. Since cross-presentation of minimal epitope 




216], encapsulation of antigen in MPs alone, or in conjunction with adjuvant might 
offer one route to further improve potency. However, since significant populations of 
antigen-specific CD8+ T cells were generated against either tumor antigen, more 
robust responses might improve effectiveness. Along these lines, recent pre-clinical 
and clinical studies reveal simultaneously activating multiple TLR pathways during 
cancer therapy can enhance therapeutic efficacy[217-220], suggesting another 
strategy based on loading of MPs with multiple TLRas.  
 
i.LN. delivery of MPs also provides some unique opportunities to impact the tumor 
microenvironment through appropriate selection of the LN for injection. In these 
studies, the inguinal LN was selected for ease of injection based on previous work 
(see Chapter 5), and what has been used in recent human trials involving i.LN. 
delivery of soluble tumor antigens to inguinal LNs[221]. However, this technique 
could also be used to target tumor draining lymph nodes (TDLN), sites which have 
recently been shown to be effective for passive targeting of cancer vaccines[48, 49, 
183, 222]. Remarkably, several landmark studies also demonstrate that both anti-
tumor T cells and regulatory T cells (TREGs) – cells that suppress anti-tumor response 
in tumors – are primed in the same LN[223, 224]. Thus, direct LN targeting of 
TDLNs might allow local polarization toward effector cells while also reducing 
suppressive TREGs that play an important role in maintaining the suppressive tumor 
microenvironment. This may further provide an opportunity to effectively combat 
tumors without affecting natural regulatory activity in other distant LNs. It is also 




specific cells that are able to migrate to tumors, but further studies will be needed to 
investigate this possibility. Finally, creating opportunities to overcome the 
suppressive characteristics of tumors by directly targeting the TDLN, or pairing with 
exciting new immunotherapies such as checkpoint blockades could also have offer 
significant potential for cancer vaccination[225, 226].  
 
6.5 Conclusion 
i.LN. injection allows direct control over the dose and combinations of materials 
administered to LNs, supporting a new approach for studying the impact of vaccines 
on the LN microenvironment. Here, it is demonstrated that a single i.LN. injection 
into both inguinal LNs of mice can lead to dramatic local changes in these tissues, 
increasing the number and function of both APCs and lymphocytes. The local 
changes result in systemic, but antigen-specific pro-immune function that provides 
functional anti-tumor immunity in a melanoma model. Thus, this approach might 
hold clinical utility for vaccines based on intra-LN controlled release of antigens and 
adjuvants, while also providing a strategy to evaluate the immunogenicity of 
biomaterial carriers themselves, or to design carriers loaded with defined 
combinations of antigens and adjuvants.  
 
This chapter studies cancer vaccines using i.LN. injection as a well-defined model, 
but an important clinical issue for cancer therapy is identifying new therapeutic 
targets. This requires new tools to study cancer cells in a meaningful 




Maryland Medical School in which I created a system to immobilize cells while 
maintaining their free-floating dynamics. This platform allowed for real time imaging 






Chapter 7: Lipid tethering of breast tumor cells enables real-
time imaging of free-floating cell dynamics and drug response6 
 
7.1 Introduction 
Cancer metastasis occurs when epithelial tumor cells travel through non-adherent 
microenvironments, like the bloodstream or lymphatics, to a distant organ. The 
presence of tumor cells in the non-adherent microenvironment of the bloodstream, 
known as circulating tumor cells (CTCs), has been detected in numerous epithelial 
cancers including breast, prostate, colon, and lung [227]. CTCs are an early indicator 
of clinical spread of disease and their levels correlate with decreased patient survival 
[228, 229]. Based on the increasing clinical relevance of CTCs, understanding their 
molecular profile is emerging as a new opportunity to gain insight on disease 
progression and patient prognosis beyond enumeration alone. Though progress has 
been made on technologies to enhance the identification and enumeration of CTCs 
[227, 230, 231], major limitations remain in performing downstream functional 
studies due to challenges with accurate detection and the low number of CTCs that 
can be retrieved from patient blood (frequency of approximately 1 in 100 million 
cells in the bloodstream) [227]. Some of the techniques currently being employed to 
analyze CTCs include fluorescence in situ hybridization, sequencing, 
________________________________________________ 
6Adapted from K. Chakrabarti*, J.I. Andorko*, R.A. Whipple, P. Zhang, E.L. Sooklal, S.S. Martin, 
and C. M. Jewell. “Lipid tethering of breast tumor cells enables real-time imaging of free-floating 
cell dynamics and drug response.” Oncotarget. 2016, 7, 10486-10497.  




immunostaining, xenograft transplantation, and RNA or protein-based analysis [227, 
230, 232, 233]. However, these methods do not allow for real-time analysis of CTCs 
in an environment that preserves their free-floating nature. 
 
Microscopy analysis of CTCs has focused almost exclusively on cells adhered to 
surfaces (glass, plastic, extracellular matrix (ECM) owing to the ease of imaging and 
characterization of cells in these static positions. However, the functional and 
molecular characteristics of adherent and non-adherent tumor cells are dramatically 
different [234-237]. Thus a critical knowledge gap exists in the understanding of 
epithelial tumor cells in non-adherent microenvironments, such as those found in 
blood vessels. Non-adherent breast carcinoma cells, for example, produce unique 
tubulin-based microtentacles (McTNs) that promote tumor cell aggregation [238, 
239], reattachment to endothelial layers [240, 241], and retention of CTCs in the 
lungs of mice [242, 243]. New enabling technologies to image tumor cells, McTNs, 
and other features in the absence of ECM attachment could vastly improve the 
understanding of dynamic cell behaviors that occur in the non-adherent 
microenvironments encountered by CTCs during metastasis. These tools could also 
support opportunities for selective targeting of drugs to McTNs or other structures 
presented preferentially by CTCs during metastatic spread, as well as help address 
rising concerns that chemotherapies meant to reduce tumor growth may actually 
increase metastatic risk [244]. Here, we exploited the discovery that McTNs form 
only when protein-based adhesions are absent to create an innovative platform for 




approach allows new types of information to be collected (e.g., McTN behavior on 
live cells over time) while reducing variables such as changes in cell function that 
occur during adhesion or the complexities of imaging cells in suspension that drift or 
are washed away during microfluidic flow.  
 
Biomaterials offer many attractive features – stability, biocompatibility, versatile 
chemistries – for controlling cell adhesion. Common approaches include chemically 
functionalizing surfaces, incorporating cell adhesion peptides, and micropatterning 
using polymer-based soft lithography or electrospinning techniques. Of particular 
note, several recent studies have exploited biomaterials to identify CTCs [245-247] or 
used microfluidic devices to isolate and immobilize CTCs by acoustic separation, 
topography, controlled flow rates, and antibody traps [248-251]. Polyelectrolyte 
multilayers (PEMs) are nanoscale, polymeric materials assembled by electrostatic or 
hydrogen bonding interactions during a layer-by-layer (LbL) deposition process. 
PEMs can be coated on topographically-complex surfaces (e.g., colloidal, 
microfluidic) and offer programmable surface functionalities depending on the 
polymers used to assemble films. PEMs have recently been employed to capture 
CTCs through incorporation of cytophilic polymers or cell-adhesive proteins that 
promote CTCs adhesion [252-254]. However, new strategies are needed to study the 
dynamics of McTNs and other unique metastatic features that form only when CTCs 





To enable this new ability, we identified three design features that would allow 
prolonged, real-time imaging and drug screening of McTNs on live tumor cells in a 
free-floating state: 1) optically-clear coatings to support imaging, 2) ability to control 
microfluidic flow over cells and 3) simple, low-energy manufacturing process. Past 
studies have demonstrated the utility of PEMs for tuning cell adhesion by varying 
polymer composition or through addition of lipids, RGD sequences, or other binding 
moieties [255-260]. Thus we leveraged PEMs to design a platform to immobilize live, 
detached tumor cells on microfluidic devices. We show that assembling cytophobic 
PEM films with cytophilic lipid tethers maintains the free-floating properties of tumor 
cells while providing spatial immobilization of cells. When tethered, McTNs on live 
cells can be visualized in real time and the dynamics of these structures can be 
assessed during microfluidic flow of drugs that enhance or destabilize McTNs. This 
technology could generate fundamental insight into a critical stage of metastasis that 
has been largely understudied due to technical challenges and support new 
approaches to exploit McTNs as biomarkers for the metastatic efficiency of tumor 
cells in diagnosis, prognosis, and targeted drug design. 
 
7.2 Materials and Methods 
7.2.1 Cell Lines & Materials  
MDA-MB-436 and MCF-7 cell lines were purchased from ATCC and cultured with 
Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and 




polyacrylamide (PAAm) (MW 5,000,000-6,000,000) were purchased from 
Polysciences. Poly(allylamine hydrochloride) (PAH) (MW ~200,000) was purchased 
from Alfa Aesar. 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
(DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were purchased 
from Avanti Polar Lipids. Colchicine was purchased from Sigma and paclitaxel was 
purchased from Enzo Life Sciences. 
7.2.2 PEM Film Deposition and Characterization on Planar Substrates  
For multilayer film deposition, similar to methods previously reported [261], PMA 
and PAAm were prepared as 0.01M solutions using ultrapure water and adjusted to 
pH 3. All polymer solutions were filtered with a 0.45 µm cellulose nitrate filter prior 
to use in multilayer film assembly. For planar substrates, quartz (Chemglass Life 
Sciences) or silicon (Silicon Inc.) were cut into 5mm x 25mm substrates using a 
dicing saw (Model 1006, Micro Automation). Cut substrates were cleaned with 
sequential washing with acetone, ethanol, methanol, and deionized water then 
charged using an oxygen plasma Jupiter III system (March). These substrates were 
first immersed in the polycationic solution PAH (0.05M) for 15 mins then rinsed 
twice using two separate baths of deionized water at pH 3 to remove any excess 
polymer. This primer layer was followed by immersion of the substrates into 
polyanionic PMA (0.01M) for 5 mins followed by rinsing as above. The substrates 
were then immersed in a polycationic solution of PAAm (0.01M) for 5 mins and 
rinsed. For additional bilayers, the process was repeated without the addition of the 
primer layer (PAH) until the desired number of bilayers was assembled. Lipid 




dioleoyl-3-trimethylammonium-propane (DOTAP) were obtained from Avanti Polar 
Lipids. These lipids were prepared as 0.01M solutions with pH 3 deionized water and 
sonicated for 60 mins in a room temperature water bath. PEMs with a lipid tether 
were prepared by immersing PEM coated substrates in each lipid solution for 5 mins 
followed by two rinsing steps. The final, coated substrates were removed from 
solution, blown dry with compressed, filtered air, and stored at room temperature 
prior to characterization. Film thickness and optical clarity after deposition onto 
silicon and quartz substrates were measured using a LSE stokes ellipsometer 
(Gaertner Scientific Corportation) and by measuring light transmittance at 600nm 
using an Evolution 60 UV-visible spectrophotometer (Thermo Scientific), 
respectively. 
 
7.2.3 PEM Film Deposition on Microfluidic Slides and Multi-well Plates  
Uncoated microfluidic slides (1µ-Slide VI 0.4) were obtained from Ibidi and tissue 
culture treated 96-well plates were obtained from Corning. To coat the microfluidic 
slides, 120μL of each polyelectrolyte solution was added to the microchannels and 
75µl of solution was added to each well of the multi-well plate. After incubation, 
solution was removed via aspiration and rinsed twice for 1 min using 120μL of pH 3 
water. Bilayers of PMA and PAAm were assembled and terminated with either 
DOPC or DOTAP as described above. Following deposition, slides were allowed to 





7.2.4 Attachment Image Analysis 
MDA-MB-436 and MCF-7 breast cancer cells were seeded on PEM coated 
microfluidic slides (50,000 cells/channel) ranging from 0 to 8 bilayers. An Olympus 
CKX4 microscope was used for all experiments to capture images at 4x 
magnification. Three pictures per channel were taken after cell seeding for each 
condition to quantify initial cell number (t0). At 6 and 24 hrs, media was removed 
from the channel and the channel was washed once before addition of new media. 
Three images per channel were taken for each condition. The area of the image 
occupied with cells (as a percent) was quantified using CellProfiler (Broad institute) 
and the average from three images was calculated. The average percentage for each 
condition was then normalized to the area occupied at t0. 
 
7.2.5 Attachment Cell Titer 
MDA-MB-436 and MCF-7 breast cancer cells were seeded on PEM coated 96-well 
plates (20,000 cells/well) ranging from 0 to 8 bilayers. At each time point (1, 3, 6, and 
24 hrs), media was removed from the well and the well was washed once before 
addition of new media. After the 24hr time point an additional wash was done on all 
wells. Cell number was determined using CellTiter reagent according to 
manufacturer’s instructions. Each time point was normalized to initial cell number 





7.2.6 PEM Viability 
MDA-MB-436 and MCF-7 breast cancer cells were seeded on PEM coated 
microfluidic slides with PMA4/PAAm4 bilayers (50,000 cells/channel). At 0, 6, and 
24 hrs Live/Dead (Life Technologies) reagent was added according to manufacturer’s 
instructions. Corresponding phase contrast, live (calcein-AM) green fluorescence, and 
dead (ethidium homodimer-1) red fluorescence images were taken in triplicate at 4x 
magnification with an Olympus CKX41 fluorescence microscope. The number of 
cells in each image was quantified using CellProfiler. The percent of live and dead 
cells were calculated by quantifying the number of green fluorescence positive and 
red fluorescence positive cells, respectively, and dividing by total number of cells in 
the phase contrast image. GFP and Texas Red filters were used to for imaging. MDA-
MB-436 and MCF-7 breast cancer cells were plated on 96-well black plates with 
PMA4/PAAm4 bilayers (20,000 cells/well). At time 0, 1, 3, 6, and 24 hours Live/Dead 
reagent was added and read on a plate reader according to manufacturer’s 
instructions. Relative fluorescence units (RFU) were normalized to time 0. 
 
7.2.7 Tethering Washing 
MDA-MB-436 and MCF-7 cells were seeded on PMA4/PAAm4 coated microfluidic 
slides with DOPC or DOTAP (50,000 cells/channel). Cells were incubated for 1 hr to 
allow for tethering. To quantify initial cell number, three images per channel were 
taken for each condition at time 0. After 1 hr, existing media was gently removed 
from the bottom port of each channel and fresh media was added to the top port. 




Olympus CKX41 microscope at 4x magnification. This process was repeated for each 
wash. The area of the image occupied with cells (as a percent) was quantified using 
CellProfiler and the average from three images was calculated. The average 
percentage for each condition was then normalized to the area occupied at time 0. 
 
7.2.8 Tethering Viability 
MDA-MB-436 and MCF-7 cells were seeded on PMA4/PAAm4 coated microfluidic 
slides with DOPC or DOTAP (50,000 cells/channel). Cells were incubated for 1 hr to 
allow for tethering. After 1 hr, one wash was done where the existing media was 
gently removed from the bottom port of each channel and fresh media was added to 
the top port. This wash was to ensure only tethered cells were analyzed. At 0 and 6 
hrs after washing, Live/Dead reagent was added according to manufacturer’s 
instructions. Corresponding phase contrast, live (calcein-AM) green fluorescence, and 
dead (ethidium homodimer-1) red fluorescence images were taken in triplicate. The 
number of cells in each image was quantified using CellProfiler. The percent of live 
and dead cells were calculated by quantifying the number of green fluorescence 
positive and red fluorescence positive cells, respectively, and dividing by total 
number of cells in the phase contrast image. GFP and Texas Red filters were used to 





7.2.9 McTN Counting 
MDA-MB-436 cells were trypsinized, spun down, and resuspended in phenol red-free 
and serum-free DMEM. Cells were seeded on PMA4/PAAm4 coated microfluidic 
slides, PMA4/PAAm4 coated microfluidic slides with DOTAP, or a low attach 24-
well plate (50,000 cells/channel). Cells were incubated for 1 hr to allow for tethering. 
After 1 hr, one wash was done where the existing media was gently removed from the 
bottom port of each channel and fresh media was added to the top port on the DOTAP 
slides. This wash was to ensure only tethered cells were analyzed. After this wash, 
CellMask orange (Life Technologies) cell membrane dye was added to each channel 
to a final concentration of 1:10,000. McTNs were scored blindly in a population of 
100 cells/well as previously described [238]. Representative images were taken at 40x 
magnification with an Olympus CKX41 fluorescence microscope. 
 
7.2.10 Imaging drift and drug treatments 
MDA-MB-436 cells were trypsinized, spun down, and resuspended in phenol red-free 
and serum-free DMEM. Cells were seeded on PMA4/PAAm4 coated microfluidic 
slides and PMA4/PAAm4 coated microfluidic slides with DOTAP (50,000 
cells/channel). Cells were incubated for 1 hr to allow for tethering. After 1 hr, one 
wash was done where the existing media was gently removed from the bottom port of 
each channel and fresh media was added to top port on the DOTAP slides. This wash 
was to ensure only tethered cells were analyzed. After this wash, CellMask orange 




Cells were treated with 5µM colchicine for 15 mins and 1µg/ml paclitaxel for 120 
mins. McTN imaging was done on an Olympus FV100 confocal laser scanning 
microscope at 60x magnification. Five 1µm slices and 20 frames at a 10 sec frame 
rate were taken for at least five image sets for each condition. The number of McTNs 
on each cell was manually counted on five cells per condition using the maximum 
intensity z-projection at the last frame. 
 
7.2.11 Statistical Analysis 
Graphpad Prism (version 6.02) was used to determine all statistic comparisons. 
Student’s t-test and one-way ANOVA tests were performed with a Tukey multiple 




The responses of cancer cells detached from ECM (i.e., in a circulating or free-
floating stage) are highly important in survival, apoptosis, metastasis, and even in the 
expression of stem cell characteristics [262, 263]. However, tumor cells in this state 
are greatly understudied due to the technical and clinical challenges of continuously 
imaging cells not adhered to surfaces. Maintaining free-floating cell behavior of 
breast cancer cells is particularly critical in promoting McTN formation [238]. Thus 
we used breast tumor cells to first test if programming the compositions of PEM 




characteristics (e.g., McTNs) of these cells (Figure 7.1A), before adding a lipid tether 
in subsequent designs.  
 
Figure 7.1: PEMs form a cytophobic layer allowing McTN visualization on microfluidic devices.  
(A) Schematic depicting coating of microfluidic slide with PEMs to maintain free-floating behavior of 
tumor cells. (B) PEM coatings increase in thickness (left axis, black) with the number of bilayers but 
maintain optical clarity (right axis, gray). Data (mean ± SEM) correspond to samples in triplicate. (C) 
Maximum intensity z-projection of MDA-MB-436 cells on PMA4/PAAm4 surfaces showing McTNs 
(arrows). Scale bar = 10µm. Percent of (D) MDA-MB-436 and (E) MCF-7 cells (mean ± SEM) 
remaining on surfaces after washing uncoated slides or slides coated with 1, 4, or 8 PMA/PAAm 






7.3.1 PEMs inhibit cell attachment allowing for McTN visualization 
We formed PEMs from two common polymers, poly(methacrylic acid)  and 
polyacrylamide (PAAm) that have previously been shown to limit cell adhesion of 
numerous cell types [255, 264]. Substrates coated with PEMs offered precise control 
over film thickness and did not limit optical transmission, a feature important for pre-
clinical and clinical imaging (Figure 7.1B). Since human breast tumor cells lines 
have not yet been tested on PEM-coated substrates, we first confirmed that 
PMA/PAAm multilayers could prevent cell adhesion in two NCI breast cancer cell 
lines, MDA-MB-436 and MCF-7. MDA-MB-436 cells seeded on slides coated with 
cytophobic PEMs maintained McTN display (Figure 7.1C), demonstrating for the 
first time maintenance of free-floating tumor cell behavior by using PEMs. We next 
coated multi-well culture plates or microfluidic slides with PEMs and allowed cells to 
attach for 0, 6, and 24 hours. The number of cells remaining after washing at each 
time point was then quantified by image analysis and cell proliferation (CellTiter). 
Imaging revealed that PEM-coatings prevented attachment of either cell line (Figure 
7.1D, 7.1E, 7.2A, 7.2B) for at least 24 hours using 1, 4, and 8 PMA/PAAm bilayers. 
Cell proliferation data also indicated that deposition of 4 bilayers and 8 PMA/PAAm 
bilayers showed reduced attachment compared with 1 bilayer for both lines (Figure 
7.3A, 7.3B). Four bilayer films were prioritized for future experiments since these 
films formed cytophobic surfaces that most efficiently decreased cell attachment 
while maintaining McTN activity. Coatings did not impact the viability of either cell 






Figure 7.2: PEM prevents attachment of MDA-MB-436 and MCF-7 breast cancer cells. 
Representative images of (A) MDA-MB-436 and (B) MCF-7 cells on microfluidic slides with 0 







Figure 7.3: PEM prevents cell attachment and does not affect cell viability. 
CellTiter analysis of the number of (A) MDA-MB-436 and (B) MCF-7 cells remaining on 96-well 
plate coated with 0 (uncoat), 1, 4, and 8 PMA/PAAm bilayers after one wash at 1, 3, 6, and 24 hrs 
normalized to initial cell number. Data represents mean cell attachment from three independent 
experiments (mean ± SEM). Viability of (C) MDA-MB-436 and (D) MCF-7 cells on a 96-well plate 
coated with 0 (uncoated), 1, 4, and 8 PMA/PAAm bilayers at 0, 1, 3, 6, and 24 hrs. Data represents 
mean viability from three independent experiments (mean ± SEM). Viability of (E) MDA-MB-436 and 
(F) MCF-7 cells plated on microfluidic slides with 0 (uncoated) or PMA4/PAAm4 bilayers calculated at 
0, 6, and 24 hrs. Green fluorescence (live) and red fluorescence (dead) positive cells were quantified 
for each and divided by total cell number to calculate percent of live and dead cells, respectively using 






Figure 7.4: PEM does not affect viability of MDA-MB-436 and MCF-7 cells. 
Representative images of the viability of MDA-MB-436 plated on microfluidic slides with 0 
(uncoated) or PMA4/PAAm4 bilayers at (A) 6 hrs and (B) 24 hrs. Representative images of the viability 
of MCF-7 plated on microfluidic slides with 0 (uncoated) or PMA4/PAAm4 bilayers at (C) 6 hrs and 
(D) 24 hrs. Phase contrast, live (green fluorescence), and dead (red fluorescence) images taken at 4x 






Figure 7.5: Triton-X is a positive control for cell death. 
Cell viability of MDA-MB-436 and MCF-7 cells treated with 0.1% Triton-X plated on (A) 96-well 
plate and (B) microfluidic slides. Green fluorescence (live) and red fluorescence (dead) positive cells 
were quantified for each and divided by total cell number to calculate percent of live and dead cells, 
respectively, using CellProfiler. Data represents mean viability from three independent experiments 
(mean ± SEM). Representative images of (C) MDA-MB-436 and (D) MCF-7 cells treated with 0.1% 
Triton-X. Phase contrast, live, and dead images taken at 4x magnification. Scale bar represents 200µm. 
 
7.3.2 Modification of PEMs with lipid tethers retains tumor cells after washing 
Although PEM-coated surfaces prevented tumor cell attachment and supported free 
floating behavior, these cells were removed during washing with buffer. Thus we 
sought to develop a strategy to maintain McTNs while also providing spatial 
localization during microfluidic flow for real-time imaging and drug screening. We 




membranes would loosely tether cells to the surface during microfluidic flow. We 
tested 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) as cationic and zwitterionic lipids, respectively, 
owing to the ability of these molecules to interact with the PEMs electrostatically 
(Figure 7.6A). Following addition of DOTAP or DOPC, total film thickness 
increased, though individual bilayers were still only 20nm and optical clarity 
remained high (Figure 7.6B, 7.6C). We next tested if the addition of lipid supported 
tethering of breast tumor cells without inhibiting free-floating features such as 
McTNs. Tumor cells were seeded on microfluidic slides coated with (PMA/PAAm)4 
without lipids (PEM-no tether) or with either terminal lipid layer (PEM-DOPC tether, 
PEM-DOTAP tether). During successive wash steps, DOTAP retained tumor cells 
more efficiently compared to non-tethered cells seeded on microfluidic slides coated 
with PEM only (Figure 7.7A, 7.7B). MCF-7 cells exhibited significantly higher 
overall cell retention with PEM-DOTAP compared to PEM only over four washes. 
MDA-MB-436 cells showed significant retention of cells with PEM-DOTAP for the 
first wash and continued to tether around 10% of cells for subsequent washes. 
Tethering was dependent on lipid composition, as after five washes, DOTAP tethered 
and retained 30% of MCF-7 cells, while DOPC was ineffective at tethering cells 
during successive washing (Figure 7.7A, 7.7B versus Figure 7.7C, 7.7D). 
Representative images of cells from each line tethered on these surfaces are shown in 
Figure 7.7E and Figure 7.8. Since DOTAP demonstrated superior tethering for both 





Figure 7.6: Modification of PEMs with lipid tethers. 
(A) Schematic depicting how lipid-terminated PEMs promote interaction with tumor cell membranes. 
(B) Film thickness and (C) optical clarity (mean ± SEM) after addition of DOTAP (blue) and DOPC 
[249]. Lipids promote growth of film while maintaining an optically-clear substrate for imaging. Data 






Figure 7.7: DOTAP tethers breast cancer cells. 
Percent cell retention of (A) MDA-MB-436 and (B) MCF-7 cells plated on microfluidic slides coated 
with PMA4/PAAm4 bilayers alone or with DOTAP. Percent cell retention of (C) MDA-MB-436 and 
(D) MCF-7 cells plated on microfluidic slides coated with PMA4/PAAm4 bilayers alone or with 
DOPC. The remaining cells after each wash was quantified with CellProfiler and normalized to the 
initial cell number. Data represents mean of triplicate independent experiments (mean ± SEM). (E) 
Representative images of MDA-MB-436 cells at time 0 and after 3 subsequent washes on 
PMA4/PAAm4 bilayers with no tether and with PEM-DOTAP or PEM-DOPC tethers at 4x 






Figure 7.8: DOTAP can tether MCF-7 breast tumor cells. 
Representative images of MCF-7 cells seeded on microfluidic slides with PEM-no tether, PEM-
DOTAP tether, and PEM-DOPC tether prior to washing and after 3 subsequent washes at 4x 
magnification. Scale bar represents 200µm. 
 
7.3.3 Lipid tethers preserve McTNs and cell viability 
We next determined if lipid tethering with DOTAP maintained free-floating tumor 
cell characteristics. As a first indicator, McTN frequency was assessed on PEM and 
PEM-DOTAP surfaces. Blinded McTN counts revealed no differences in McTN 
frequency on PEM-no tether and PEM-DOTAP surfaces compared to previously 
published counts on low-attach multi-well plates (Figure 7.9A). These results 
indicate lipid tethering does not impact the ability of MDA-MB-436 cells to assemble 
McTNs, results confirmed by epifluorescence imaging of McTNs on cells incubated 
with each type of PEM or substrate (Figure 7.9B, 7.10A). MCF-7 cells exhibited 
similar results (Figure 7.9A, 7.10B), though these cells assembled McTN at lower 




does not impact tumor cell viability (Figure 7.9C-E, Figure 7.10C-F). Thus for the 
first time, our approach allows maintenance of free-floating tumor cell behavior while 
spatially fixing the location of tumor cells.   
 
Figure 7.9: Lipid tethering retains free-floating characteristics of breast tumor cells and does not 
affect cell viability. 
(A) McTN quantification of MDA-MB-436 and MCF-7 cells suspended on a low-attach plate, 
microfluidic slides with PEM-no tether, and microfluidic slides with PEM-DOTAP tether. Data 
represents blinded quantification of McTN frequency from three independent experiments with 100 
cells counted for each (mean ± SEM). (B) Representative images of McTNs (arrows) on MDA-MB-
436 cells seeded on PEM-no tether and PEM-DOTAP tether microfluidic slides at 40x magnification. 
Scale bar = 10µm. Viability of (C) MDA-MB-436 and (D) MCF-7 cells calculated at 0 and 6 hrs after 
seeding on microfluidic slides with PEM-DOTAP tether. Data represents mean cell viability from three 
independent experiments (mean ± SEM). (E) Representative images show viability of MDA-MB-436 
cells tethered by DOTAP for 6 hrs. Phase contrast, live (green fluorescence), and dead (red 






Figure 7.10: Lipid tethering retains microtentacles and does not affect cell viability. 
(A) Representative image of McTNs (arrows) on MDA-MB-436 cells on a low-attach plate at 40x 
magnification. Scale bar represents 10µm. (B) Representative images of McTNs (arrows) on MCF-7 
cells on a low-attach plate, microfluidic slide with PEM-no tether, and microfluidic slide with PEM-
DOTAP tether at 40x magnification. Scale bar represents 10µM. Viability of (C) MDA-MB-436 and 
(D) MCF-7 cells calculated at 0 and 6 hrs after seeding on microfluidic slides with PEM-DOPC tether. 
Green fluorescence (live) and red fluorescence (dead)  positive cells were quantified for each and 
divided by total cell number to calculate percent of live and dead cells, respectively, using CellProfiler. 
Data represents mean cell viability from three independent experiments (mean ± SEM). (E) 
Representative images of MCF-7 cells seeded on microfluidic slides with PEM-DOTAP tether for 6 






7.3.4 Lipid tethers allow for real-time high resolution McTN imaging in response to 
drug treatments 
One of the greatest challenges in studying free-floating cells is the difficulty in 
measuring their functional properties or behavior in real time. This is especially 
apparent when trying to image free-floating cells over time and in three dimensions. 
Epifluorescence is unable to capture McTNs in high resolution (Figure 7.9B). 
Confocal microscopy of cells labeled with a fluorescent membrane dye improves 
signal to noise and allows McTNs to be imaged with high contrast (Figure 7.11Ai, 
arrows). However, since McTNs occur on free-floating cells, the time required to 
generate a 3-dimensional stack of z-slice images for tracing McTN length yields 
significant blurring as free-floating cells drift over a surface to which they cannot 
attach. This limitation was encountered when imaging cells exposed to PEM surfaces 
without lipid tethers (Figure 7.11Aii, arrows). The blurring effect of cell drift is even 
more apparent across a time projection (Figure 7.11Aiii). In contrast, tethered breast 
tumor cells not only maintained McTNs (Figure 7.11Aiv, arrow), but also eliminated 
blurring of McTNs in z-stacks. This strategy also allowed microtentacle length to be 
traced efficiently across z-stacks (Figure 7.11Av, arrow) and limited drift of the cell 
body during time-lapse imaging (Figure 7.11Avi). These phenomena are evident 
during time-lapse movies of drifting tumor cells seeded on PEM-no tether surfaces, 
whereas DOTAP tethering caused cells to remain fixed in one location while 
preserving McTN dynamics. It is interesting to note that debris can be seen moving 






Figure 7.11: Lipid tethering allows for real-time McTN imaging in response to drug treatment 
and minimizes effects of drift. 
(A) McTN (arrows) imaging of MDA-MB-436 cells seeded on microfluidic slides with PEM-no tether 
(i-iii) and PEM-DOTAP tether (iv-vi). Representative 1µm slice (i and iv), maximum z-projection of 5 
slices at one time point (ii and v), and maximum t-projection after 20 frames (iii and vi) are shown at 
60x magnification. (B) McTN (arrow) imaging of MDA-MB-436 cells seeded on microfluidic slides 
with PEM-DOTAP tether after treatment with 5µM colchicine for 15 mins and 1µg/ml paclitaxel for 
120 mins. Maximum intensity z-projections of five 1µm slices at one time point are shown at 60x 
magnification. Complete time-lapse movies are available in Fig. S7. Scale bar = 10µM. (C) Manual 
quantification of the average number of McTNs per cell (mean ± SEM) in MDA-MB-436 cells treated 





The major advantage in imaging McTNs over time is being able to study their 
responses to drugs not only by McTN frequency, but also McTN dynamics. To 
demonstrate this potential, we recorded three dimensional z-stacks of untreated 
MDA-MB-436 cells, cells treated with the microtubule destabilizing agent, 
colchicine, or the microtubule stabilizing agent, paclitaxel. Addition of colchicine 
decreased McTNs while paclitaxel enhanced McTNs (Figure 7.11B). Over time, 
colchicine shrunk McTNs and increased cell blebbing, whereas paclitaxel 
hyperstabilized McTNs, dramatically decreasing their dynamics compared to vehicle 
control. These new trends are clearly observable in high resolution movies that would 
be otherwise impossible without lipid tethering, since microfluidic flow would wash 
these cells away or drift would cause blurring. This strategy also creates new 
opportunities to study free-floating cell properties on a per-cell basis. For example, 
we measured time-dependent drug response and discovered that treatment with 
colchicine decreased the mean number of McTN per cell from 21.6 ± 7.2 to 1.8 ± 1.5, 
while paclitaxel treatment increased the frequency of these structures to 39.6 ± 7.5 
McTNs/cell (Figure 7.11C). 
 
7.4 Discussion 
The majority of cancer-related deaths are due to the spread of tumor cells through the 
circulation from the primary site to a secondary organ [266]. While in the circulation, 
tumor cells are in a non-adherent microenvironment that is unlike the conditions in a 
primary tumor or the metastatic site. In these non-adherent conditions, tumor cells 




therapies and their overall metastatic efficiency [241, 267]. Classical drug studies and 
microscopy focus on analyzing tumor cells attached to a substrate due to the practical 
ease of analyzing cells under static conditions, but these methods do not recapitulate 
the free-floating environment of CTCs. Therefore, we have developed a microfluidic 
device that can anchor tumor cells using a lipid moiety while preventing their 
attachment to a substrate.  
 
In this proof-of-concept study we show that tethering is an effective way to retain the 
free-floating behavior of cancer cells and provides new opportunities to study their 
functional properties with high-resolution microscopy through spatial localization. 
This strategy offers the ability to coat a variety of surfaces, including microfluidics. 
We show that incorporating a lipid moiety on PEMs can passively immobilize tumor 
cells in a manner that preserves McTN formation and does not affect cell viability. In 
this method, no cellular adhesive properties are necessary because the interaction of 
the cell membrane with the lipid results in cell tethering. Lipids have previously been 
used to immobilize cells [258, 260]; here we have advanced this idea to create a 
simple system for studying McTNs on free-floating tumor cells. This approach 
eliminates the need for solvents, patterning, designed topographies, or antibodies used 
in other recent studies aimed at promoting adhesion of CTCs. Further, cells can be 
tethered in complete media and in a short time frame, both enabling real-time study of 
McTNs on individual CTCs. Therefore, using this technique, tethering of any cell 
type can be achieved in a simple and rapid manner, making this a robust platform to 





In our studies, each PEM lipid formulation tethered cancer cells, but the lipid moiety 
itself altered cell retention, with DOTAP – a cationic lipid – driving the best 
tethering. DOPC – a zwitterionic lipid – contains a phosphate group which may cause 
less favorable interactions with cell membranes compared to DOTAP. While cells 
were immobilized on the substrate, they remained free-floating owing to the 
cytophobic nature of the initial PEM coating. There was some loss of tethered cells as 
a function of the number of washes, but it is likely these interactions can be 
strengthened by incorporation of cross-linkable lipids [258, 260, 268, 269]. We also 
observed a difference in the tethering efficiency as a function of cell line, with MCF-
7 breast cancer cells exhibiting better tethering compared to MDA-MB-436 cells. 
These changes may be due to the differences in membrane composition or surface 
marker expression of each cell line [270].  
 
We demonstrate the utility of tethering for tumor cell analysis by assessing the 
response of McTNs to microtubule-targeting drugs. Unlike our previous studies, it is 
now possible to add drugs via microfluidic exchange without displacing cells, 
allowing time-lapse measurements of colchicine-dependent McTN disruption [238] 
and paclitaxel-dependent McTN enhancement [244] to be measured with time-lapse 
imaging for the first time. Our discovery that paclitaxel hyperstabilizes McTNs, for 
example, is significant since microtubule stability can enhance McTN formation and 
increase the re-attachment efficiency of tumor cells [244]. Mouse models of 




greater lung trapping of tumor cells [238, 242, 244]. Therefore, analyzing McTN 
dynamics and their response to drugs has important implications on the metastatic 
ability of tumor cells. These technological advances should allow many additional 
quantitative McTN metrics to be accurately measured (length, dynamics, etc.) and 
also improve on qualitative observations that have until now not been possible on a 
live, individual cell basis. 
 
High numbers of CTCs correlate with increased metastasis and decreased survival of 
patients with metastatic cancer [228, 229, 271, 272]. However, CTC enumeration 
alone may not be a good marker for disease staging and prognosis [271]. Therefore, 
improved biologic characterization of CTCs is necessary to better understand their 
clinical value. Numerous new approaches have been designed to improve CTC 
detection and enumeration, but the ability to study the functional properties of CTCs 
remains difficult [227]. Ex vivo culture of CTCs in non-adherent conditions has 
provided one method to analyze CTCs from patients [232]. This PEM-lipid tethering 
technology may be applied to these culturing methods to keep cells from adhering, 
but offers the unique capabilities of rapid single-cell analysis through staining and 
imaging in real-time.  
 
Studying the biology of CTCs has suggested important consequences for both 
metastatic efficiency and the sensitivity of these structures to candidate cancer drugs. 
Of note, patterns of drug sensitivities have been linked to the genetic mutations 




indicating that a change in tumor genotypes during the course of treatment can lead to 
drug resistance [232, 267, 273]. Our work shows tethering tumor cells allows rapid 
analysis of specific drug responses in real-time. Markers of epithelial-to-
mesenchymal transition (EMT) are also upregulated in CTCs with mesenchymal 
markers specifically enriched in CTC clusters. These clusters have increased 
metastatic capabilities compared with single cells alone [233, 274]. Thus our 
approach can be applied to these existing techniques for fundamental CTC studies at 
the single-cell level. Assessing the effects of drugs on cell viability, EMT markers, or 
McTNs could all have implications on their metastatic phenotype. Tethering would 
also allow these studies to be conducted in a manner that more closely recapitulates 
the free-floating environment found in circulation. Though our study focuses on the 
analysis of tumor cells, this simple and rapid tethering technology is translatable to 
numerous other cell types that are encountered in the blood stream (i.g., red blood 
cells, platelets, lymphocytes, macrophages) and may function differently in a free-
floating environment. With new technologies, CTCs will play an increasing role in 
informing therapy and disease progression of cancer patients. Toward this goal, 
tethering CTCs with PEM-lipid films could serve as a new tool to analyze CTC 
samples to provide better personalized treatment decisions for patients.  
 
7.5 Conclusion 
Metastatic cancer cells exhibit dynamic properties when suspended in a free-floating 
state (e.g., McTNs) that upon evaluation, could inform decisions regarding the 




the PEM-lipid tethering system provides a unique platform to immobilize cells while 
maintaining their free-floating phenotypes. While the above studies just began to 
investigate the many uses for this technology, it is apparent that the ability to screen 
cells in real-time could provide useful information rapidly to researchers and 
clinicians alike.  
 
The previous chapters revealed that properties of materials including their state of 
degradation can influence the immune system and studied how materials impact 
immune cells and tissues. These results highlight the opportunities to engineer new 
materials to specifically control immune function. An exciting field of research where 
this potential is particularly evident is in tissue engineering and regenerative 
medicine. Toward realizing this opportunity, Chapter 8 summarizes the current state 
of understanding the effect materials have on immunity in vaccine and 
immunotherapy fields and provides a forward looking perspective on how these 
properties could be incorporated within tissue engineering constructs to promote a 







Chapter 8: Designing biomaterials with immunomodulatory 
properties for tissue engineering and regenerative medicine7 
 
8.1 Introduction 
Biomaterials have enabled advances in fields spanning tissue engineering, drug 
delivery, vaccination and immunotherapies, and implantable devices. This breadth is 
due to the ability of these materials to encapsulate and protect cargos (e.g., chemicals, 
cells, proteins), to provide biocompatible supports (e.g., devices, scaffolds), and to 
allow facile modification of chemical and physicochemical properties.[275, 276] Not 
surprisingly, biomaterials range from naturally-occurring biological building blocks 
to fully synthetic substances. This ever-expanding use of biomaterials is also creating 
increasing need for deeper understanding of the interactions between materials and 
the biological environments they encounter. Nowhere is this need more evident than 
the immune engineering field. Biomaterials are being widely-explored in vaccines 
and immunotherapies to combat infectious disease, cancer, and autoimmunity, but the 
early clinical successes of these approaches are few and far between. One of the 
interesting findings in the field – described in seminal papers published less than a 
decade ago[9, 45] – is that many biomaterials exhibit intrinsic material properties that 
can activate immune pathways. This is certainly an opportunity to gain knowledge 
________________________________________________ 
7Adapted from J.I. Andorko and C.M. Jewell. “Designing biomaterials with immunomodulatory 
properties for tissue engineering and regenerative medicine.” Bioengineering and Translational 




that informs design of materials that could actively bias immune responses toward 
desired functions. In tissue engineering, many emerging strategies are also employing 
immune cues and cells in biomaterial-based structures for engineering organs and 
tissues, and for regenerative medicine. In contrast to vaccine and immunotherapy 
research, the immunological role that scaffolds or other materials might play – 
through intrinsic properties, modification of surface chemistry, or other tunable 
strategies – has yet to take center stage. Since essentially every tissue engineering 
application either interacts with or specifically seeks to avoid the immune system, 
understanding these roles could provide a new lever to improve tissue engineering 
and regenerative medicine.  
 
This review will discuss what has been learned about the role physicochemical 
properties of biomaterials play in directing immune responses from the vaccine and 
immunotherapy fields, and analyze how these concepts might be exploited for tissue 
engineering and regenerative medicine. We begin with a brief introduction to the 
immune system and the response to injury and implanted materials. Next, we discuss 
what is known about how immune response is impacted by biomaterial properties 
such as size, shape, and stability/molecular weight, along with surface features such 
as chemical functionality, charge, and hydrophobicity (Figure 8.1). Then, we 
describe how the introduction of biomaterial scaffolds, and the specific features of 
these tissue engineering constructs exhibit intrinsic immunogenic features that can 




research directions leveraging the intrinsic properties of materials to control immune 
function and push the forefront of tissue engineering and regenerative medicine. 
 
Figure 8.1: Intrinsic properties of materials influence immune responses.  
Biomaterials commonly used in vaccine, immunotherapy, and tissue engineering exhibit features 
including size, shape, surface charge, hydrophobicity, and molecular weight that alter interactions with 
the immune system. Encountering components of the innate and adaptive immune system with these 
materials results in formation of fibrotic capsule to isolate the material, differential activation of 
dendritic cells and macrophages, recognition and removal by antibody and complement proteins, and 





8.2 The Immune Pathways Activated by Pathogens and Other Foreign Molecules also 
Respond to Biomaterials 
Across vaccines, immunotherapies, and tissue engineering, the immune system 
represents both an opportunity for and barriers against successful outcomes. In order 
to protect the body from harmful pathogens, the immune system has evolved over 
time to quickly recognize pathogens or other non-self agents through general 
physicochemical features that are uncommon in the body. These include the 
particulate nature of bacteria and viruses, repetitive molecular patterns such as the 
polysaccharides that comprise bacterial cell walls, and structural motifs such as 
hydrophobic regions or double stranded RNA often found in molecules from viruses 
and bacteria.[156, 277] One component of the innate immune system – the segment 
that provides rapid, but less specific immune responses – are pattern-recognition 
receptors (PRRs. PRRs are present on antigen presenting cells (APCs), including 
dendritic cells (DCs) and macrophages, that scan the body for danger-associated 
molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs).[25, 26] PRRs, including toll-like receptors (TLRs) and the inflammasome, 
identify specific DAMPs and PAMPS and initiate different signaling pathways 
leading to the clearance of potentially harmful agents.[110, 278] The inflammasome 
is a cytoplasmic complex of proteins which activates caspases and the release of IL-
1β, a key cytokine involved in initiating inflammatory processes.[110, 278] 
Interestingly, the inflammasome has been associated with immune cell activation in 
response to treatment with adjuvants, materials commonly added to vaccine 




alum, an FDA-approved adjuvant consisting of particulate aluminum salt 
formulations.[110, 278, 279] Since many existing vaccines use alum, and numerous 
technologies involving microparticles and nanoparticles are in development as 
vaccines and immunotherapies, continued research into how these materials activate 
the inflammasome is of great interest. The complement system is another mechanism 
of the immune system, consisting of serum proteins that assemble after encountering 
microbes or other extracellular pathogens. These proteins form complexes that tag, 
destroy, and eliminate the invading pathogens.[25, 280] Supporting these fast-acting 
innate immune responses is the adaptive immune system. In contrast to innate 
immunity, adaptive immunity arises more slowly, but is more specific and can lead to 
the generation of immunological memory. Broadly speaking, adaptive immunity 
includes cell-mediated and antibody-mediated responses against specific, foreign 
molecules, terms antigens.[25] Cell-mediated immunity involves activation of T 
lymphocytes that differentiation into cytotoxic T cells able to destroy self-cells 
infected with intracellular pathogens such as viruses. Antibody-mediated immunity 
arises from the activation of B lymphocytes that, upon differentiation, secrete 
antibodies that bind extracellular pathogens (e.g., bacteria) or toxins to neutralize and 
clear these targets.  
 
The immune system, particularly innate immune cells, also plays a large role in the 
response to injury and after implantation of biomaterials.[25, 281-286] Initially, 
neutrophils and other innate immune cells infiltrate the site of injury to clear 




recruit other immune cells (e.g., macrophages).[25, 283, 284] The first macrophages 
to arrive at the injury site exhibit an inflammatory phenotype known as M1. These 
M1 macrophages phagocytose pathogens and damaged cells, and produce pro-
inflammatory factors such as inducible nitric oxide synthase (iNOS), TNF-α, and IL-
12. These factors promote inflammation and removal of pathogens, and recruit 
lymphocytes involved in generating adaptive immune repsonses.[284-290] M1 
macrophages typically persist at the wound or implant site for 2-3 days after injury, at 
which time the function of these cells shifts towards the M2 macrophage phenotype; 
this phenotype is crucial for tissue repair and generating new blood vessels.[284-290] 
M2 macrophages are functionally different from M1 macrophages. This phenotype 
exhibits increased expression of key genes involved in wound-repair (e.g., arginase 
and Fizz1), secretes cytokines and growth factors to stimulate cell proliferation, and 
deposits extracellular matrix to support tissue regeneration.[25, 283-286] 
Macrophages also influence the response to implants by forming specialized foreign 
body cells. These cells create a fibrotic capsule around implanted materials that 
isolate the material from the surrounding environment of the body.[283] Since M1 
and M2 macrophages have different functions, there is an opportunity to target these 
cells as immunomodulatory players to direct responses to tissue engineering 
constructs. Currently, it is understood that the phenotype and activation of 
macrophages is not always a binary process but rather a spectrum where cells 
upregulate or downregulate specific markers as they transition from one form (pro-




biomaterials involves these same mechanisms, there is a need to understand how the 
properties of materials alter immune interactions in the context of tissue engineering. 
 
Many biomaterials exhibit structural features that trigger recognition as DAMPs and 
PAMPs. In particular, the immune system commonly responds to the repetitive 
patterns of polymer chains that can resemble bacterial polysaccharides, hydrophobic 
portions of materials, and the particulate nature of microparticles and nanoparticles 
that share characteristic dimensions of bacterial and viral pathogens.[123, 291, 292] 
Over the past decade, many studies have revealed that even the most common 
biomaterials can activate immune or inflammatory pathways in the absence of other 
immunostimulatory signals, and that the physicochemical material properties can alter 
the magnitude or features of this response. For example, DCs incubated on thin 
biomaterial-based films of naturally-derived polymers (e.g., alginate, agarose, 
chitosan, hyaluronic acid) or synthetic polymers (e.g., polylactic-co-glycolic acid 
(PLGA)) induce differential expression of surface activation markers. These signals 
include DC maturation markers (e.g., CD40), major histocompatibility class II 
(MHCII) complexes – proteins responsible for presenting antigens to naïve B and T 
cells, and co-stimulatory markers (e.g., CD80, CD86). These co-stimulatory signals 
act as a second signaling cue necessary for activation of B and T cells in response to 
antigen presented in MHC complexes.[25, 157] In other studies, particulate systems 
of PLGA, polystyrene, or silica were treated in conjunction with an inflammatory 
signal (e.g., TLR agonists) and the DC response to these treatments was evaluated.[9, 




treated along with particles, the particles synergistically increased the activation of 
DCs relative to the TLR agonist alone or the polymers alone. The pro-inflammatory 
responses were also associated with inflammasome signaling at levels comparable to 
those measured by alum, the strong human adjuvant discussed above.[9, 45, 293] 
These revelations have prompted a new area of study to understand which 
physicochemical properties influence intrinsic immune response and how these 
interactions occur. New studies are also now exploring such intrinsic immune features 
of materials to direct vaccine responses more specifically, to improve cancer 
therapies, and to promote immune tolerance in combating autoimmune diseases.[10, 
104, 105, 294-301] 
 
8.3 Understanding Intrinsic Immunogenicity of Biomaterial Delivery Systems Could 
Inform Tissue Engineering Applications 
In the past few years the field has learned a great deal about how the properties of 
biomaterial vaccine and immunotherapy carriers trigger innate immune pathways. 
Many studies, recently reviewed[302-309], seek to overcome or evade immunological 
barriers by modulating these properties of biomaterials-based carriers. This is 
valuable insight that could be leveraged as the tissue engineering and regenerative 
medicine fields move forward. In this section, we will explore which properties of 





8.3.1 The Size of Biomaterial Carriers Alters Uptake and APC Activation 
To drive immune responses, vaccines must reach lymph nodes, tissues that coordinate 
adaptive immunity through interactions between antigen-experienced APCs and naïve 
B and T cells. Many vaccines rely on particle size or drainage through the lymphatics 
to provide a pathway from peripheral injection sites to the lymph nodes.[21, 22, 49, 
67, 310] Past studies have shown particles with diameters between 20-50nm can 
passively drain through lymphatics, and larger particles are more dependent on 
phagocytosis by APCs which carry the engulfed cargo to lymph nodes.[22, 67] The 
phenomena occur because particle trafficking is driven in part by the pressure 
gradient that exists between the blood and lymphatic vessels, causing convective 
forces that propel smaller particles into lymphatic vessels.[22, 67, 310] As particle 
size increases, particles flow at much lower rates due to steric hindrance in the 
interstitial space, or mechanical size limitation for micron-size particles. These larger 
particles are thus more reliant on internalization and trafficking by APCs to reach 
lymph nodes.[22, 67, 310] Thus, the size of particles used to deliver vaccines and 
immunotherapies plays a large role in the uptake, trafficking, and retention of the 
cargo and carrier in immune cells and tissues.[30, 167, 311]  
 
While particle size impacts trafficking and can alter how much carrier, drug, or 
vaccine reaches lymph nodes, changes in particle size also play a major role in 
modulating immune response. For example, with the same antigens and adjuvants 
present in a material-based vaccine, the size of these particles biases the interaction 




In one recent study, gold nanoparticles with diameters of 3nm and 12nm were 
incubated with human-derived DCs. These sizes caused different levels of DC 
activation, as indicated by common surface maturation markers (e.g., CD80, CD83, 
CD86, MHCII) and inflammatory cytokine secretion.[312] While both sizes of 
particles activated DCs, 3nm particles caused higher activation levels and greater 
secretion of IL-12 and IFN-γ. These effects translated to increased pro-inflammatory 
T cell function during co-culture.[312] In contrast, treatments with the 12nm particles 
increased IL-4 production, skewing the resulting T cell-mediated immune responses 
towards a different function, wound healing.[312] In another study, macrophages 
treated with particles of varying sizes induced different effects on the levels of the 
anti-inflammatory cytokine IL-10 and the pro-inflammatory cytokine TNF-α.[108] 
While the largest particles did not induce cytokines, smaller particles with diameters 
ranging from 2-40µm induced size-dependent production of IL-10 and TNF-α; this 
activation was also shown to involve TLR-2 stimulation.[108] Many tissue 
engineering approaches involve implantation of macroscopic scaffolds or devices that 
degrade, release fragments, or experience wear effects.[283] Thus, particulates can be 
generated that also trigger the same size-dependent modulatory immune 
pathways.[283] Additionally, bulk wear or fracture of implantable devices or 
scaffolds is often a key design focus since this can lead to acute device failure. From 
an immunological perspective, however, the inflammatory profile of the nano- and 
micro-scale wear products or particles will take on an emerging roll in tailoring 





8.3.2 Immune Activation is Influenced by Biomaterial Shape 
While size is an important feature in determining trafficking, uptake, and intrinsic 
immunogenicity, the shape of materials also impacts these responses.[122, 313-316] 
For example, in one study, gold nanorods were internalized by macrophages at 
greater levels than nanospheres owing to preferential uptake of the former via 
micropinocytosis.[317] In a separate study, glass rods were used as a tool to assess 
shape dependence by incubating rods of varying lengths with macrophages.[318] 
Short rods were more rapidly taken up than longer rods, but interestingly, the longer 
rods, while not readily phagocytosed, induced greater levels of the inflammatory 
signals IL-1α and TNF-α.[318] This inflammatory response was attributed to 
“frustrated” phagocytic interactions, a phenomenon that occurs when cells are unable 
to phagocytose larger-scale objects. This failure results in the production of reactive 
oxygen species and inflammatory cytokines which ultimately could lead to chronic 
inflammation and fibrosis.[318] This shape effect might also be important in the 
context of scaffolds and implants since these constructs are commonly too large for 
engulfment and often shed long fibers or other geometries upon degradation or wear. 
Other work has studied shape effects using titanium dioxide to prepare particles with 
diameters of 7-10nm (anatase) or 15-20nm (rutile), or nanotubes with diameters of 
10-15nm and lengths of 70-150nm.[319] These studies revealed shape dependence 
across cytokine secretion, production of reactive-oxygen species, and DC 
maturation.[319] In particular, the nanotubes generally caused the largest 
immunogenic effects,[319] further demonstrating that particle shape impacts 




studies beginning to ascertain how the interactions of differently-shaped particles 
with immune cells cause these differential effects. 
 
The extent to which the shape of particulate carriers impacts inflammasome 
activation is important because, while seminal work has shown particle-based carrier 
systems can act as adjuvants through inflammasome signaling, other work 
demonstrates these outcomes are not a feature of all particulate systems.[9, 45, 119, 
279, 293, 320] In a study from Vaine et al., particles synthesized from block 
copolymers to either exhibit rough or smooth surfaces (Figure 8.2A) differentially 
activated the inflammasome in mice.[121] In this study, polystyrene-polyethylene 
oxide particles with a rough surface morphology increased neutrophil recruitment and 
IL-1β secretion compared with smooth polystyrene-polyethylene oxide particles.[121] 
This study also found that while the particles had comparable diameters, rough 
particles were preferentially taken up by macrophages, leading to increased 
inflammasome activity that was comparable to a positive control treatment with alum. 
Interestingly, this activation was absent when uptake was inhibited, suggesting that 
phagocytosis and endosomal destabilization were needed for the materials to activate 
the inflammasome.[121, 293] In another study, antigen-coated gold nanostructures 
formed as spheres, rods, or cubes (Figure 8.2B) triggered differential levels of 
cytokine secretion in DCs, leading to differences in antibody production in 
mice.[321] The rod-shaped particles induced an IL-1β (i.e., inflammasome-mediated) 
response, while spheres and cubes activated less specific (e.g., TNF-α) inflammatory 




inflammatory signaling cascade of the innate immune system, can be manipulated 
simply by altering particle shape. More work is needed to understand why these 
effects occur with some material shapes and not others. In particular, tissue 
engineering uses materials spanning biological building blocks to synthetic polymers, 
enabling a variety of shapes and topographies. Thus, understanding how these 
different parameters promote or diminish inflammasome activation could allow the 








Figure 8.2: Particle shape dictates immune cell uptake and activation.  
(A) Spherical polymeric particles fabricated from polystyrene-polyethylene oxide that exhibit rough 
surfaces (left) were preferentially taken up by macrophages and induced a pro-inflammatory response 
compared to smooth particles (right) (Scale bar, 10µm; inset scale bar, 5µm). (B) Electron micrographs 
of gold nanoconstructs with spherical (left), cube (center), or rod-like (right) shapes. When incubated 
with DCs, rod-like particles induced inflammatory IL-1β and activated the inflammasome, while 
sphere and cubes caused secretion of TNF-α (Scale bar, 40nm). (C) Spherical PLGA particles that are 
mechanically stretched to form ellipsoidal particles increase surface interactions with immune cells, 
leading to increased T cell proliferation. (Scale bar, 10µm). (A) reprinted with permission from ref 
[121]. (B) reprinted with permission from ref [321]. (C) reprinted from ref [41] with permission from 
Elsevier. 
 
Research from the Green and Schneck groups has focused on using polymeric 
particles as artificial antigen presenting cells (aAPCs), mimicking the ability of APCs 
such as DCs to simultaneously present antigen fragments and costimulatory markers 




on T cell response.[41, 322, 323] Spherical PLGA nanoparticles were first 
synthesized, then mechanically stretched to form elongated, ellipsoidal particles with 
different aspect ratios (Figure 8.2C). To properly mimic the way natural APCs 
interact with T cells, both antigen and costimulatory molecules need to be presented 
in the correct contexts to promote T cell activation and proliferation. To accomplish 
this, antigen within MHC molecules along with a co-stimulatory antibody (anti-
CD28) were coupled to the surface of either spherical or ellipsoidal particles to the 
form biomimetic aAPCs.[41, 322, 323] Since aAPCs need to interact with T cells, the 
parameters to ensure they remain extracellular were explored by incubating both 
spherical and ellipsoidal particles with macrophages and human umbilical cord vein 
endothelial cells. These studies revealed spherical aAPCs were phagocytosed quicker 
and at higher levels compared to ellipsoidal aAPCs.[322] As a result, ellipsoidal 
aAPCs injected intravenously in mice experienced increased circulation time and 
greater biodistribution compared to spherical formulations. Since ellipsoidal aAPCs 
with increased circulation time had more opportunity to interact with T cells, this 
shape ultimately led to increased T cell proliferation compared to spherical 
aAPCs.[322] Further analysis of aAPC properties revealed that the degree of 
stretching influenced the extent of T cell proliferation, with optimal stimulation 
occurring when aAPCs were stretched 2-2.5 fold, relative to the original diameter.[41, 
322] One possible reason for this difference is that the ellipsoidal aAPCs allowed 
increased contact length with T cells, supporting increased numbers of surface-to-
surface interactions.[41] Ultimately, treatment with ellipsoidal aAPCs displaying 




tumor burden and increased survival.[323] The examples in this section demonstrate 
that micro- and nano-scale shape changes can significantly alter the interactions with 
immune cells, promoting either a pro-inflammatory or pro-regenerative niche. These 
phenomena need to be further explored with tissue engineering constructs which 
exhibiting complex conformations, commonly employed to recapitulate the natural 
tissue the implant is replacing while allowing for multiple contact points with the 
cellular environment. 
 
8.3.3 Biomaterial Surface Features and Chemical Functionality Impact Immune 
Recognition 
As alluded to in section above, upon injection or implantation, surface features (e.g., 
roughness) and specific chemical moieties or properties can impact both the extent of 
interactions with immune cells and the immunogenicity.[124-126, 128, 324] An 
important aspect along these lines is the role hydrophobicity plays in intrinsic 
immunogenicity.[120, 123] The immune system has evolved to recognize molecules 
with highly hydrophobic portions as foreign, potentially-dangerous materials (see 
Chapter 8.2). This property can thus trigger PRRs, leading to elimination.[123] In 
one study, gold nanoparticles functionalized with increasingly hydrophobic chemical 
groups (Figure 8.3A) were incubated with immune cells isolated from the spleens of 
mice.[120] Particles with greater hydrophobicity increased gene expression of pro-
inflammatory cytokines (e.g., TNF-α, IFN-γ) and similar effects were observed after 
intravenous injection in mice (Figure 8.3B).[120] To combat the immunogenic 




(PEO) and polyethylene glycol (PEG) are often added to delivery vehicles and tissue 
engineering scaffolds to increase hydrophilicity and reduce surface protein 
absorption.[325-327] This increased hydrophilicity and resistance to protein 
absorption can also lead to decreased interactions with immune cells, which might 
reduce immunomodulatory responses.[325-327] While diminishing interactions with 
immune cells could be beneficial in combating undesirable, pro-inflammatory 
responses, future approaches could leverage changes in surface chemistry to bias 
immune response toward natural healing responses to injury.  
 
Figure 8.3: Surface chemistry of particulate systems impacts immunogenicity.  
(A) Gold nanoparticles are functionalized with different chemical (‘R’) groups to exhibit varied 
hydrophobicity, denoted as ‘Log P’. (B) Immune cells isolated from mouse spleens were treated with 
these particles and revealed a correlation between increased hydrophobicity and elevated gene 
expression of pro-inflammatory cytokines (TNF-α). (C) Silica particles functionalized with different 
polypeptides with defined charges and levels of hydrophobicity increase the IL-1β response to 
treatment with an immune stimulant (LPS). Increasingly hydrophobic surface chemistries promote 
increased IL-1β secretion. (D) When these silica particles were treated in conjunction with a model 
antigen (OVA), particle immunogenicity increased T cell production of pro-inflammatory IFN-γ, with 
cationic particles inducing the highest levels. (A-B) Adapted with permission from ref [120]. 






The surface charge of a biomaterial also plays an important role in modulating 
immune function.[118, 119, 317, 329] For example, using the same gold nanorod 
platform discussed in above,[317] surface charge of the nanoconstructs was found to 
impact immunogenicity, in addition to size and shape. Nanorods altered the 
inflammatory profile of macrophages, as indicated by changes in gene expression and 
surface activation markers, depending on the exposed functional groups.[317] Amine-
terminated nanorods exhibiting a positive surface charge shifted macrophages to an 
anti-inflammatory M2 phenotype, while carboxylic acid-terminated nanorods with a 
negative surface charge induced an inflammatory M1 phenotype.[317] Interestingly, 
other studies have revealed particles with positively charged surfaces lead to 
activation of the inflammasome at greater levels than negatively charged 
particles.[119] Further, other work has shown particles with a negative surface charge 
can actually block or inhibit immune function.[99, 329] In one such study, particles 
synthesized from carboxylated PLGA, polystyrene, or microdiamonds, all exhibiting 
negative surface charges, were able to suppress inflammatory macrophages.[99] 
These cells were the drivers of various mouse models of disease, including West Nile 
Virus brain infection, kidney injury, colitis, multiple sclerosis, and cardiac infarction. 
In each case, suppression was achieved following treatment with negatively charged 
particles by shifting macrophage accumulation from sites of disease to the spleen, 
where apoptosis of these cells occurred, leading to reduced inflammatory responses 
and promoting regulatory T cell phenotypes.[99] As discussed directly in the coming 




intrinsic immunogenicity, the difficulty in decoupling related properties such as 
hydrophobicity and chemical functionality.  
 
Several studies have focused directly on the role of chemical functionality presented 
on surfaces to decipher how immune response is altered.[328, 330, 331] For instance, 
peptides synthesized with either an L or D stereochemistry have been linked to a 
model antigen (ovalbumin, OVA) and used to vaccinate mice.[330] The D 
stereochemistry, which is less susceptible to enzymatic degradation, led to stronger 
antibody responses and prolonged antigen presentation compared to the L 
stereotype.[330] Additionally, it was determined that when macrophages were treated 
with particles that contained either oxidized, reduced, or native protein antigens, the 
particles with native or reduced antigen were preferentially taken up in vitro, and 
promoted strong immune responses in mice.[331] The Fahmy Lab has used silica 
particles as a platform to understand how surface modification with polypeptides 
exhibiting different hydrophobicities and charges influence inflammasome signaling 
and DC activation in vitro.[328] As expected based on the discussion above, these 
studies determined inflammasome activation was size dependent.[328] Interestingly, 
however, investigation into how the surface chemistry of 300nm particles impacted 
IL-1β secretion revealed that particles functionalized with amino acids of increasing 
hydrophobicity drove increasing IL-1β secretion (Figure 8.3C).[328] Anionic 
particles caused the highest levels of activation, while cationic particles, shown above 
to activate pro-inflammatory responses, induced lower levels of IL-1β in this case. 




a result supported by a reduction in IL-1β secretion when uptake was chemically 
inhibited.[328] When cells were treated with these particles mixed with OVA, 
cationic particles caused increased IFN-γ production by T cells. Additionally, these 
elevated expression levels correlated to increasing particle hydrophobicity (Figure 
8.3D).[328] Since the balance of M1 and M2 macrophages play a major role in many 
tissues engineering applications, the studies in this section highlight opportunities to 
modulate immune cell phenotypes by altering the hydrophobicity, charge, or surface 
chemical functional groups of materials used to fabricate tissue engineering 
constructs. Two common, naturally derived biomaterials, alginate and hyaluronic 
acid, are highly studied as scaffold materials and both exhibit negatively charged 
surfaces. The studies above have revealed that a negatively charged surface could 
either halt or promote immune responses. These differences highlight the need for 
more detailed studies to elucidate how hyaluronic acid, alginate, or other materials 
can be formulated to leverage surface charge in supporting regenerative outcomes. 
 
8.3.4 Molecular Weight and Extent of Material Degradation Impact Immunogenicity 
Many drug delivery and tissue engineering approaches employ biodegradable 
materials as vehicles or scaffold to deliver signals to target cells or tissues over time. 
However, most of the studies investigating the intrinsic immunogenicity of materials 
have focused on a single snapshot in time or at stage of degradation. Thus, there is a 
strong need to understand how the immunogenicity of materials change over time as 





Early research investigating how the degradation of biomaterials influenced 
immunogenicity centered on hyaluronic acid, an extracellular matrix 
glycosaminoglycan.[107, 111-113] In this work, hyaluronic acid was enzymatically 
degraded to form fragments of varying molecular weight, then incubated with DCs or 
in DC and T cell co-cultures. These experiments revealed low molecular weight 
hyaluronic acid (1500-5300 Da) increased DC activation, inflammatory cytokine 
secretion, and T cell proliferation by triggering TLR-2 and TLR-4 signaling.[107, 
111-113] Subsequent research has studied how macrophage differentiation is 
impacted by hyaluronic acid fragments with different molecular weights.[114, 332] In 
these studies, macrophages were polarized to an M1 phenotype by low molecular 
weight hyaluronic acid, while high molecular weight hyaluronic acid induced a M2 
phenotype, preferred for tissue repair and healing.[114, 332] 
 
Our lab has investigated how the immunogenicity of synthetic polymers evolves as 
degradation progresses. Poly(beta amino esters) (PBAEs) provide an ideal system to 
address this question since these polymers are rapidly degradable and can be readily 
synthesized with different functionalities in a high-throughput manner.[129, 163, 333, 
334] In one study investigating the effect of PBAE formulation and degradation on 
immunogenicity, PBAEs were formulated via Michael-addition reactions between a 
diamine and one of three diacrylate monomers differing in the number of carbons in 
the polymer backbone (e.g., 4, 6, 10 carbons) (Figure 8.4A). These reactions resulted 
in polymers with varied starting molecular weight but similar degradation profiles 




for defined times to form distinct molecular weight ranges, then incubated with DCs 
in either a soluble or particulate form. In soluble form, none of the PBAE 
formulations activated DCs.[334] However, when condensed into a particulate form, 
PBAEs activated DCs in a molecular weight specific manner. PBAE-4 particles 
activated DCs at molecular weights corresponding to early stages of degradation (less 
degradation time). Meanwhile, PBAE-6 particles activated DCs after intermediate 
degradation times and PBAE-10 showed little to no immunomodulatory activity, with 
minimal activation occurring only after long degradation times.[334] Together, these 
results indicated that irrespective of degradation stage, the greatest activation levels 
were induced by particles formed from PBAEs fragments with molecular weights 
between 1500-3000Da (Figure 8.4C).[334] When DCs were treated with particles in 
the presence of an antigen, then co-cultured with T cells, both antigen presentation 
and T cell proliferation increased significantly.[163] Similarly, when injected into 
lymph nodes of mice using a new technique to control the dose and combination of 
signals,[13, 14, 163] immunogenic PBAE particles (‘Particle’) activated lymph node 
resident innate immune cells compared to a sham injection (‘Vehicle’), or an injection 
of soluble PBAEs (‘Free’) (Figure 8.4D).[163] These studies highlight the fact that 
materials may be non-immunogenic or pro-inflammatory at one time point, but as the 
material degrades, the physicochemical properties can change in ways that alter the 
immunogenicity. Analogous experiments are still necessary with other common 
polymers (e.g., PLGA) or extracellular matrix components (e.g., collagen, hyaluronic 
acid, fibronectin) that cause differential immune responses as the scaffold degrades or 




be advantageous to choose a material whose immunogenic profile promotes a natural 
wound healing response, with the implanted construct first promoting inflammation 
and immune cell recruitment then, as the material degrades, shifting towards a 
regenerative microenvironment.   
 
Figure 8.4: Polymer degradation and molecular weight influence DC activation in cell culture 
and mice.  
(A) PBAEs formulated with 4 (PBAE-4, blue), 6 (PBAE-6, red), or 10 (PBAE-10, green) carbons in 
the diacrylate monomer backbone were synthesized with (B) different starting molecular weights, but 
similar degradation profiles. (C) PBAEs were degraded to distinct molecular weight ranges, formulated 
into particles, and used to treat DCs. Maximum activation, as indicated by CD40 expression on live 
(DAPI-) DCs, correlated with a molecular weight range of 1500-3000Da. (D) After introduction into 
mice, immunogenic PBAE particles (red) induced statistically significant activation of lymph node 
resident immune cells compared to treatment with soluble (blue, ‘Free’) or buffer control (gray, 
‘Vehicle’) treatments. (A-C) adapted with permission from ref [334]. (D) reprinted with permission 
from ref [163]. 
 
With the growing understanding of the intrinsic immunogenicity of materials, an 
important concept is the interconnected nature of these properties. For instance, 
changing the shape of a particle by stretching may also change the size.[41, 322] 
Similarly changing a functional group on the surface of a material may also change 
the surface charge and hydrophobicity; any of these variations might change the 
immune signatures of the materials.[328] Therefore, one goal of future research 
should be to understand the relative contributions of properties or sets of properties to 
modulate immune function. An alternate strategy to understanding these interactions, 
is to mimic the attractive features of synthetic materials, but eliminate carriers 




340] However, all of these strategies share the same goal, to design materials – 
whether natural or synthetic – that better control immune function. 
 
8.4 Tissue Engineering Constructs Exhibit Intrinsic Immunogenicity 
Classical tissue engineering approaches generally consist of scaffolds incorporating 
signals or cells that upon implantation, induce proliferation of the encapsulated cells, 
alter the phenotype of native cells infiltrating the implant, or promote changes in 
tissue growth and function. Mesenchymal stem cells are an immunomodulatory cell 
type that has been particularly important in this area to enhance responses to tissue 
engineering constructs.[341-346] These cells have the ability to differentiate into a 
number of cell lineages, making them attractive in tissue engineering and regenerative 
medicine approaches aimed at a range of tissue types.[341-344] Additionally, 
mesenchymal stem cells have the ability to interact with innate and adaptive immune 
cells, for instance, by secreting immune suppressive molecules such as prostaglandin 
E2.[341-344] Integration of chemical signals, growth factors, and cytokines into 
scaffolds is another important component widely explored in the field.[25, 302, 305, 
306] While these cells and signals incorporated in scaffolds and implants are being 
intensely studied, there is a gap in the understanding of how intrinsic immunogenicity 
of materials might be exploited to help tune and improve outcomes in tissue 
engineering. Building on the discussion above of what has been learned about 
inherent immunogenicity from the vaccine and immunotherapy area, this section will 
focus on how the physicochemical properties of common tissue engineering materials 




8.4.1 Macrophage Responses to Injury are Influenced by the Presence of Acellular 
Biomaterial Scaffolds 
Most tissue engineering approaches involve implants made from metallic, ceramic, or 
composite materials, or scaffolds comprised of synthetic materials, decellularized 
constructs, or extracellular matrix components.[283] These structures must be able to 
overcome immunological rejection, a process resulting from recognition by innate 
and adaptive immune cells.[25, 292] As explained in Chapter 8.2, macrophages play 
a large role in tissue repair with a balance of M1 and M2 phenotypes needed to 
promote proper healing. Interestingly, new studies show that the activation state of 
macrophages at the time of encounter with a biomaterial impact the uptake of the 
biomaterial and subsequent macrophage activation.[347] For example, in the case of 
an injury where the wound is too large for conventional wound healing to occur, 
recovery would generally result in scar tissue formation. To test if addition of an 
acellular biomaterial scaffold could reduce adverse effects and promote proper 
healing, one recent report fabricated a scaffold by isolating extra cellular matrix 
components from a portion of the small intestine. This scaffold was then implanted at 
the injury site.[348] In this study, the macrophage response to an untreated injury 
resulted in a pro-inflammatory M1 phenotype, while implantation of the scaffold 
shifted this response to the M2 phenotype.[348] This example highlights how just the 
presence of a biomaterial at an injury site can shift the immune response to promote 
tissue repair, motivating research to tease out the mechanisms that modulate immune 




8.4.2 Scaffold Composition Alters Interactions with the Immune System 
There are a variety of biomaterials that can be used as tissue engineering constructs. 
Early research from the Babensee Lab highlights how DCs incubated on thin films of 
naturally occurring or synthetic materials - including PLGA, chitosan, alginate, 
hyaluronic acid, and agarose - cause differences in DC activation, cytokine 
production, and T cell proliferation.[109, 125, 157] Based on these findings, recent 
studies have directly explored how materials commonly used in tissue engineering 
impact innate immune cells. In one study, extracellular matrix scaffolds were derived 
from diverse tissue sources including matrices from small intestine submucosa (SIS), 
urinary bladder (UBM), skeletal muscle (mECM), brain (bECM), esophagus (eECM), 
skin (dECM), liver (LECM), and colon (coECM) and enzymatically solubilized with 
pepsin.[349] These solubilized extracellular matrix scaffolds were then used to treat 
macrophages. The level of M1 and M2 phenotype were determined by assessing 
iNOS and Fizz1 expression as markers for the M1 and M2 phenotypes, 
respectively.[349] SIS, bECM, eECM, and coECM treatments induced an M2 
phenotype at levels comparable to macrophages treated with a positive control signal 
(IL-4) used to promote M2 differentiation (Figure 8.5A).[349] In contrast, dECM 
treatment promoted a shift toward M1, with heightened iNOS expression on the 
macrophages stained with a classical macrophage marker, F480 (Figure 8.5A).[349] 
Further  investigation of macrophage lysates following treatment revealed SIS, UBM, 
bECM, and coECM solubilized ECM scaffolds caused decreased iNOS expression, 
while SIS, UBM, eECM, coECM increased CD206 expression; CD206 is another 




wound healing phenotype could be induced, and emphasizes that the selection of the 
tissue from which a scaffold is derived from can significantly bias immune function 
to improve scaffold performance.[349]  
 
Figure 8.5: Scaffolds derived from extracellular matrix components of specific tissues polarize 
macrophage function.  
(A) Macrophages (stained with F4/80) and treated for 18 hours with control cytokines (MCSF, IFN-γ + 
LPS, IL-4) or solubilized extracellular matrix scaffolds cause differential expression of markers for the 
pro-inflammatory M1 macrophage phenotype (iNOS) and the wound-healing M2 macrophage (Fizz1). 
Solubilized scaffolds were produced via pepsin incubation of small intestine submucosa (SIS), urinary 
bladder (UBM), skeletal muscle (mECM), brain (bECM), esophagus (eECM), skin (dECM), liver 
(LECM), or colon (coECM) extracellular matrix components. MCSF was used as a negative control 
for macrophages while pepsin was a control for ECM solubilization, IFN-γ + LPS was a positive 
control for M1 macrophages, and IL-4 was a positive control for M2 macrophages. (B) Treatment with 
matrices also induces varied levels of M2 associated (CD206) and M1 associated (iNOS) proteins in 
macrophage lysates. Adapted with permission from ref [349]. 
 
While the studies above used scaffold prepared directly from complex tissues, other 
recent studies are investigating constructs formed from specific biological molecules 
or synthetic materials.[350-354] One such molecule is collagen, a protein abundant in 
the extracellular matrix that has been widely explored as a scaffold component.[355] 
During recent studies in mice, a collagen scaffold with silica integrated between the 
collagen fibers activated monocytes. These cells have the ability to differentiate into 




bone and blood vessel formation.[350] The authors hypothesized this response 
resulted from increased IL-4 detected in serum one week after implantation; IL-4 has 
previously been shown to induce wound healing phenotypes.[350] Fibrin and 
fibrinogen have also been frequently used for tissues engineering applications; both 
of these proteins play a crucial role in the formation of blood clots during normal 
response to injury.[25, 283-285] One study investigating the effect of fibrin and 
fibrinogen found that thin films of fibrin promoted macrophage secretion of anti-
inflammatory IL-10, and were able to reverse the secretion of inflammatory cytokines 
(e.g., IFN-γ) from macrophages stimulated with a TLR4 agonist.[351] In contrast, 
soluble fibrinogen increased the pro-inflammatory cytokine, TNF-α. Interestingly, 
when macrophages were co-treated with both fibrin films and soluble fibrinogen, 
fibrin played a dominate role, resulting in an anti-inflammatory response.[351] In a 
separate study, fibrinogen was prepared as a porous scaffold and the 
immunomodulatory effects on immune cells were investigated during a bone injury 
model. After implantation in mice, the fibrinogen scaffold outperformed sham 
implantations, promoting bone regrowth. These improvements were correlated with 
altered cytokine gene expression and changes in both the local and systemic immune 
cell responses.[352] Similarly, other studies have investigated synthetic ceramic 
materials. These studies have revealed that treatment with a clinical standard for 
ceramic implants (tricalcium phosphate–hydroxyapatite) promotes an M1 
macrophage phenotype.[353] Alternatively, treatment with scaffolds formed from 
newer ceramic materials (e.g., baghdadite and strontium–hardystonite–gahnite) 




phenotypes.[353] Lastly, synthetic polymers have also played a large role as scaffold 
materials. One recent example demonstrates that nondegradable polypropylene 
meshes induced M1 macrophages, while meshes coated with dermis or urinary 
bladder extracellular matrix components promote M2 macrophages.[354] After 
implantation in rats, the meshes coated with extracellular matrix components also 
decreased the number of foreign body cells, a signal that a fibrous capsule would not 
form around the implant.[354] These studies highlight how even with commonly used 
polymers or extracellular matrix components, dramatically different responses are 
possible because of differences in interactions with immune cells. However, further 
studies are needed to ascertain which properties of the scaffold are ultimately 
responsible for the immunogenic responses. With continued investigation into the 
chemical and biological differences between these ECM matrices and synthetic 
scaffolds, one could identify the key signals needed to shift the immune response 
towards a wound healing phenotype. After ascertaining which cues are important, 
future tissue engineering constructs could be designed with either synthetic materials 
supplemented with the pro-regenerative signals or from a subset of the tissue ECM 
scaffolds that only contains the desired signals. This approach would allow for the 
fine tuning of the immune system response to the implanted biomaterial and promote 





8.4.3 Physicochemical Properties of Tissue Engineering Constructs Also Alter 
Intrinsic Immunogenicity 
As with particle based delivery systems, the physicochemical properties of materials 
used in scaffolds can dramatically impact the interactions with the immune system. 
While this vein of research has garnered interest for particulate systems (see Chapter 
8.3), interest in the tissue engineering field is just arising over the past few years. 
New studies are investigating how shape, composition, and charge of tissue 
engineering constructs impact the immune response.[356-361] For example, 
polymeric scaffolds have been synthesized by electrospinning polycaprolactone, then 
the resulting fibers were modified to exhibit different shapes.[356] Scaffolds were 
then formed from either the random or aligned fibers. Afterward, these scaffolds were 
left unmodified or expanded to exhibit macro-scale thicknesses of 3mm or 
10mm.[356] Following subcutaneous implantation into rats, macrophages were able 
to infiltrate into scaffolds formed from randomly aligned fibers with expanded 
thickness of 3mm or 10mm. However, scaffolds formed from aligned fibers that were 
expanded to 3mm supported greater macrophage penetration and the smallest number 
of giant cells, a trait the authors attributed to the gap distance between the aligned 
fibers.[356] In a similar study, scaffolds with varying pore sizes were formed from 
electrospun polydioxanone. These experiments revealed a correlation between 
increased pore size and a shift towards M2 function and away from M1 
macrophages.[357] An ongoing question in the tissue engineering field centers on the 
balance between the porosity of scaffolds and the mechanical properties required for 




tissue engineering constructs can promote pro-regenerative environments by altering 
macrophage function. However, this change in scaffold structure may negatively 
influence mechanical strength and, in the case of tissue-mimicking implants for 
structural components (e.g., bone), the mechanical strength of the scaffold needs to 
recapitulate that of the native tissue. Thus, while scaffold shape and porosity can be 
exploited to promote inflammation or repair by modulating macrophage phenotype 
and limiting fibrosis (i.e., reducing the number of foreign body cells), there is also a 
need to better understand the interplay between these immunological outcomes and 
material properties.[356, 357] 
 
Another new avenue of research has focused on the chemical composition of 
scaffolds and how this influences the functions of DCs and macrophages. One study 
showed that calcium alginate gels promote inflammatory responses in cells and in 
mice by releasing calcium, a signal that increased DC activation and IL-1β 
secretion.[358] This work revealed the intrinsic immune function stemmed from the 
calcium, as gels formed with barium instead of calcium led to reduced scaffold 
immunogenicity.[358] Since alginate hydrogels are commonly used for tissue 
engineering constructs and generally use calcium as the divalent ion for crosslinking, 
this discovery provides evidence that even the choice of molecule for cross linking 
could impact the resulting immune response and thus inform which divalent 
molecules should be used for crosslinking hydrogels. Experiments with hyaluronic 
acid formed into films via electrostatic interactions with poly-L-lysine caused 




Interestingly, after crosslinking the hyaluronic acid with aldehyde, there was a 
reduction in TNF-α and IL-1β secretion and slight increases in anti-inflammatory 
cytokines.[359] This result is in agreement with the studies discussed in above 
relating to molecular weight, revealing increased activation from low molecular 
weight hyaluronic acid fragments; these particles might be generated as non-
crosslinked scaffolds begin to degrade. However, using crosslinking, the rate of 
degradation and the production of low molecular weight hyaluronic acid fragments 
generated via degradation could be slowed. This reduction decreased the overall level 
of pro-inflammatory molecules. Other work investigated how the charge of hydrogel 
scaffolds impacts immunogenicity by evading foreign-body reactions.[360] In this 
study, zwitterionic poly(carboxybetaine methacrylate) hydrogels prepared from a 
carboxybetaine monomer and a carboxybetaine cross-linker shifted macrophage 
phenotype to an anti-inflammatory state compared to samples treated with poly(2-
hydroxyethyl methacrylate) hydrogels, a commonly used molecule similar to PEG 
that reduces protein absorption.[360] Thus, the hydrogels were able to diminished 
macrophage activation in mice by reducing the underlying protein adsorption to the 
scaffold after implantation.[360] This feature could be beneficial for future implanted 
biomaterial scaffolds designed to limit fibrotic buildup and implant rejection. 
Together, the results from this section suggest that the material with which a hydrogel 
is formed, the extent of crosslinking, and the molecule used for crosslinking can all 
impact the immunogenicity of the scaffold. Similar to the discussion above, there is 
an ongoing need to understand the interplay between these properties. For instance, if 




crosslinking of this scaffold with calcium may result in reduced immunogenicity by 
reducing the degradation but could also cause a local increase in pro-inflammatory 
cytokines. Therefore, it will be crucial for future tissue engineering approaches to 
understand which properties of hydrogels are the main drivers of this intrinsic 
immunogenicity.  
 
In an elegant study by Christo et al., complex surface nanotopography and chemical 
composition commonly seen in tissue engineering constructs were mimicked to test 
the impact on the response of innate immune cells.[361] Glass cover slips were 
coated with gold nanoparticles exhibiting varying diameters. These materials were 
then modified by deposition of allylamine, (AA), octadiene (OD), or acrylic acid 
(AC) to create surfaces abundant in either amino, alkyl, or carboxylic acid groups, 
respectively (Figure 8.6A).[361] Because the surfaces were formed with 
nanoparticles of varying diameters, these constructs mimicked scaffolds with either 
smooth surfaces or exhibited tunable degrees of surface roughness (Figure 
8.6B).[361] When neutrophils were incubated with the surfaces, rough and, in 
particular, acidic surfaces increased section of MMP-9, a protein involved in 
extracellular matrix degradation.[361] Additionally, when incubated with 
macrophages, these surfaces caused differential effects on the secretion of pro-
inflammatory cytokines. The rough, acidic surfaces again shifted the environment 
away from inflammation by decreasing the secretion of pro-inflammatory cytokines 
TNF-α, IL-6, and IL-1β (Figure 8.6C).[361] This type of experiment, where multiple 




scaffolds fabricated with physicochemical properties that can modulate the immune 
response between inflammation and tissue repair. 
 
Figure 8.6: Implant surface morphology and chemical composition induces innate cell activation 
and cytokine secretion.  
(A) Schematic depiction of glass cover slips coated with gold nanoparticles, then functionalized with 
allylamine (AA), octadiene (OD), or acrylic acid (AC) to form biomimetic surfaces abundant in amino, 
alkyl, or carboxylic acid groups, respectively. (B) Atomic force micrographs showing 2-D (top) and 3-
D (bottom) surfaces with different roughness due to the different particles diameters. (Top scale bar, 
1µm; lower scale 5µm x 5 µm). (C) Macrophages cultured on these surfaces exhibited different 
secretion levels of pro-inflammatory cytokines TNF-α (left), IL-6 (center), and IL-1β (right); cells 
cultures on the roughest surfaces (prepared with 68nm particles) reduced inflammatory cytokine 
secretion. Reprinted with permission from ref [361].  
 
8.5 New Technologies and Analysis Methods will Exploit Intrinsic Immunogenicity 
to Advance Tissue Engineering Capabilities  
Recent studies in tissue engineering investigating the impact of material properties on 
immune activation have yet to fully elucidate the mechanism through which this 
activation occurs. Future research endeavors will need to incorporate more 
experimental parameters and higher, more complex animal models to determine the 




from the Langer and Anderson labs, mouse, rat, and non-human primate models were 
used to investigate how the size and shape of various biomaterial implants fabricated 
from ceramics, hydrogels, metals, and plastics activated innate cells and led to 
fibrosis.[116] First, alginate particles were prepared with sizes from 0.3mm to 
1.9mm, then implanted in mice.[116]  Following implant retrieval after two weeks, 
particles size was inversely correlated with expression of genes involved in fibrosis: 
α-SMA (Figure 8.7A, left), collagen 1a1(Figure 8.7A, center), and collagen 1a2 
(Figure 8.7A, right).[116] After determining that size impacted the foreign body 
response to alginate, the authors compared the response to different biomaterials 
exhibiting similar sizes. Particles with a diameter of 0.5mm were formulated from 
alginate, stainless steel, glass, polycaprolactone, or polystyrene, then implanted 
intraperitoneally in mice. The implants were removed after 14 days, and all resulted 
in fibrotic growth (Figure 8.7B, top).[116] Interestingly, particles fabricated from the 
same materials but with larger diameters (1.5-2mm) reduced fibrotic tissue formation 
(Figure 8.7B, bottom), a phenomena attributed to reduced infiltration of macrophages 
and neutrophils at the implant site.[116] Further investigation with alginate particles 
of medium (0.5mm) and large (1.5mm) sizes implanted into non-human primates 
resulted in similar findings.[116] After implantation of both medium (0.5mm) and 
large (1.5mm) particles into mice, the number of neutrophils and macrophages on the 
excised particle as well as macrophage phenotype was determined at various times 
post-implantation (e.g., day 1, 4, 7).[116] Larger particles caused a shift towards 
immune regulatory and wound healing macrophage phenotypes, while medium 




from the Anderson lab, the mechanism through which fibrosis occurred after 
implantation of alginate spheres was determined.[362] This study incorporated both 
mouse and primate models to study the response to the implanted particles. While 
implantation of alginate spheres increased the macrophage, neutrophil, and B cell 
responses to the implants, macrophages and not neutrophils were determined to be the 
main cell type that drives fibrosis.[362] Using knock out mice for neutrophils, 
macrophages, and B cells, it was determined that macrophages were essential for the 
formation of fibrosis on the alginate spheres and lead to B cell recruit which further 
promoted fibrosis.[362] High throughput gene expression analysis revealed colony 
stimulating factor-1 receptor was ultimately the driving mechanism for fibrosis in 
response and direct inhibition of this receptor was able to control fibrosis without the 
complete depletion of macrophage function.[362] These studies highlight the utility 
of using multiple animal models and emerging technologies to determine how 
specific physicochemical properties influence immune responses to tissue engineering 
constructs. Such approaches could provide a generalizable framework for other 






Figure 8.7: Implanted materials with distinct sizes and compositions alter fibrotic capsule 
formation.  
(A) Following implantation of alginate spheres of different sizes the peritoneum of mice, gene 
expression profiles of the pro-fibrotic markers α-SMA (left), collagen 1a1 (center), and collagen 1a2 
(right) revealed larger particles reduced fibrotic build-up. (B) Images revealing the level of fibrosis for 
particles with diameters of 0.5mm (medium) or 1.5-2mm (large) prepared from alginate, stainless steel, 
glass, polycaprolactone, or polystyrene. For all materials, large particles were associated with reduced 
fibrosis 14 days after implantation. (Scale bar, 2mm). Adapted with permission from Macmillan 
Publisher Ltd: Nature Materials from ref [116], copyright 2015. 
 
Other recent research has focused not just on innate immunity, but on the role of 
implanted materials in modulating adaptive immunity. In a study by the Elisseeff and 
Pardoll labs, scaffolds were derived from bone (B-ECM) and cardiac muscle (C-
ECM) extracellular matrix components, then used to treat critical muscle injuries in 
mice.[363] The response to these scaffolds was compared to collagen scaffolds and 
saline treatments to study the underlying immune mechanisms.[363] In a normal 
immune response to a pathogen, APCs such as macrophages and DCs present antigen 
to naïve, CD3+ T cells which then proliferate and, depending on the signals also 
delivered to the T cell, differentiate into various T cell subsets.[25] These subsets 




include T helper 1 (TH1) cells which assist in M1 macrophage activation, T helper 2 
(TH2) cells that promote M2 macrophage activation, and TH17 T cells which cause 
inflammation through activation of neutrophils.[25] In wild type mice, treatment with 
collagen, B-ECM, and C-ECM scaffolds increased CD4+ T cells and the expression 
of IL-4 genes, an important cytokine for TH2 cell differentiation and tissue repair via 
M2 macrophages.[363] Supporting this finding, transcriptome analysis of genetic 
material from CD3+ T cells one week after treatment with the biomaterial scaffolds 
revealed increased messenger RNA that drives development of TH2 responses 
(Figure 8.8A).[363] When repeating these treatments in Rag1-/- mice, which are 
deficient in mature B and T cells, IL-4 gene expression was decreased to levels 
comparable to saline treatments, further supporting the hypothesis that T cells were 
responsible for IL-4 production.[363] Additional studies showed the increase in IL-4 
expression was present in both the draining (e.g., inguinal) and distal lymph nodes 
(e.g., axillary, brachial) (Figure 8.8B), indicating local changes to immune function 
can lead to systemic responses.[363] When mice deficient in CD4+ T cells were used, 
this response was diminished, though not as low as measured when both B and T cells 
were knocked out in Rag1-/- mice (Figure 8.8B).[363] These results suggest TH2 cells 
play a critical role in wound healing and creating a regenerative microenvironment, 
while other adaptive immune cells (e.g., CD8+ T cells, B cells) may play a supporting 
role in these processes.[363] While the majority of research in tissue engineering has 
focused on the innate immune cells (e.g., macrophages) that play a major role in both 
regeneration and in scaffold failure, this study reveals the need for more work 




repair. Through a better understanding of how T cells support tissue regeneration or 
how antibodies produced by B cells impact a host reaction to implanted materials, 
future constructs could be designed with materials that control these pathways. 
 
Figure 8.8: Adaptive immune cells play a role in the response to implanted scaffolds.  
After inducing a critical muscle injury in mice, scaffolds derived from collagen, bone (B-ECM), or 
cardiac muscle extracellular matrix (C-ECM) were implanted. (A) CD3+ T cell transcriptome analysis 
was used to evaluate the gene expression of markers for distinct immune cell populations and 
phenotypes compared to a sham saline surgery control, denoted as ‘RQ to Saline’. Treatment with B-
ECM and C-ECM scaffolds revealed an increase in TH2-associated genes (e.g., Jag2, IL-4). (B) 
Treatment with scaffolds in wild-type mice (blue, ‘WT’) increased IL-4 gene expression in local (left) 
and distal lymph nodes (right) compared to saline treatments. When CD4+ T cell-deficient mice (green, 
‘Cd4-/-), or B and T cell-deficient mice (red, ‘Rag1-/-) were treated with ECM scaffolds, IL-4 gene 
expression decreased. (A-B) from ref [363]. Reprinted with permission from AAAS. 
 
As the field of tissue engineering and regenerative medicine progresses, novel 
biomaterials and scaffold preparation methods will motivate further studies to 
investigate the immunogenicity of these new materials. One exciting avenue of 
research is 3-D printing of tissue engineering constructs.[364-367] These new 
approaches allow for the synthesis of implants with precise shapes and architectures 
fabricated from a variety of materials. In a recent study from Kang et al., 
biodegradable polymers and hydrogels encapsulating cells were printed together in 




mixing of polycaprolactone with hydrogels consisting of gelatin, fibrinogen, 
hyaluronic acid, and glycerol to create stable structures with various pore sizes.[368] 
Scaffolds prepared in this way supported high viability of implanted cells and 
promoted tissue reconstruction for a variety of tissues types, including bone, cartilage, 
and muscle.[368] While this research presents a new, flexible system to synthetically 
create biomaterial-based scaffolds, the researchers note that the host immune 
response to their new materials was not investigated.[368] This comment highlights 
some of the broader issues facing the field, in particular, that systematic studies will 
be important to fully understand the mechanisms through which the immune system 




The vaccine and immunotherapy fields have provided valuable insight into how 
materials properties impact immune responses. This work has already shown 
physicochemical features alter the immunogenicity of biomaterials and is helping to 
inform the design of better materials that actively drive immune response towards a 
desired outcome. The field of tissue engineering provides a rich avenue to explore 
some of these same concepts and opportunities. With new knowledge of how these 
physicochemical properties influence the response to implanted materials, greater 
flexibility will arise for controlling immune response by carefully designing or 
selecting the material properties of implants and scaffolds. To reach this goal, future 




architecture might impact intrinsic immunogenicity, and utilize animal models where 
material constructs with systematically introduced property variations are studied. 
Conducting these studies in the absence, and in the presence, of other 
immunomodulatory factors will help reveal the interplay between material properties 






Chapter 9: Outlook and Future Directions  
 
9.1 Outlook 
The research conducted in this dissertation has revealed for the first time that 
poly(beta-amino esters) (PBAEs) exhibit intrinsic immunogenicity and that this 
phenomena is a function of polymer form (e.g., soluble versus particulate) and 
physicochemical properties (e.g. molecular weight, MW). Additionally, through the 
use of intra-lymph node (i.LN.) injection, this research revealed that the deposition of 
biomaterial carriers and immune cues into the lymph nodes (LNs) of mice alters the 
local microenvironment by increasing the number of innate immune cells, ultimately 
leading to increased local and systemic antigen-specific immunity and survival in 
melanoma cancer models. These developments also revealed a number of research 
avenues for future exploration. The key areas are outlined in the sections below.  
 
9.2 Future studies exploring polymer intrinsic immunogenicity  
As revealed in Chapters 3-5, PBAEs degraded to form low MW fragments and 
fabricated into particles exhibit properties that activate dendritic cells (DCs), promote 
antigen presentation, and cause T cell proliferation. These effects were also 
maintained in animals when introduced into mice via i.LN. injection. Since these in 
vivo studies were conducted with a single polymer formulation, at one extent of 




future studies should explore PBAE immunogenicity in mice with more experimental 
groups and time points. For instance, each of the PBAEs synthesized in Chapter 4 
could be introduced into LNs of mice at various states of degradation (e.g., after 0, 1, 
3, or 7 days of degradation), and the activation state of LN-resident DCs and 
macrophages could be quantified at multiple time points corresponding to initial cell 
uptake (e.g., 1, 2, or 4 hours after injection), innate cell activation (e.g., 8, 12, 24, or 
48 hours after injection), or at the onset and height of the adaptive immune response 
(e.g., 3, 7, or 14 days after injection). These types of studies could elucidate how the 
immunogenicity of PBAEs shown in cell culture translates to mice and the 
persistence and phenotype of activation over time.  
 
In the work conducted in Chapters 3-5, PBAEs were complexed with a model anion 
(poly(sodium 4-styrenesulfonate), SPS) via electrostatic condensation to mimic a 
common DNA vaccine delivery strategy. Ongoing research could be conducted with a 
control oligonucleotide or nucleic acids designed to be non-immunogenic. This 
choice would provide a better model for DNA delivery and could help to reduce any 
confounding, immunostimulatory effects from the SPS. Additionally, in a separate 
research arm, PBAEs could be complexed with known immunostimulatory nucleic 
acids such as TLRa (e.g., PolyIC, CpG, PolyU). In this type of study, PBAEs would 
act as both an additional immune stimulant and as a controlled release vehicle, 
providing an opportunity to tune the release of the other immunogenic cargos. These 
studies could be used to test complexes as potentially new adjuvants while also 





Supplementary studies to understand the intrinsic immunogenicity of polymers would 
benefit from the formulation of a library of polymers with varied degradation rates. 
This way, instead of just comparing chemical structure and starting MW, distinctly 
different degradation rates could be compared to determine the impact on 
immunogenicity. This could be accomplished by a variety of polymers (e.g., PBAEs, 
polycaprolactone, PLGA) or using the same polymer (e.g., PLGA) synthesized with 
varied monomer ratios. In a pilot study exploring this idea, the ability of PLGA and 
Poly1 particles to adjuvant the immune response to soluble antigen was explored. 
After confirming that the PLGA and Poly1 degraded at different rates (Figure 9.1A), 
microparticles were formed from each polymer using the double emulsion, solvent 
evaporation methods detailed above and treated with soluble antigen (OVA) via i.LN. 
injection. Next, the systemic response was quantified by measuring the frequency of 
antigen-specific T cells weekly and comparing the response to control treatments 
including untreated mice, mice treated with just the particles and no antigen, or 
treatment with antigen alone (Figure 9.1B). Interestingly, it can be seen that while 
soluble antigen elevates antigen specific cells seven days after treatment, treating with 
PLGA particles and OVA increases this response while treating with Poly1 particles 
does not. This response then further increases at Day 14 post treatment, possibly due 
to the immunogenicity of PLGA particles evolving as the materials begin to degrade. 
Continued research is needed to confirm these preliminary results, discern what 
polymer properties cause these differences, and reveal features maintained across 





Figure 9.1: PLGA particles increase the antigen-specific response to soluble antigen treatment. 
(A) The degradation of Poly1 (red) and PLGA (blue) was quantified via gel permeation 
chromatography. (B) After treating mice via i.LN. injection, the antigen-specific T cell response in 
blood was quantified. 
 
Additional future studies should also be conducted to understand the mechanism of 
action for DC activation in response to polymer treatment. These studies could use 
assays including TLR reporter cell lines that respond only to activation of particular 
TLRs or knockout mice that lack the machinery for specific signaling pathways (e.g., 
inflammasome or TLR). By fluorescently tagging polymers, degradation products 
could be tracked in cells and mice to also help determine the mechanism of activation 
and with which cells and organelles these polymer products are interacting with. For 
example, after systemic injections, it would be important to understand with which 
immune tissues the treatments are interacting. Additionally, on a cellular level, it 
would be important to ascertain whether the materials remain extracellular where 
certain immune receptors could be activated, or if vaccines are able to enter the 





9.3 Continued research for engineering the local LN microenvironment  
The work in Chapters 5 and 6 provides clear evidence that deposition of 
biomaterials and immune cues in LNs results in potent, antigen-specific local and 
systemic immune responses. These responses were quantified over time to determine 
the longevity of the resulting immune responses while providing new knowledge 
about the interplay between local LN rearrangement and antigen-specific responses in 
untreated tissues and blood. Future mechanistic studies could analyze specific cell 
migration or transport mechanisms to elucidate the prominent cell types or signals 
that are needed to provoke a potent systemic response. These studies should 
investigate if the particles or immune signals (e.g., antigen and adjuvant) are 
trafficking to uninjected LNs after i.LN. administration or if activated cells (e.g., DCs 
and macrophages) traffic from the treated nodes to other tissues to subsequently 
activate naïve lymphocytes in these tissues. Each immune cargo could be 
fluorescently labeled and tracked using whole animal imaging to determine the 
biodistribution of signals following treatment. Additionally, through the use of 
transport inhibitors such as FTY720, lymphocyte egress from LNs could be blocked. 
In this type of study, mice treated via i.LN. injection with biomaterial vaccines would, 
based on previous data from this work, activate the local cells. However, by treating 
with first FTY720, these activated cells would be unable to move out of LNs via 
efferent lymphatics and thus be sequestered in the treated tissues. Therefore, if cells 
in other, untreated LNs were found to be activated, it could be reasoned that the 





Building on the work from Chapter 6, pilot studies were conducted to determine if 
the localization of immune signals to one or more LN were necessary for cell 
activation (Figure 9.2A). Microparticles containing an adjuvant (PolyIC) were mixed 
with soluble whole protein antigen (ovalbumin, OVA) and injected via i.LN. 
injection. Seven days after injection, the local response to treatment was quantified 
and each week the systemic antigen-specific responses in blood were evaluated 
(Figure 9.2B). Seven days after treatment at the height of T cell expansion, treatment 
with PolyIC MPs and OVA lead to increased levels of T cells within the treated nodes 
that were specific to the antigen (Figure 9.2C). As expected, LNs that were treated 
with vaccines containing OVA had dose dependent responses, with the One LN and 
Split treatment having the highest levels of antigen-specific T cells, while the Two 
LN treatment, which received half the dose of vaccine per LN, had a diminished 
response. Interestingly, priming both LNs resulted in the highest levels of antigen-
specific T cells, followed by treating One LN, and finally the Split LN treatment 
(Figure 9.2D). When evaluating the B cell-mediated antibody response, serum 
collected from treated mice seven days after treatment had slightly increased levels of 
OVA-specific IgG antibodies (Figure 9.2E). However, at day 28 after treatment, the 
difference between groups was even more pronounced, with all groups inducing a 





Figure 9.2: Localization of vaccines to numerous LNs results in heightened immune responses.  
(A) Schematic representation of vaccination strategy used to treat multiple LNs in mice via i.LN. 
injection. Using the treatment scheme in (B), local and systemic immune responses were determined. 
Antigen-specific tetramer levels both in the treated LNs (C) and blood (D) were quantified via flow 
cytometry. Antigen-specific IgG titers were evaluated 7 (E) and 28 (F) days after treatment.  
 
While these initial studies will need to be repeated, the results reveal that both B and 




the phenotype of these cells. To do this, germinal centers (GCs), the LN 
microdomains formed when activated B cells undergo proliferation, somatic 
mutation, and affinity maturation, can be quantified to determine whether the 
localization or the combination of specific immune signals impacts the GC numbers. 
Further experiments could also investigate the antibody isotypes that form after 
treatment to determine if treatment causes any antibody isotype class switching. Other 
mechanistic studies could exploit knockout mice that are genetically modified to be 
deficient in particular cells types. By using mice that lack important immune cell 
subsets (e.g., B cells, T cells, antigen presenting cells), the role that each of these cells 
play in response to i.LN. treatment could be evaluated and could motivate future 
studies that target the most prominent cell types with signals specifically selected to 
modulate the immune response towards a desired function.   
 
Pilot studies were also conducted to build on the results presented in Chapter 6 
showing that i.LN. injection could cause protection in cancer models. In these studies, 
the same treatment scheme as in Figure 9.2A was used to determine if vaccine 
localization impacts survival. In these studies, treatments of one LN were injected 
into both the tumor draining LNs (tdLNs) and non-tumor draining LNs (non-tdLNs). 
Additionally, when splitting the vaccine components between LNs, groups had either 
PolyIC MPs in the tdLN or OVA in the tdLN. Seven days after vaccination, mice 
were 1,000,000 B16-0VA melanoma cells, cancer cells modified to overexpress OVA 
antigen. As expected, a sham treatment of PBS had no therapeutic effect and 




or one LN, regardless of whether this LN was tumor-draining or not, mice had 
decreased tumor incidence and increased survival, with all but one of the treated mice 
never establishing a tumor (Figure 9.3B). Interestingly, when splitting the treatments 
between LNs, having the PolyIC MP in the tdLN had a larger therapeutic effect than 
having OVA in the tdLN. When PolyIC was in the LN, only 1 mouse succumbed to 
their tumor while five of six mice established tumors in the other group. 
 
Figure 9.3: Vaccine localization impacts anti-cancer immunity. 
(A) Individual tumor traces of mice treated with PBS (Sham), PolyIC MPs and soluble OVA in two 
LNs, one LN, or split between LNs in tdLNs and non-tdLNs. (B) Treatments lead to decreased tumor 
incidence and increased survival.  
 
Future studies expanding on the cancer models presented in Chapter 6 and the pilot 




and the longevity. First, mice that were primed via. i.LN. injection with a vaccine, 
then inoculated with cancer cells who do not form a primary tumor could be re-
challenged with a second inoculation of cells. In these studies, mice that have 
immunological memory would have lymphocytes that are antigen-specific and could 
thus clear the tumor when re-encountering the cells. This study could help 
differentiate the treatments that are only able to clear initial tumors and those 
treatment regimens that result in a potent response that produces memory cells. 
Another way to test the robustness of vaccination would be to isolate T cells from 
mice following i.LN. treatment and then adoptively transfer these cells to naïve mice. 
The recipient mice could then undergo a cancer challenge and the ability to confer 
immunity to the recipient mice can be quantified. Similarly, T cells could be removed 
from treated mice and ex vivo assays to quantify CD8-specific killing of cells could 
determine the optimal treatment scheme. Finally, while this work has shown efficacy 
in melanoma models, in order to convey the robustness of the i.LN. platform, other 
models could be used with different, clinically-relevant antigens and other cancers 








Chapter 10: Contributions 
 
My research has resulted in 15 manuscripts published: 7 first author publications and 
8 manuscripts where I was a supporting author. 2 of my first author papers were 
based on PBAEs and their intrinsic immunogenicity, 2 focused on intra-lymph node 
injection and how to use this technique to understand changes in lymph nodes, 1 
paper centered on immobilizing cells while maintaining their free-floating dynamics, 
and 2 were review papers that discussed how biomaterials can be used to engineering 
the lymph node microenvironment and how the intrinsic immunogenicity of materials 
could inform tissue engineering approaches. I also have another first author 
publication in preparation based on the work in Chapter 7. For the 8 additional 
papers where I was a supporting author (See Appendix A), my contributions included 
isolation, fluorescent staining, and imaging of treated lymph nodes, providing insight 
and assistance with forming electrostatic complexes, and aiding experimentally in 
various cell and animal studies. A portion of this research has also resulted in 1 issued 
US patent, 1 US utility patent application, and 1 international patent application (See 
Appendix B). The issued patent centers on intra-lymph node injection and was voted 
as a finalist for the 2014 University of Maryland Invention of the Year. The utility 
patent and international patent applications both focus on the immobilization of cells 
and a licensing agreement has been reached for this work. I have also presented my 
research 18 times at a number of conferences including those for the Biomedical 
Engineering Society, American Chemical Society, Society for Biomaterials, World 




Keystone Symposia on Vaccines. To support these presentations, I have received 7 
travel awards. My research has been funded by 3 fellowships including the University 
of Maryland Graduate Dean’s Dissertation Fellowship, the American Association of 
Pharmaceutical Scientists Foundation Graduate Fellowship, and a National Institutes 
of Health T32 Host-Pathogen Interaction Fellowship. I have also been awarded a 
Keystone Symposia Future of Science Fund Scholarship, named as the recipient of 
the 2016 Bioengineering Outstanding Graduate Student Research Award, was chosen 
as a University of Maryland Clark School Future Faculty Program Fellow, and 
received the 2017 University of Maryland Graduate School Michael J. Pelczar Award 
for Excellence in Graduate Study. My work with PBAEs is the first to systematically 
investigate how the intrinsic immunogenicity of materials is altered during 
degradation. Our work is unique in the use of intra-lymph node injection to 
specifically study the role that vaccine carriers and immune cues play in altering the 
local and systemic immune responses without relying on passive drainage following a 
systemic injection. Investigations using this technique have identified that altering the 
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